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1 Summary 
The family of ATP binding cassette (ABC) transporters comprises a number of export 
proteins which are responsible for the organismic homeostasis and are expressed at 
endothelial barriers of different tissues. Furthermore, recent findings of ABC transporters 
being transiently expressed in stem and progenitor cells of various tissues, also suggest them 
to play a functional role in sustaining cellular homeostasis for maintaining their stem cell 
character. Not least these proteins are of fundamental importance for the brain homeostasis by 
regulating transport of metabolites across the blood brain barrier and were therefore recently 
linked to neurodegenerative proteopathies of the brain like Alzheimer’s disease (AD). Here, 
ABC transporters have been found directly responsible for the efflux of the toxic β-amyloid or 
Aβ which is the origin of neurodegenerative Aβ-plaques.  
This study was carried out to assess the involvement of ABC transporters in neurogenic 
functions of the healthy and diseased adult brain. To do so, neurogenic progenitors in the 
hippocampal dentate gyrus were quantified in adult ABC deficient mouse strains which 
lacked either ABCB1 (ABCB1
0/0
), ABCG2 (ABCG2
0/0
) or ABCC1 (ABCC1
0/0
), using 
immunofluorescence techniques. These analyzes revealed significantly impaired neuronal 
differentiation in the adult NSPC pool of ABCB1
0/0
 mice. Additionally, analogues and 
comparative analyzes were performed in brains after utilization of a controlled cortical injury 
(CCI). The CCI was used to model neuroregeneration after brain injuries and for triggering 
neurogenesis. The neuroregeneration was assumed as to be impaired as a result of ABC 
depletion. Interestingly, deficit of ABCC1 did not seem to affect adult neurogenesis in the 
healthy brain, while these animals suffered from significantly impaired neuroregeneration 
after cortical injury as like as ABCB1 deficient mice did. Adult neurogenesis was also 
assessed in transgenic mouse strains expressing the human amyloid precursor protein (hAPP) 
and presenelin 1 (hPS1) when simultaneously lacking either one of the three questioned ABC 
transporters. These analyzes were carried out to assess neurogenic processes in brains 
suffering from β-amyloid proteopathy. While ABC transporters were already known to be 
involved in AD pathology, the question remained in which way ABC deficiency would 
contribute to neurogenic processes in the AD-affected brain. The experiments showed, as like 
previous studies stated for distinct other AD mouse models, that adult neurogenesis is 
triggered in the AD-affected brain. The relative increase in neurogenesis during β-amyloid 
deposition compared to the non-transgenic counterparts was most significantly increased in 
ABCG2
0/0
 transgenic APP/PS1
+/0
 mice. 
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Analyzes were also performed in vitro to answer the question whether ABC transporter 
activity is of cell-intrinsic importance for stem cell functions using primary NSPC cultures 
isolated from the ABC deficient mouse strains. The cultured NSPCs were used for 
proliferation and differentiation analyzes to find possible impairments as a result of ABC 
depletion. Also synthetic Aβ was used to observe NSPC functions with regard to AD 
pathology and ABC transporter functions in vitro. The results showed that only proliferation 
was significantly increased by lack of ABCG2, while capability for neuronal differentiation 
was not affected by ABC depletion. Aβ administration only showed a significant pro-neuronal 
effect during NSPC differentiation in cells of the control line without revealing significant 
deficits as a result of lacking ABC expression. 
To assess possible alterations of ABC-depletion on brain ontogenesis, histological analyzes 
were performed and revealed minor alterations in the cortical cytoarchitecture in ABCB1 and 
ABCC1 deficient animals. As a result of alterations in adult neurogenesis and altered cortical 
cytoarchitecture found in ABC deficient animals, behavioral assessments were carried out to 
find possible impairments in behavioral phenotypes. Again ABCB1
0/0
 and ABCC1
0/0
 mice 
revealed significantly altered anxiety and activity levels. 
The overall outcome of this study concluded in the finding that ABC transporters are indeed 
involved in neurogenic processes of the adult brain. But otherwise than suggested in former 
studies, deficit of single ABC transporters do not necessarily contribute to impaired NSPC 
functions on a cellular level. Rather deficiency of distinct ABC transporters seem to have far 
ranging effects on the brain homeostasis, especially on that of the stem cell niche, resulting in 
impaired neuroregenerative functions in the adult brain. Therefore impaired stem cell 
functions should be considered much more as a result of altered brain homeostasis. These 
resulting deficits seem to affect even brain ontogenesis leading to distinct behavioral 
phenotypes as well.   
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2 Introduction 
2.1 Adult neurogenesis 
For a long time the dogma of neurogenesis occurring only during prenatal brain ontogenesis 
and ending with birth was well accepted in the scientific community, assuming a slow loss of 
neuronal cells during neurodegenerative events until death. While first speculations about 
some “indifferent cells” or “medulloblasts”, possibly giving birth to neurons in the adult 
brain, came up at the beginning of the 20
th
 century, it took until the 1960s when Sidman, 
Altman and colleagues published first evidence supporting such theories.  
By intrathecal injection of the radioactive nucleotide [H
3
]-thymidine, newly generated cells 
were labeled as a result of [H
3
]-thymidine incorporation into the DNA and allowing their 
identification by histological means [1]. By analyzing autoradiograms of brain slices of rats, 
Altman and colleagues found individual positive cells in the neocortex while a vast number of 
cells in the ependymal and subependymal layers of the lateral ventricles, as well as in the 
granular cell layer of the hippocampal dentate gyrus also showed robust [H
3
]-thymidine 
labeling [2]. These early findings were controversially discussed and not well accepted in the 
scientific community. Some years later, studies of Kaplan and colleagues supported the earlier 
findings of Altman and the theory of adult neurogenesis. Here also [H
3
]-thymidine labeling 
was used to mark proliferating cells, but the further analysis of ultra-structural properties of 
those cells revealed them as to be in fact neurons [3]. Still the question remained whether 
these single generated neurons really contribute to neuronal circuitry and thereby to 
neuroregenerative effects. Than in 1984 Paton and Nottebohm proved for the first time the 
functional integration of newly generated neurons in songbirds. By combining [H
3
]-thymidine 
labeling prior to in vivo measurements of neuronal depolarization after acoustic stimuli and in 
vivo cell labeling of the measured cells, they could later document by utilizing 
immunohistochemical methods that a small amount of the measured cells were indeed 
positive for [H
3
]-thymidine. Thereby the functional integration of newly generated neurons in 
the adult brain was proven, at least in birds [4].  
Also more sophisticated cell culturing methods contributed to the growing knowledge of 
neural stem cells in the adult brain. In 1992 two workgroups could show independently the 
proliferative potential of isolated primary cells from the rodent striatum and their ability to 
differentiate into neural linage cells. Reynolds and colleagues could show that virtually all in 
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vitro proliferated cells were expressing Nestin, a cytoskeletal protein only expressed in neural 
stem and progenitor cells. They also showed the dependency of proliferation on the presence 
EGF and a non-adhesive matrix [5]. With a similar approach Richards and his group managed 
to differentiate these primary NSPCs into neurons in vitro and thereby evidenced the 
existence of stem cells in the adult brain [6]. 
Rapid gain of knowledge about adult neurogenesis was achieved after the introduction of 5-
bromo-2’0-deoxyuridine (BrdU). Incorporation of this nucleotide analog into newly 
synthesized DNA and the ability of labeling BrdU incorporation by means of 
immunohistochemistry allowed easy lineage tracking of proliferating cells. This new tool led 
to observations of adult neurogenesis in virtually all analyzed mammalian brains and even in 
humans [7]. Much progress was made and it became clear that neurogenesis occurred only in 
distinct regions of the brain. It was observed that neurogenesis only occurred in two brain 
areas the hippocampus, were the dentate gyrus gives rise to new neurons, and the 
subventricular zones of virtually all ventricles. Here it was also observed that neurons from 
the subventricular region enter the rostral migratory stream and migrate to the olfactory bulb 
to become interneurons throughout adulthood [8].  
As a result of a vast number of previous studies in the field of neuroregenerative potential of 
NSPCs, we already have a quite good understanding about the general mechanisms of NSPC 
differentiation and know the cellular markers expressed in each of the transient steps from 
early progenitors to mature neurons. It has been shown that apart from minor differences 
between hippocampal and subventricular NSPCs, neurogenic functions are based upon the 
proliferation and differentiation capacity of special astrocyte-like cells, the so-called radial 
glia or type-1 cells [9, 10]. It is believed that radial glial cells are remnants from 
neuroepithelial cells. They give rise directly to neurons (during embryonal development only) 
or intermediate progenitor cells (IPC) by asymmetrical diversion which are also referred to as 
type-2 cells [10]. Different early committed progenitors of neuronal (nIPC) or 
oligodendrocytic lineage (oIPC) are possible. During brain development the radial glia cells 
become less frequent and seem to be substituted by so called B-cells, which still reflect the 
morphological features of radial glia (e.g. morphology and marker expression (GFAP/Nestin)) 
and have the stem cell-like property of giving birth to all neural linage cells [9]. 
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Figure 1: Neural cell lineage during neurogenesis (adapted from [9]) 
 
2.1.1 Subventricular zone (SVZ) 
In the subventricular zone neurogenic processes occur most prominently in the walls of the 
lateral ventricles which most likely resemble the embryonic SVZ. Neurogenesis in the SVZ 
emanates from B cells which show astrocytic marker expression and resemble a radial glia 
cell-like morphology even though they show a less prominent basal-apical morphology and 
are also referred as to be SVZ-astrocytes [9, 11]. Even though the cell bodies of B cells are 
located under the ependymal cell layer these cells are equipped with small apical processes 
standing in contact with the ventricle and extent one single cilium into it which is supposed to 
be important for signal reception [12]. With their long basal processes containing special end 
feet B cells also stand in contact with blood vessels [13]. Even IPCs are often found to have 
direct contact to blood vessels. According to their special morphology it is assumed that B 
cells and IPCs receive signaling also from the vasculature regulating neurogenic functions. 
Anyway these B cells give rise to intermediate progenitor cells which are also known as C 
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cells [14]. The C cells or IPCs are highly proliferative and develop into neuroblasts or A cells 
which are neuronal committed precursor cells and migrate through the rostral migratory 
stream (RMS) to the olfactory bulb [15]. When arrived at the olfactory bulb these A cells 
differentiate into divers subtypes of interneurons [16]. Most of the cells become GABAergic 
granule neurons lacking axonal processes and form dendro-dendritic synapses. A very small 
part of the cells become either dopaminergic or glutamatergic neurons [17]. 
 
Figure 2: Process of subventricular neurogenesis (adapted from [11]) 
 
2.1.2 Subgranular zone of the dentate gyrus (SGZ) 
The dentate gyrus of the hippocampus is the other main region of neurogenic processes in the 
adult mammalian brain. In contrast to neurogenesis in the SVZ, hippocampal neurogenesis 
has been directly linked to cognitive functions like learning and memory functions while 
impairments were found in patients suffering for example from epilepsy or depression 
(reviewed in [18]). 
 Similar to the situation in the SVZ, also in the dentate gyrus special cells with astrocytic 
features function as neural stem cells. These neural stem cells resemble a radial glia like 
morphology with long processes leading through the granular cell layer and having contact to 
the vascular system and small processes horizontal to the subgranular zone [19]. According to 
the direct neighborhood of hippocampal neural stem cells and the vasculature even here a 
possible regulation of neurogenesis by soluble factors from the vascular system is presumed. 
Unlike ordinary astrocytes the hippocampal neural stem cells are characterized by 
simultaneously expression of GFAP and Nestin and are referred to as type-1 progenitors [10]. 
Type-1 cells give rise to neural intermediate progenitors known as type-2 progenitors [20] or 
D cells [21] which are characterized by transient expression of e.g. PSA-NCAM, NeuroD or 
DCX amongst others according to state of differentiation. Interestingly radial type-1 cells and 
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type-2 progenitors form clusters where a number of type-2 progenitors are bundled along the 
radial processes which led to the presumption that type-1 cells also somehow regulate the 
further development of the surrounding D cells. A lot of stimuli like adrenal steroids, exercise, 
environmental enrichment or inflammation and antidepressant drugs have influence on 
neurogenesis (see [9]). Soluble factors from the vasculature or electrophysiological activity 
from the surrounding granule cells may influence the radial glia cell which in turn might 
regulate D cell functions.  
 
Figure 3: Process of hippocampal neurogenesis (adapted from [11]) 
Immature neurons differentiated from D cells migrate into the inner granule cell layer and 
become dentate granule cells. The immature neurons begin to integrate into neuronal circuitry 
by extending dendrites to the molecular layer and growing axons toward CA3. During neuron 
maturation new neurons are tonically activated as a result from nearby GABA release from 
neighboring interneurons, later getting synaptic GABAergic inputs finally followed by 
glutamatergic synaptic inputs. Newborn neurons are initially hyperexcitable and were 
observed to have an increased synaptic plasticity compared to adult granule cells (reviewed in 
[11]). Neurons generated during adult neurogenesis show basically similar 
electrophysiological properties while it is still unclear by which amount adult generated 
neurons contribute to general neuronal circuitry.  
2.2 ABC Transporters 
ATP binding cassette (ABC) transporters are proteins which are expressed ubiquitous 
throughout the three kingdoms of life: archaea, eubacteria and eukarya. Its members 
constitute one of the largest known superfamilies of genes. These transport proteins are 
expressed in cellular membranes and utilize chemical energy from ATP dephosphorylation for 
translocation of a wide range of metabolites and ions across cellular membranes. The 
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transport is always of unidirectional nature. Apart of some exceptions, mostly found in 
prokaryotes, these transporters carry out export functions. According to their functional 
properties and occurrence, these transporters are mostly divided into three different 
subclasses. The first group of import proteins is found only in prokaryotic cells where these 
transporters manage the incorporation of nutrients and ions [22, 23]. The second group, which 
is of interest in this study, is involved in export functions like secreting dietary agents or 
exposing cytotoxic metabolites across biological membranes (reviewed in [24],  and even 
transporting signaling molecules [25]. The third group is more involved in nuclear processes 
like DNA repair and chromatin reorganization and also RNA trafficking and telomere 
maintenance [26-28]. 
Of this large group of genes, there are 49 members currently known to be expressed in 
humans, which are further classified into subgroups according to the phylogeny based on 
amino acid sequence similarities. These 7 subgroups are named ABCA to ABCG [29, 30]. 
ABC transporters show overlapping transport capacities for a wide range of peptides, 
hydrophobic compounds as well as drugs and drug conjugates. According to those features 
they also form an effective chemo-defense network against all sorts of xenobiotics [31]. 
Actually ABC transporters were first discovered in chemoresistant cancer cells [32, 33], and 
were since a scientific subject in cancer-related research. Based on that research, many ABC 
transporters were even found being expressed in stem cells due to the high resemblance in 
gene expression profiles of stem and cancer cells.  
Apart from that ABC transporters are mostly found expressed at biological membranes which 
are defining different tissues or compartments against each other. A prominent example is the 
blood brain barrier which functions as a barrier between the brain parenchyma and the rest of 
the body which is impenetrable by undirected diffusion to secure the brain from xenobiotics 
and pathogens in general. Here, mostly all metabolite transport is regulated by ABC transport 
proteins. According to that, ABC transporter malfunctions have been recently found to be 
linked to proteopathies of the brain like Alzheimer’s disease [34, 35]. Here, ABC transporters 
are responsible for the clearance of Aβ peptides across the blood brain barrier while lack of 
transport capacity for those peptides results in accumulation of Aβ and thereby in plaque 
formation. Recent studies underlined the overlapping transport capacities of ABC transporters 
of different subclasses for β-amyloid and most importantly evidenced the transporter ABCC1 
to be most critical in the pathology of Alzheimer’s disease by having the highest transport 
capacity for Aβ [36].  
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2.2.1 Structure and function of ABC transporters 
The common structure of all ABC transport proteins is comprised of two TMDs 
(transmembrane domain) and two cytosolic ABCs (ATP binding cassettes) or NBDs 
(nucleotide binding domain). The TMDs contain multiple hydrophobic segments which span 
the membrane as α–helices multiple times. In general a TMD consist of 6-11 transmembrane-
spanning α-helices. The TMDs are needed to form the transmembrane channel and are 
thought to contain the substrate binding sites. In contrast to the various TMD sequences the 
NBDs are highly conserved. They contain the Walker A and Walker B motifs for ATP 
binding as well as the so-called ‘LSGGQ’ motif which forms the diagnostic signature of all 
ABC transporters and is assumed to be responsible for triggering the interaction between 
different domains [37]. These NBDs function as molecular motors, transforming the chemical 
energy from ATP dephosphorylation into mechanical energy for initiating the conformational 
change of the ABC transport protein during substrate translocation. The most common form 
of ABC transporter is the full-transporter in which all single domains are aligned in the 
sequence TMD-NBD-TMD-NBD (full transporter). Other arrangements like NBD-TMD-
NBD-TMD, TMD-NBD and NBD-TMD (half transporter) are possible as well.  
The course of the ABC-transporter mediated efflux of substrates across the plasma membrane 
is still only insufficiently understood. Three different models of possible transport mechanism 
should be mentioned at the example of ABCB1 as one of the most studied members of the 
ABC transporter family [38].  
The first and classical model assumes the two TMDs of ABCB1simply being arranged in a 
way forming a pore within the plasma membrane, letting the transporter actively expel 
metabolites from the cytoplasm into the extracellular compartment [39]. 
In contrast to that the “vacuum cleaner model” assumes that ABCB1is able to expel substrates 
into the extracellular space while the substrate is either within the intracellular medium or 
even when it is still located within the lipid bilayer of the plasma membrane. According to 
that assumption the transporter would function as a hydrophobic vacuum cleaner, floating 
across the plasma membrane and clean hydrophobic substrates from the membrane even 
before being able to enter the cytoplasm [38, 40].     
Another model which was initially introduced by Higgins and Gottesman in 1992 and which 
is still the most favored explanation is the so-called flippase model [41]. The model assumes 
the substrate binding site of the TMDs to be located in the inner leaflet of the plasma 
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membrane. The substrate has to diffuse laterally in the direction of the binding site while 
being orientated hydrophobic side facing the inner leaflet of the membrane while the charged 
hydrophilic site is faced towards the cytoplasm. In the moment the substrate is bound to its 
binding site faced correctly, the TMDs flip the substrate to the outer membrane leaflet under 
consumption of the energy provided by ATP dephosphorylation at the NBDs. Once the 
substrate is flipped to the outer membrane leaflet, the substrate diffuses into the aquatic phase 
of the extracellular medium [41]. Actually genetic homology between ABCB1 and ABCB4, 
both proteins with flippase activity, supports this model of action [38].   
Even with the flippase model given as the most likely possible transport mechanism, it is still 
unclear in which way the TMDs are capable to bind such a massively varying portfolio of 
substrates. Studies on transcriptional regulators revealed them to contain binding sites for 
specific drugs which are composed as hydrophobic pockets. While larger compounds 
completely fit into these pockets, smaller substrates are surrounded by water molecules, 
filling the gap between the substrate and the surrounding binding site. Hence it is postulated 
that even the multidrug binding sites of ABC transporters are characterized by an architecture 
similar to that of these transcriptional regulators. Due to the fact that large loop-domains are 
bound intra- and extracellular at the TMDs it is presumed that the actual substrate binding 
sites are sculpted by these domains [42]. By using antibodies to locate the substrate binding 
sites, the large intracytoplasmic domain separating TMD1 and TMD2, the linker domain 
between TMD2 and TMD3 and the last two transmembrane segments were identified as 
possible binding sites in ABCC1 [43]. This kind of adapting hydrophobic basket could 
sufficiently explain the variability of binding capacities for various compounds and the 
largely overlapping transport capacities of ABC transporters.  
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2.2.2 ABCB1 
The group of human ABC transporters of the ABCB-family consists of 11 members. The full-
transporters of this group contain 12 transmembrane domains. ABCB1 is with 1280 amino 
acids one of the largest proteins of this group (Figure 4).  
 
Figure 4: 2-dimensional representation of ABCB1 (adapted from [44]). 
ABCB1, which was primarily called P-glycoprotein, was identified first in a hamster cell line, 
where it was found to maintain cell membrane permeability [32]. Further studies on multidrug 
resistant Chinese hamster ovary cell lines could link chemoresistance to the expression of 
ABCB1 [33]. Later it was found being expressed in several kinds of cancers. Since then 
substantial effort was undertaken to elucidate the physiological role of ABCB1. Hence, 
ABCB1 was found to be expressed in a variety of different tissues which include the small 
and large intestine, adrenal gland, kidney, placenta and the endothelial cells in the blood brain 
barrier and blood testis barrier where it seems to have export functions to maintain 
homeostasis of these body compartments (reviewed in [45]). ABCB1 was actually the first 
ABC transporter that was identified in the human blood brain barrier [46]. Here it was found 
to secure the brain from intoxication with passively diffusing lipophilic compounds [47]. To 
do so, it is located at the luminal side of the cerebral endothelial cells where it can expel the 
transported substrates directly into the blood stream. It was also recently linked to 
Alzheimer’s disease when Aβ was identified as a substrate of ABCB1 [48-50]. Beside its role 
in Alzheimer’s disease pathology it is also found expressed in stem cells of various tissues 
(reviewed in [51]). This is very comprehensible because cancer cells, in which it is involved 
in drug resistance, show a gene expression profile largely overlapping with that of stem cells 
[52]. Also ABCB1 was recently found expressed in neuronal stem cells in vitro. It was also 
observed that transient ABCB1 expression vanished when cell differentiation proceeded [53, 
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54]. Hence it was presumed that ABC transporters might play a crucial role in the 
maintenance of “stemcellness” in NSPCs [55]. 
2.2.3 ABCG2 
The transporter ABCG2 was first isolated from multidrug resistant breast cancer cells which 
explains its synonymous designation BCRP1 (breast cancer related protein 1) [56]. In contrast 
to ABCB1, ABCG2 is essentially a so-called half transporter due to its composition out of 
only one TMD comprised of 6 transmembrane α-helices and one NBD (Figure 5). It is 
therefore assumed to build homodimers for achieving full functionality as an ABC transporter 
[57, 58]. ABCG2 is also highly expressed in tissues of toxicological relevance, comparable 
with that of ABCB1 or even ABCC1 (reviewed in [59]).   
 
Figure 5: 2-dimensional representation of ABCG2 (adapted from [44]). 
A structural precursor of heme (pheophorbide) was found to be a substrate of ABCG2 due to 
decreased intracellular accumulation of heme precursor proteins after the beginning of 
ABCG2 expression. Therefore it was suggested that the ability of stem cells to survive 
hypoxic conditions could be linked to abundant ABCG2 expression which prevents the 
accumulation of toxic heme, naturally occurring under such conditions [60]. Hence ABCG2 is 
expressed in various stem cell lines [60] and is abundantly expressed in various kinds of 
human malignancies like digestive tumors, genito-urinary tumors, female reproductive 
tumors, lung tumors and others [61]. Comparable to ABCB1 also ABCG2 was found 
transiently expressed in NSPCs prior to cell differentiation [62]. Hence even also ABCG2 was 
suggested to be responsible for maintenance of stem cell functions [55]. 
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2.2.4 ABCC1 
In contrast to other full transporters, 5 of the C-family ABC transporters (ABCC1, ABCC2, 
ABCC3, ABCC6 and ABCC10) show an atypical structure. These proteins are comprised of 
rather 5 than 4 domains. Here another TMD (TMD0) containing 5 transmembrane α-helices is 
added at the NH2-terminal (Figure 6). Another main characteristic of all transporters of the C-
family is the relatively low sequence homology between the two NBDs. Here NBD1 lacks 13 
amino acids between the Walker A and Walker B motifs which are comprised in NBD2 as in 
mostly all NBDs of every other ABC subclass’ members. Further studies also evidenced 
functional differences between the two nucleotide binding domains (reviewed in [63]). 
 
Figure 6: 2-dimensional representation of ABCC1 (adapted from [44]). 
Even ABCC1 was initially identified in a lung tumor [64] but was as well found to be 
robustly expressed in other cancer cells like for example in a group of hematological and solid 
tumors (reviewed in [59]). Analog to other ABC transporters also ABCC1 is found in various 
tissue types like lung, small intestine, testis, kidney, muscle, heart, peripheral blood 
mononuclear cells, the choroid plexus and the placenta. ABCC1 shows a wide range of 
substrate specificity. Typical substrates of ABCC1 are free and conjugated bilirubin, oxidized 
glutathione and a number of xenobiotic substrates including many chemotherapeutic agents 
(reviewed in [65]). ABCC1 was also found to be expressed in the choroid plexus [66] where it 
was recently found to be the major ABC transporter involved in Aβ efflux from the brain 
[36]. 
2.2.5 ABC transporters in stem cells 
While ABC transporters were found highly expressed in the diverse cancer cells, it was not 
surprisingly to find them also expressed in stem cells of various tissues. ABCB1 was the first 
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of the ABC transporter family which was observed in CD34
+
 human hematopoietic stem cells 
as a result of their increased efflux capacity for the dye Rhodamine123 which is known to be 
a substrate of ABCB1 [67]. Using Rhodamine123 and the dye Hoechst3342, which is another 
ABC-transporter substrate, for analyzes of bone marrow cells in fluorescence activated cell 
sorters, a small subset of cells positive for phenotypic markers of hematopoietic stem cells 
was revealed [68]. After administration of ABC transporter inhibitors, this cell population was 
lost [68]. Staining for incorporation of Hoechst3342 was found to be useful for isolating cell 
populations which are highly enriched with stem cells [69]. According to the distinct staining 
profile of these cells with their high efflux capacity for Hoechst 3342, those were called side 
population (SP) and according cell populations were since found also in other tissues [70]. 
Other cell populations in which the SP cells were observed are mesenchymal, heart, liver and 
pancreatic stem cells (reviewed in [55]). Beside the initial ABC transporters ABCB1 and 
ABCG2 also ABCA3 was found expressed in the primitive stem cells of different tissues [71]. 
While these transporters are found robustly expressed in stem cells again and again and were 
therefore suspected to possibly have regulating functions on stem cell fate (reviewed in [55]), 
in a distinct SP of hepatocellular carcinoma moreover other transporters like ABCB2, ABCC7 
and ABCA5 were found to be up regulated several fold compared to none SP cells [72]. These 
findings might suggest overlapping functions and co-regulation between ABC transporters 
distinct for specific cell populations. 
Accordingly it was found that for example ABCG2 expression was highly regulated with the 
highest expression found in primitive cells followed by subsequent down regulation following 
commitment to differentiation. Accordingly forced expression of ABCG2 hindered in less 
hematopoietic development and resulted in less progeny in the bone marrow and peripheral 
blood after transplantation experiments of ABCG2 overexpressing progenitor cells [73]. 
Hence it was presumed that ABCG2 for instance might be capable of expelling substrates 
needed for differentiation or that ABCG2 is involved in stem cell interactions with their 
microenvironment by mediating extracellular signals. Therefore comparable experiments with 
ABCB1 overexpressing cells resulted in prolonged survival rates in vitro and increased 
repopulation capacity in vivo [74]. Together these findings might indicate specific functions 
for ABCB1 and ABCG2 in different types of stem cells, proliferating and quiescent ones. 
Beside the expression of ABCB1 and ABCG2 widely known from other stem cell populations 
also ABCA2 was found expressed in early neural stem cells when derived from hematopoietic 
stem cells in vitro. Even though, the expression of ABCA2 seems to be region-dependent and 
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specific for oligodendrocytic progenitors, a subset of cortical GABAergic interneurons and 
pyramidal glutamatergic neurons [75]. Recent in vitro studies showed robust expression of 
ABCB1 and ABCG2 in neurosphere forming NSPCs. It was also shown that the high 
abundance of these transporters decreases at the stage of lineage commitment together with 
the down regulation of Nestin and up regulation of GFAP. Therefore it was proposed that 
both ABCB1 and ABCG2 may be seen as markers of NSPCs and may have a functional role 
in upholding the stem cell status [53, 62].  
 
Figure 7: Presumed effects of ABC transporter function on NSPCs (adapted from [55]) 
 
2.3 Alzheimer’s disease (AD) 
Since Alzheimer’s disease was described first by Alois Alzheimer in 1906 when he found 
characteristically intra- and extracellular protein deposits in the brain of one of his former 
patients suffering from dementia, Alzheimer’s disease soon became the most frequently cited 
cause of dementing cerebral cortex pathologies [76]. 
The pathology of AD is a slow progress starting most often years before first clinical 
symptoms are observable. The pathology can be divided into stages with increasing severity 
of clinical symptoms. Initially patients at least start noticing disturbances in their short-term 
memory accompanied by unexplainable mood-shifts, impairments of language and first mild 
effects of spatial disorientation. The intermediate state, when dementia has become certified, 
organizing and performing all-day tasks like for example shopping, cooking or even dressing 
become increasingly difficult while patients also get more emotionally instable or even 
undergo personality changes. They become unable to differentiate between past and presence 
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and to recognize even near relatives. During the last stage, patients become bedridden and 
completely dependent from long-term-nursing. In most cases death results from infections as 
secondary and final pathologies (pneumonia, influenza, nephritis, etc.)  
Beside the intracellular neurofibrillary tangles comprised of hyperphosphorylated Tau protein, 
the most prominent hallmark of AD is the occurrence of extracellular protein deposits or 
neuritic plaques which are composed of aggregated Aβ peptides. These Aβ peptides are 
generated as cleavage products of the amyloid precursor protein (APP) after cleavage by three 
different secretases. Their interplay defines the nature of APP cleavage resulting in either the 
amyloidogenic or non-amyloidogenic pathway [77, 78]. While the role of APP itself is still 
under discussion and assumed to be related to neuronal differentiation, survival and neurite 
outgrowth [79, 80], along with its soluble cleavage product sAPP [79], the short Aβ peptides 
resulting from the amyloidogenic cleavage pathway have been shown to be clearly of 
pathogenic nature.   
 
Figure 8: APP cleavage adapted from [81] 
The three secretase families involved in APP cleavage are the α-, β- and γ-secretase group 
each cleaving the APP at distinct positions. The activity of these secretases dictates the fate of 
APP cleavage. The initial cleavage of APP by the β-secretase (beta-side APP-cleaving 
enzyme-1, BACE-1) followed by γ-secretase, which is a multi-protein complex composed of 
Presenelins 1 and 2 (PS1, PS2), Nicastrin, Pen2 and Aph [82], results in the generation of 
toxic Aβ peptides. If in contrast APP is first cleaved by one of the α-secretases (a disintegrin 
and metalloproteinase domain-containing protein –ADAM- 10 9, and 17), further cleavage of 
γ-secretase cannot lead to generation of Aβ.  
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But as long as the equilibrium of APP cleavage is shifted towards the amyloidogenic pathway, 
the toxic Aβ peptides are generated. As a result of a certain inaccuracy of secretase cleavage 
Aβ peptides have lengths between 38, 40 and 42 amino acids. Thereby the most prominent Aβ 
species is the Aβ42 which also seems to be the most toxic variant and is most prone to fibril 
formations since it is the major Aβ species found in plaques [83].  Today it is relatively clear 
that not the beta-amyloid plaques are the main cause of neurodegeneration but more likely the 
neurodegenerative effect of soluble Aβ contributes to neurodegeneration much earlier than 
plaque formation has even begun. Accordingly studies revealed that neurodegeneration, or 
indirectly cognitive decline, much more correlates to concentration of soluble Aβ than plaque 
load [84, 85]. Much more than its shorter siblings Aβ38, and Aβ40, Aβ42 has a very high 
tendency to form small soluble oligomers. Hence, Aβ42 spontaneously assembles to trimeric 
or tetrameric complexes very early [86] followed by larger oligomers of pentameric or 
hexameric conformation which themselves are able to aggregate forming oligomers of higher 
order [87]. During the process of Aβ oligomerization fibrils are finally generated and begin to 
deposit in form of neuritic plaques.  
Still only less than 1% of all AD cases [88] could be linked to genetic variants and contribute 
to the so called familial form of AD [83]. In contrast the vast majority of AD patients seem to 
suffer from the so-called sporadic form of AD. Until now only three genes are known to bear 
mutated variants contributing to AD pathology. These three are the two presenelin genes 1 
and 2 which code for essential proteins of the γ–secretase complex and the APP gene itself 
which bears several mutations which are more prone to β-secretase cleavage. The mutations 
lead to enhanced amyloidogenic APP processing and thereby to AD pathology. While 
pathology of the sporadic form of AD does not develop before advanced age, forms of 
familial AD tend to develop before the age of 65 and in some individuals even at an age of 30 
years.  
Beside the enhanced Aβ peptide generation as a result of increased amyloidogenic APP 
cleavage, also malfunctions in transport processes across the blood-brain-barrier contribute to 
AD pathology. It is already known that Aβ is a substrate for certain ABC transporters like 
ABCB1 or ABCC1 [36, 49]. A recent study found impairments in ABC transport activity 
significantly severs AD pathology as a result of insufficient Aβ clearance in ABC deficient 
mouse models of Alzheimer’s disease [36]. Due to the fact that lot of drugs chronically 
subscribed in elderly significantly impair ABC transporter function, these drugs could 
possibly also increase the risk of developing AD pathology.  
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Figure 9: Cortical tissue samples from ABC transporter deficient AD mice reveal the significance of ABC 
transporter-mediated Aβ-clearance out of the brain parenchyma. ABCB10/0 (lower left) and ABCC10/0 
(lower right) transgenic mice show significantly increased plaque load compared to transgenic control mice 
(upper left) from [36]   
 
2.3.1 Neurogenesis in Alzheimer’s disease 
During the pathogenesis of AD, the hippocampus as one of the two major sites of 
neurogenesis is affected very early. Even though the effect of AD pathogenesis on neurogenic 
functions remains very controversial due to the fact that, somehow depending on the 
techniques used for the respective study, there were either impairment, enhancement or even 
no changes in neurogenesis observed at all. Postmortem studies on human brain samples of 
AD patients utilizing Western blot analyzes, revealed increased amounts of neurogenic 
markers [89]. For example proteins like TUC-4, PSA-NCAM, DCX and NeuroD, which are 
all proteins expressed at different stages of neuronal differentiation whose expression  levels 
were observed to be increased in comparison to age-matched control samples in histological 
analyzes [90, 91]. In contrast, another study found no significant alteration in the number of 
DCX expressing neuroblasts. There was also found no evidence for altered cell proliferation 
when quantifying for the expression of the proliferation marker Ki67, at least in the 
neurogenic niche of the dentate gyrus. At least Ki67 was found to be expressed in a number of 
cells located in the CA1 and CA3 regions of the hippocampus. Here cell proliferation was 
therefore assumed to be related to glia cell proliferation which should be resulted from the 
gliosis occurring during AD pathology [92]. Studies focusing on the early stem cell 
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compartment also revealed intriguing results. While the level of Musashi1 expression, a 
posttranscriptional regulator highly expressed in proliferating stem and progenitor cells, was 
heavily decreased in AD brains, the number of GFAP and Nestin positive cells was 
significantly increased. These results imply severe impairments in NSC functionality, a 
hypothesis which is also supported by findings of primary SVZ-NSPCs isolated from AD 
brains that showed impaired viability and earlier senescence exhibition [93]. Studies of human 
AD infected brains also showed that SVZ and SGZ seem to be differentially affected by AD 
pathology due to findings of decreased numbers of SVZ-progenitors [94] and increased 
numbers of SGZ progenitors [89]. 
Since rodents do not suffer from pathologies like Alzheimer’s disease, research depends on 
animal models which can only model distinct aspects of AD. These aspects are β–amyloid 
deposition or Tau pathology. Here human genes have to be introduced to generate transgenic 
animal models. Accordingly a lot of mouse models expressing different human genes under 
the control of several, mostly neuron-specific promoters exist today which significantly 
impedes comparative studies on neurogenesis in AD.  
 Authors Subject markers 
Increased 
neurogenesis 
[89] Human postmortem samples TUC4, DCX 
[95] PDGF-APP(swed, indian) mice DCX, NeuroD, BrdU 
[96] PDAPP mutant mice (SGZ) DCX, BrdU 
[97] APP23 mutant mice 
DCX, BrdU, GFAP 
NeuN 
No changes 
[92] Human postmortem samples Ki67, DCX, GFAP 
[98] PS1-mutant mice TUC4, PSA-NCAM 
Impaired 
neurogenesis 
[99] APP/PS1 mutant mice BrdU, NeuN 
[96] PDAPP mutant mice (SVZ) DCX 
[100] APP/PS1 mutant mice MCM2, DCX 
[97] 
Nestin-GFP x APP/PS1 mutant 
mice 
Nestin-GFP 
[101] 
APP mutant mice and 
NSPC experiments in vitro 
BrdU, E-NCAM, GFAP 
Table 1: AD pathology’s effects on adult neurogenesis are highly discussed 
Increased neurogenic activity was observed in a double-mutant AD mouse model with human 
APP (Swedish and Indian mutation) under the control of platelet derived growth factor. There 
it was found that BrdU incorporation and DCX positive cells were both increased in SVZ and 
SGZ though these observations were made at an age prior to significant plaque deposition 
[95]. Another AD model (APP23 mutant mice) did not show alterations in neurogenesis prior 
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to plaque deposition while at an age of 25 months neurogenesis was significantly increased 
compared to control mice as revealed by histological analyzes after staining for neurogenic 
markers [97]. No alteration of adult neurogenesis was therefore found in an AD mouse model 
based on overexpression of PS1 which is known to be somehow involved in embryonic 
development [98]. Actually much more studies implied a negative influence of AD-pathology 
on neurogenesis. By utilizing immunohistological methods several studies on different single 
human APP transgenic [96] or combined PS1 overexpressing and human mutant APP mouse 
models found decreased numbers of neuronal progenitors at different stages of differentiation 
[97, 99, 100].   
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2.4 Overall motivation and aims 
ABC transporters, as part of one of the oldest and most ubiquitously expressed protein 
families throughout life, have recently been known for their relevance in the pathology of 
neurodegenerative disorders like especially Alzheimer’s disease. They were also often 
discussed regarding their relevance in stem cell functions and in particular in neuronal stem 
cells. It was therefore assumed that expression of ABCB1 and ABCG2 in particular might be 
necessary for the maintenance of the NSPC’s stem cell character.  
This study was performed in order to contribute more understanding to the basic functional 
relevance of ABC transporters in neurogenic functions like adult neurogenesis in general and 
especially with relevance to brain pathology in form of cortical injury and neurodegenerative 
diseases like Alzheimer’s disease. With regard to ABC transporter involvement in AD as also 
in stem cell functions, the study sought to answer the question whether functional 
impairments of ABC transporters also contribute to AD pathology in the sense of impairments 
of neurogenic functions. 
The following questions were to answer: 
1. Does ABC transporter deficiency alter neurogenic functions in general? 
2. Are possible alterations in stem cell functions of cell intrinsic nature? 
3. Does ABC deficiency lead to further alterations in brain ontogenesis and do such 
alterations result in a distinct behavioral phenotype? 
4. How do pathogenic effects like injury or neurodegenerative disorders affect 
neurogenic functions? 
To analyze the functional relevance of ABC transporters for neurogenic functions in vivo, 
ABC deficient mouse strains were comparatively analyzed by quantification of neuronal 
progenitor cells and cell proliferation capacity on cryogenic brain slices. In order to assess the 
question whether the ABC deficiency-induced alterations in NSPC functions were of cell 
intrinsic nature, NSPCs were isolated from the ABC deficient mouse strains and analyzed in 
vitro for proliferation and neuronal differentiation capacity. To find possible ABC deficiency-
dependent deficits during brain ontogenesis, the different mouse strain’s brains were 
comparatively analyzed for cortical morphology. Behavioral assessment was performed to 
find distinct behavioral phenotypes as possible results of presumed impairments during 
ontogenesis. To find out whether pathogenic events contribute to adult neurogenesis in 
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dependency of ABC transporter equipment, a CCI model was used to model cortical injury 
and sub-sequentially quantifying neurogenesis. Additionally a transgenic AD mouse model 
was crossbred with ABC-deficient mouse strains to analyze neurogenesis during Aβ 
deposition in dependency of ABC transporter function. The function of Aβ on proliferating 
and differentiating NSPCs was also determined in vitro.   
3 Experimental procedures 
3.1 Chemicals 
Agarose Biozym Diagnostik GmbH 
Bond-MaxTM Bond Polymer Refine Detection-Kit Leica 
BrdU Sigma-Aldrich 
CaCl2*(2H2O) Carl Roth 
Chicken serum Vector Labs 
Chloroform Carl Roth 
Cresyl violet Leica 
Culture flask T-25cm² Greiner-Bio One 
DAPI Invitrogen 
DePex Serva Electrophoresis 
D-Glucose Sigma 
Dimethylsulfoxide (DMSO) Sigma-Aldrich 
EGF PeproTech 
Ethanol 96% Carl Roth 
Ethidium bomide Invitrogen 
FGF PeproTech 
Glacial acetic acid Carl Roth 
sterile centrifuge tubes 15mL/50mL Greiner-Bio One 
HCl  Carl Roth 
Heparin Sigma-Aldrich 
Hexafluoroispropanol (HFIP) Sigma-Aldrich 
Igepal A630 Fluka Biochemika 
KCl Carl Roth 
Ketamin (Ketanest) Pfizer 
Matrigel BD Bioscience 
MgCl2*(6H2O) Carl Roth 
microcentrifuge tubes 1.5mL Eppendorf 
microcentrifuge tubes 2mL Eppendorf 
NaCl Carl Roth GmbH 
NaH3 Carl Roth 
NaHCO3 Carl Roth 
NeuroCult Basal media StemCell 
NeuroCult differentiation supplements StemCell Inc. 
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NeuroCult proliferation supplements StemCell Inc. 
OCT-compound Leica 
Paraffin Leica/Menarini 
PBS (10x) Sigma-Aldrich 
Pen/Strep 10x PAA 
petri dish 100mm Greiner-Bio One 
petri dish 50mm Greiner-Bio One 
PFA (4% in PBS) Formafix Switzerland AG 
Proteinase K Carl Roth 
RNAlater Applied Biosystems 
Succrose Carl Roth 
TaqPCR kit Qiagen 
Tris-HCl Carl Roth 
Triton X-100 Carl roth 
TRIzol Invitrogen 
Trypan Blue Carl Roth 
Trypsin/EDTA  Invitrogen Corp. 
Tween 20 Merck 
Xylazine (Rompun) Bayer 
Xylene Carl Roth 
3.2 Equipment 
Bond-Max staining system Leica 
Centrifuge  Hermle Z 400 K 
CO2 incubator Binder 
Cryostat CM350S Leica 
Elevated Plus-maze TSE Systems 
Gel documentation system  DeconScience Tec 
Light/Dark-box TSE Systems 
LSM 700 Zeiss  
Microscope Stemi Zeiss  
Mirax Desk Zeiss  
Rotorgene Q Qiagen 
Stereotactic frame Stoelting  
Thermocycler Tprofessional Basic Biometra 
Videotracking system TSE VideoMot2 TSE Systems 
Y-maze TSE Systems 
3.3 Software 
AxioVision Zeiss 
MS Office Microsoft 
Prism 5 GraphPad Software 
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3.4 Animal procedures 
Mice were bred in the animal care facility of the Neurodegeneration Research Lab (NRL) and 
were housed under a 12h/12h light/dark cycle at a mean temperature of 22°C. All animals had 
access to food (Sniff, Germany) and water ad libitum. 
All protocols involving the use of animals were approved by the local authorities (LALLF M-
V TSD 7221.3-1.1-035/10 and LALLF M-V TSD 7221.3-1.1-024/11). 
3.4.1 ABC knockout mice 
FVB.129P2-Abcg2
tm1Ahs
 N7 (ABCG2
0/0
), FVB.129P2-Abcb1a
tm1Bor
Abcb1b
tm1Bor
 N12 
(ABCB1
0/0
), and FVB.129P2-Abcc1
atm1Bor
 N12 (ABCC1
0/0
) mice were purchased from 
Taconic Farms (Denmark) [102-104] including a breeding permission. Accordingly animals 
were bred as required in the NRL’s animal care facility.  
3.4.2 APP/PS1-, ABC knockout- and combined mouse models 
A combination of the human transgenes Thy-1-APPKM670/671 and Thy1-PS1L166P, from 
here on referred to as APP/PS1, was introduced into C57BL/6J mice resulting in a mouse 
model of Alzheimer’s disease [105] which was kindly provided by M. Herzig, R. Radde and 
M. Jucker (University of Tübingen, Germany).  
APP/PS1 transgenic mice had to be crossbred in a way to only generate heterozygous 
APP/PS1
+/0
 mice. Due to the fact that homozygous mice showed decreased viability as a 
result of excessive transgene expression and because of zygosity is not assessable by means of 
PCR technique, APP/PS1 breeding was always performed by mating ♂APP/PS1+/0 with 
♀APP/PS10/0. 
Due to the different background strains of APP/PS1 (C57BL/6J) and ABCko strains (FVB), 
the APP/PS1 transgene had to be introduced by crossbreeding the APP/PS1-C57BL/6J with 
the respective ABCko-FVB mice for at least 9 generations to ensure maximum background 
homogeneity. To do so, male APP/PS1
+/0
 mice were bred to female FVB mice. The resulting 
male APP/PS1
+/0
 mixed C57BL/6J/FVB offspring were each repeatedly bred to female 
homogeneous FVB mice for at least another 8 generations. Thereby the APP/PS1 transgene 
could be transferred from the C57BL/6J into the FVB background. Further crossbreeding with 
the respective ABC knockout strains only needed two generations to introduce the FVB-
APP/PS1 transgene into the FVB-ABC knockout strains (F0 ♂APP/PS1
+/0
 x  F0 ♀ABC
0/0  
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F1 ♂APP/PS1
+/0
-ABC
+/0
 x F1 ♀APP/PS1
0/0
-ABC
+/0
  F2 APP/PS1
+/0
-ABC
0/0
). The individual 
mice’s genotypes were analyzed by means of PCR techniques as described in 3.9.1.2.  
3.4.3 BrdU application 
5’-bromo-deoxyurodine (BrdU) is a bromine-labeled thymidine-analog. If present, BrdU is 
incorporated instead of thymidine into newly synthesized DNA during the cell cycle’s S-
phase.  The detection of DNA-incorporated BrdU, by means of immunological techniques, 
allows the detection of newly synthesized DNA and thereby proliferative activity [106].  For 
the histological detection of proliferative activity in the neurogenic zone of the hippocampus, 
BrdU was applied to the animals for 7 days prior to sacrifice.  
To all animals, used for histological experiments, BrdU was administered daily in form of an 
intraperitoneal injection of 50µg/g body weight (Table 2). BrdU was therefore diluted in 
sterile saline (NaCl 0.9%, Bayer) to a concentration 10mg/mL. 
 FVB ABCB1
0/0
 ABCG2
0/0
 ABCC1
0/0
 
Controls 3♀ / 3♂ 3♀ / 3♂ 3♀ / 3♂ 3♀ / 3♂ 
CCI 3♀ / 3♂ 3♀ / 3♂ 3♀ / 3♂ 3♀ / 3♂ 
Table 2: Animals which have received BrdU administrations 
 
3.4.4 Controlled cortical impact 
Resident NSPCs of the neurogenic brain regions are known to be able to compensate loss of 
neurons during neurodegenerative processes in limited amounts. Traumatic brain injury for 
example is a neurogenic effect, able to activate proliferation and differentiation of NSPCs 
[107]. The controlled cortical impact (CCI) is a conventional model of traumatic brain injury 
commonly used for studies of adult neurogenesis [107, 108].  
For each group (FVB controls, ABCB1
0/0
, ABCG2
0/0
, ABCC1
0/0
), 6 mice (3 males, 3 females) 
were used for controlled cortical impact-surgery at the age of 90 days (Table 2).  
The animals were anesthetized using a ketamine (Ketanest, Pfizer Pharma)/xylazin (Rompun, 
Bayer) mixture. Both injectable solutions were diluted in sterile saline (NaCl 0.9%, Bayer) to 
a final concentration of 1.9mg/mL ketamin and 0.5mg/mL xylazine. The mixture was 
administered intraperitoneal with a volume of 20µg/g bodyweight. Within 5 minutes the 
animals were anesthetized and ready for surgery. Anesthesia lasted for ca. 20 minutes. After 
further 30 minutes animals were fully awakened. 
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The animals were put into a stereotactic frame (Motorized standard lab stereotaxic, Stoelting 
Co). After sanitizing the scalp with ethanol (70%) a midline incision exposed the skull. A drill 
(ø 2mm, Dremel) was used to open the skull at position bregma -2.0mm anterior and bregma -
2.0mm lateral. A steel cannula of 1.2mm in diameter (B. Braun) with a manually deformed tip 
was used as impact device for the CCI. The impact device was driven 2.2mm into the cortex 
right above the hippocampus. The wound was closed using suture clips after surgery. The 
animals were positioned under an infrared lamp until fully awakened to prevent hypothermia.  
3.5 Biopsy 
3.5.1 Sample preparation for histological and molecular biological experiments 
Materials needed for sample preparation:  
- Dissecting set  
- Micro-tubes 
- Paraformaldehyde (PFA 4% in PBS) 
- Liquid nitrogen 
Animals were killed by cervical dislocation. Animals were transcardially perfused with 20mL 
PBS (10x: 0.137 mM NaCl, 2.7 mM KCl, 8.0mM Na2HPO4, in dH2O, pH 7.4, Sigma-
Aldrich). If whole brains were used for histological analyzes, animals were perfused 
additionally with 20mL PFA (paraformaldehyde 4% in PBS, Formafix Switzerland AG). 
Scalp was cut using small scissors and the skull was opened by use of forceps at the 
commissure between the parietal and interparietal bone fragments. The interparietal bone 
fragment was extracted first, before elevating both parietal and frontal bone fragments with 
great care to expose the brain. A small and flat spatula is used to lift the brain out of the 
opened skull. The brains were cut sagittal to use each hemisphere for further processing for 
either molecular biological experiments (snap frozen in liquid nitrogen) or histological 
experiments (put into paraformaldehyde for tissue fixation).   
3.5.2 Sample preparation for cell culturing experiments 
Material needed for tissue preparation: 
- Dissecting set (sterile) 
- Sterile centrifuge tubes 50mL / 15 mL (sterile) 
- Culture dishes 50mm / 100 mm (sterile) 
- ice box 
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- Microscope (Stemi D4, Zeiss) 
- Ethanol (70%) for disinfection 
- aCSF media pH: 7.4 (sterile and ice cold) 
Components MW C [mM] 
NaCl 58.44 124 
KCl 74.56 5 
MgCl2*(6H20) 203.3 3.2 
CaCl2*(2H2O) 147.02 0.1 
NaHCO3 84.01 26 
D-glucose 180.16 100 
Pen/Strep   
Table 3: Artificial CSF-media 
 
3.6 Histology 
3.6.1 Sample preparation 
For paraffin embedded tissue. 
Tissue samples were post-fixed in PFA for 14 days. After fixation, tissue samples were 
dehydrated before embedding in paraffin (Table 2). 
Step Reagent Duration [min] 
1 PFA 4% 5 
2 Ethanol 70% 180 
3 Ethanol 80% 60 
4 Ethanol 80% 120 
5 Ethanol 90% 60 
6 Ethanol 90% 60 
7 Ethanol abs. 120 
8 Ethanol abs. 120 
9 Xylene 120 
10 Xylene 120 
11 Paraffin 60°C 120 
12 Paraffin 60°C 120 
Table 4: Tissue dehydration and paraffin embedding 
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Embedding tissue for cryo-slices 
Tissue samples were post-fixed for 24 hours in PFA. After fixation, tissue was immersed 
sequentially in 15% and 25% sucrose (in PBS) at 4°C for 2 hours each. Brain hemispheres 
were put on cork plates and completely covered with OCT-compound (LEICA, Germany) and 
snap-frozen with liquid nitrogen. Samples were stored at -20°C.  
3.6.2 Immunohistochemistry on paraffin slices 
Coronal sections (5µm thick) were cut from paraffin embedded brains and mounted on glass 
slides. Sections had to be deparaffinized prior to immunohistochemical protocols (Table 5).  
Step Reagent Duration [min] 
1 Xylene 10 
2 Xylene 10 
3 Ethanol abs. 2 
4 Ethanol 95% 1 
5 Ethanol 70% 1 
6 Ethanol 50% 1 
7 Ethanol 30% 1 
8 NaCl 0.85% 2 
9 PBS 2 
Table 5: Deparaffinization protocol 
Immunostaining was initiated after blocking endogenous peroxidase (5min). Primary 
antibodies against NeuN were incubated routinely for 30min at room temperature with a 
dilution of 1:200. Primary antibodies were detected with the Bond-Max
TM
 Bond Polymer 
Refine Detection-Kit and standard protocol DABR30 (Leica, Germany). The stained slides 
were dried and covered with coverslips using Pertex mounting media (Leica, Germany). 
3.6.3 Immunofluorescence on cryo section 
Cryo sections (16µm thick) were cut using a cryostat (CM 350S, Leica). Cryo-slices were 
stained free-floating. Prior to incubation with antibodies, DNA had to be denatured by 
incubating slices for 30min in 1.5M HCl at 37°C. The DNA denaturation step was followed 
by three subsequent washing steps, incubating the slices for 10min each in PBS. To block 
unspecific protein bindings, the slices were incubated for 1h in blocking buffer containing 5% 
chicken serum (vector labs) and Triton X-100 (0.05%), for blocking unspecific antigen 
binding and membrane permeabilization, diluted in PBS. Slices were incubated overnight at 
4°C with the appropriate primary antibody combinations (Table 6) diluted in blocking buffer. 
Primary antibody incubation was followed by three subsequent washing steps in PBS for 
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10min each. The slices were incubated with the appropriate secondary antibodies (Table 6), 
diluted in PBS, for 1h in the dark. Incubation with secondary antibodies was followed again 
by 3 subsequent washing steps with PBS for 10min each in the dark. To stain nuclear DNA, 
slices were rinsed for 10sec in DAPI solution (1µg DAPI/1mL PBS) before the final washing 
step in PBS. The slices were mounted on glass slides and dried for 30min in the dark. After 
drying the slices were embedded in DePex (Serva) and covered with glass coverslips.   
Combination Primary antibody Secondary antibody 
Sox2 Anti-BrdU Anti-mouse-Cy2 
Anti-Sox2 Anti-goat-Cy3 
DCX Anti-Brdu Anti-mouse-Cy2 
Anti-DCX Anti-goat-Cy3 
Calretinin Anti-Brdu Anti-mouse-Cy2 
Anti-Calretinin Anti-goat-Cy3 
Table 6: Antibody combinations 
3.6.4 Nissl staining on cryo slices 
The Nissl stain is a classical histological staining technique which is used to stain nucleotide 
rich parts of the cell (nucleus, endoplasmic reticulum). The Nissl bodies, named after the 
german neurologist Franz Nissl (1860-1919), are rough endoplasmic reticulum with lots of 
free ribosomes. A common Nissl stain is obtained by the thiazine stain cresyl violett. 
Cryo slices were mounted on glass slides and were than further processed for Nissl staining. 
Needed materials: 
- Staining dishes and slide racks 
- Glass slides and cover slips 
- Deionized H2O 
- Ethanol 100% 
- Glacial acetic acid 
- Cresyl violet (add 1.25g cresyl violet and 0.75mL glacial acetic acid to 250mL 
deionized H2O) 
- Acid 70% ethanol (2mL glacial acetic acid in 200mL 70% ethanol) 
- Mounting media (DePex) 
 The slices were prepared as explained in Table 7.  
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Washing out lipids and fatty acids 95% ethanol 15min 
70% ethanol 1min 
50% ethanol 1min 
Rehydration Deionized H2O 2min 
Deionized H2O 1min 
Cresyl violet stain 2min 
Staining Deionized H2O 1min 
Dehydration 50% ethanol 1min 
70% acid ethanol 1min 
95% ethanol 1min 
95% ethanol A few dips 
100% ethanol 1min 
Mounting Mounting in DePex  
Table 7: Nissl staining protocol using cresyl violet   
Microphotographs of the stained slices were prepared using a bright field microscope with a 
digital camera mount. The images were processed using the AxioVision software package 
(Zeiss). An area of the hippocampal granular zone of at least 500µm length was measured and 
cells within this area were counted. The cell number was normalized to [n cells/500µm] based 
on the measured area length.   
3.7 Microscopy techniques 
3.7.1 Bright field microscopy 
Bright field microscopy was performed using a computerized semi-automated Mirax Desk 
microscope (Zeiss, Germany). The Mirax Desk system allowed the digitization of whole 
tissue sections. The tissue was digitized at a resolution of 0.23µm/pixel. Further processing 
was achieved with the Axiovision software suite (Zeiss, Germany).  
3.7.2 Confocal laser scanning microscopy 
Microphotographs of fluoresecence labeled cryo-slices were achieved by using the confocal 
laser scanning microscope LSM700 (Zeiss, Germany) equipped with solid state lasers 
emitting at wavelengths of 405nm, 488nm, 555nm and 639nm. Microphotographs were taken 
using a 63x oil emersion objective (Zeiss) at a resolution of 1024 x 1024pixel. 
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3.8 Cell culture 
3.8.1 Isolation of neuronal stem and progenitor cells from the subgranular zone 
Neural stem and progenitor cells were isolated according to established protocols from the 
hippocampi of young adult mice (around 50d of age) from all of the studied mouse strains 
(FVB, ABCB1
0/0
, ABCG2
0/0
, ABCC1
0/0
) [109]. 
Animals were sacrificed by cervical dislocation. Animal’s heads were sterilized afterwards by 
rinsing with 70% ethanol. Scalp was cut sagittal to expose the skull. The skull was cut along 
the sagittal suture and the interparietal, parietal and frontal bones were dissected to expose the 
brain. The brains were scooped into petri dishes containing ice-cold and sterile aCSF media 
(Table 3). The brains were positioned flat on their ventral surfaces. A scalpel was used to 
make a coronal cut 6-8mm from the olfactory bulbs. A second coronal cut is used to dissect a 
ca. 2mm thick slice embodying the lateral ventricles. A fine curved scissor was used to isolate 
the lateral ventricles from the surrounding tissue. The isolated ventricular tissue was placed 
into a new petri dish containing aCSF media and was thoroughly minced using a scalpel.  
3.8.2 Culture and passage of neurosphere cultures 
Minced tissue was transferred into a 15mL sterile centrifuge tube. After centrifuging at 200g 
for 8min (centrifuge Hermle Z 400 K), the supernatant was discarded and the tissue was 
dissociated for 15min at 37°C under repeated agitation using 2mL warm Trypsin/EDTA 
solution (Invitrogen Corp.). After dissociation process, 10mL NeuroCult Basal media was 
added and tissue samples were centrifuged for 8min at 200g. After discarding the supernatant, 
an additional washing step was performed using 10mL NeuroCult Basal media. After 
resuspending the pellet in 1mL NeuroCult Basal media, cells were mechanically dissociated 
by pipetting the cell suspension in and out for 50 times. Cell concentration was analyzed with 
a hemocytometer (Fuchs-Rosenthal). To discriminate vital cells from dead cells and debris, 
cell suspension was mixed 1:2 with Trypan Blue. Trypan blue allows the discrimination of 
bright living cells from blue stained dead cells due to its trait of being expelled in living cells 
but being accumulated in dead cells. Only bright cells with a clearly round shape were 
counted within the grid area corresponding to 0.2µl were counted and used to extrapolate the 
overall cell concentration of the cell suspension. 
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NeuroCult™ Basal medium, StemCell Inc. 90mL 
NeuroCult™ proliferation supplements, StemCell Inc. 10mL 
EGF 100µl [10µg/mL] 
FGF 50µl [10µg/mL] 
Heparin 50µl [0.2%] 
Table 8: Complete proliferation medium (100mL) 
Cells were seeded at a concentration of 1.9 x 10
5
 cells per 10mL complete proliferation 
medium (Table 8) in T-25cm² flasks and incubated at 37°C and 5% CO2 (Incubator CO2, 
Binder). Cells were allowed to proliferate until neurospheres were grown to a size of 100-
150µm. Thus, cultures were passaged every 7 to 10 days. Therefore cultures were transferred 
into 15mL flasks and centrifuged at 200g for 8min. The supernatant was discarded. The cell 
pellet was resuspended in 1mL complete proliferation medium and the neurospheres were 
mechanically dissociated using a pipette. The cell concentration was counted using a 
hemocytometer and cells were re-cultured at a concentration of 1 x 10
5
 cells in 10mL 
medium. Cell lines were passaged at least 4 times prior to usage for further experiments. 
3.8.3 Proliferation experiments 
To determine the proliferation capacity of NSPCs, cells were seeded on matrigel coated 
coverslips and incubated for 24h at 37°C and 5% CO2. BrdU incorporation was quantified via 
immunofluorescence. The relative amount of BrdU labeled cells reflects the proliferative 
activity of the cell culture. 
Sterile coverslips were put into 24-well culture plates. Coverslips were coated by adding 500µ 
L ice-cold NeuroCult Basal medium with Matrigel (2mg/24mL Basal medium). Matrigel was 
allowed to coagulate over night at 4°C. NSPCs were seeded at a concentration of 5 x 10
4
 
cells/well in complete proliferation medium for 24h. Half an hour prior to fixation BrdU 
(10µM final concentration) was added to the cell cultures. Cells were fixated for 20min using 
PFA (4% in PBS). After three washing steps with PBS, DNA was denatured with 1.5M HCl 
at 37°C for 30min. After three additional washing steps with PBS, cells were incubated in 
blocking buffer (10% chicken serum, 0.05% Triton X-100 in PBS) for 1h. Anti-BrdU 
antibody (1:500) was incubated overnight in blocking solution. After 3 additional washing 
steps with PBS, anti-mouse Cy3 (1:1000 in PBS) was incubated 1h to label anti-BrdU 
antibodies bound to BrdU incorporated into DNA of newly proliferated cells. Coverslips were 
washed three times with PBS and were incubated in DAPI solution (1µg/mL in distilled 
water) for 5sec prior to a final washing step in PBS. Coverslips were dried in the dark for 
3min at 37°C before embedding in DePex on glass slides. 
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3.8.4 Differentiation experiments 
To determine the neuronal differentiation capacity, NSPCs were seeded on matrigel coated 
coverslips under differentiation conditions. The amount of Tuj1
+
 cells (neurons) in relation to 
the overall cell number reflects the capability for neuronal differentiation of NSPCs. 
NeuroCult™ Basal medium, StemCell Inc. 90mL 
NeuroCult™ differentiation supplements, StemCell Inc. 10mL 
Table 9: Complete differentiation medium (100mL) 
Sterile coverslips were put into 24-well culture plates. Coverslips were coated by adding 
500µL ice-cold NeuroCult Basal medium with Matrigel (2mg/24mL Basal medium) to the 
coverslip filled wells. Matrigel was allowed to coagulate over night at 4°C. NSPCs were 
seeded at a concentration of 1 x 10
5
 cells/well in complete differentiation medium (Table 9). 
After 24h the medium was replaced by fresh differentiation medium. The cells were allowed 
to differentiate for 72h. Thereafter cells were fixated for 20min using PFA (4% in PBS). After 
three washing steps with PBS, cells were incubated in blocking buffer (10% chicken serum, 
0.05% Triton X-100 in PBS) for 1h. Than the cells were incubated with the primary 
antibodies against -III-tubulin (Tuj1, Covance, 1:500) and glial fibrilary acid protein (anti-
GFAP, DAKO, 1:2000) diluted in blocking buffer overnight at 4°C. Three subsequent 
washing steps with PBS for 10min each followed the primary antibody incubation. The 
secondary antibodies against GFAP (anti-rabbit Cy2, Dianova, 1:1000) and -III-tubulin 
(anti-mouse Cy3, Dianova, 1:1000) were diluted in PBS. The cells were incubated with the 
secondary antibodies at room temperature for 1h in the dark. After three additional washing 
steps (in PBS for 10min each) in the dark, the cells were rinsed for ca. 10sec in DAPI 
(1µg/mL in water) and finally rinsed in PBS before drying for 30min in the dark. The 
coverslips containing the labeled cell cultures were mounted on glass-slides using DePex.    
3.9 Molecular biological experiments 
3.9.1 Nucleic acid based methods 
3.9.1.1 DNA extraction 
DNA extraction was needed for genotyping purpose in order to organize the breeding 
procedures after determining the actual state of transgene or knock out inheritance by each 
animal.  
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For genotyping, the sample material had to be retrieved. Therefore, the tail was cut ca. 4mm 
from the tip to retrieve a tissue sample from all animals, which were bred in house. The tissue 
samples were digested overnight in DNA extraction buffer (Table 10) at 55°C under vigorous 
agitation in a thermo block to let the proteinase k digest all the proteins and expose the nucleic 
acids. Samples were incubated at 95°C for additional 30min to denature the proteinase k and  
were than stored at 4°C until further use.  
DNA extraction buffer 
Tris-HCl, pH9.0 10mM 
KCl 1M 
Igepal A630 0.4%  
Tween 20 0.1%  
Proteinase K 1.5%  
Table 10: DNA extraction buffer 
 
3.9.1.2 Polymerase-chain-reaction (PCR) 
The PCR technique allows the amplification of distinct DNA sequences by using a DNA 
polymerase and adequate primer pairs, enclosing the sequence of interest, in vitro. The PCR is 
characterized by three distinct steps of action. First, the DNA has to be denatured into two 
single strands at a temperature of 95°C. In the second step the primer pairs have to bind their 
complementary target positions at the 3’ ends of the target sequence on both sense- and anti-
sense strand at a primer sequence depending annealing temperature which is suitable for the 
annealing of both primers. In the last step the DNA polymerase binds the “primed” DNA 
positions and starts the elongation of the primer DNA in 3’ direction according to the 
complementary strand’s DNA sequence. These three steps have to be repeated several times 
depending on the initial concentration of the template DNA to obtain sufficient amounts of 
target DNA [110]. 
To perform PCRs, a commercially available PCR kit (Taq PCR kit, Qiagen) was used. One 
microliter DNA extract was used as template for polymerase chain reaction (Table 13 - Table 
16). Amplification reaction was performed using a thermocycler (TProfessional Basic, 
Biometra). 10µl amplificate was used for agarose gel electrophoresis (2% agarose in TAE-
Buffer [Table 11], containing 3µl ethidium bromide/100mL). After electrophoretic separation 
of different sized DNA fragments, gels were illuminated by an ultraviolet illuminator and 
photographed for documentary means (Gel documentation System, DeconScience Tec).  
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TAE-Buffer (50x) 
Tris-base 242g 
Acetic acid (glacial) 57.1mL 
EDTA 100mL 0.5M EDTA 
Table 11: TAE-buffer (50x) 
 
ABCB1 
wt (600bp) 
ko (540bp) 
N192 wt 5’-GAGAAACCATGTCCTTCCAG-3’ 
N193 wt 5’-AAGCTGTGCATGATTCTGGG-3’ 
N194 Ko 5’-GCCTTCTATCGCCTTCTTGA-3’ 
ABCG2 
wt (368bp) 
ko (595bp) 
N218 wt for 5’-CTTCTCCATTCATCAGCCTCG-3’ 
N219 wt rev 5’-CAGTCGATGGATCCACTTAGG-3’ 
N207 ko rev 5’-GGAGCAAAGCTGCTATTGGC-3’ 
ABCC1 
wt (900bp) 
ko (600bp) 
N131 wt rev 5’-AAGACAAGGGCTTGGGATGC-3’ 
N221 wt for 5’-CCATCTCTGAGATCTTGCCG-3’ 
N207 ko rev 5’-GGAGCAAAGCTGCTATTGGC-3’ 
APP/PS1 transgene 
(246bp) 
N205 for 5’-GAATTCCGACATGACTCAGG 3’ 
N206 rev 5’-GTTCTGCTGCATCTTGGACA-3’ 
Actin as internal control 
(400bp) 
N278 for 5’ CCTCATGAAGATCCTGACCG 3’ 
N279 rev 5‘ GCACTGTGTTGGCATAGAGG 3’ 
Table 12: PCR primers for genotyping analyzes 
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ABCB1 Cstock Cfinal V 
H2O   2.7µL 
Taq mastermix   5.5µL 
Primer N192 10µM 1.15µM 1.3µL 
Primer N193 10µM 0.7µM 0.7µL 
Primer N194 10µM 0.7µM 0.7µL 
Vmastermix   10.9µL 
VDNA   1µL 
Vtotal   11.9µL 
Thermocycler program 
ABCB1 
 Initial denaturation 5min 95°C 
Cycle 35x 
DNA denaturation 30sec  95°C 
Primer annealing 60sec 58°C 
Elongation 60sec 72°C 
 Final elongation 5min 72°C 
 Storage ∞ 4°C 
Table 13: ABCB1 PCR mastermix and thermocycler protocol 
 
ABCG2 Cstock Cfinal V 
H2O   5.1µL 
Taq mastermix   5.5µL 
Primer N218 25µM 0.28µM 0.1µL 
Primer N219 25µM 0.28µM 0.1µL 
Primer N207 25µM 0.28µM 0.1µL 
Vmastermix   10.9µL 
VDNA   1µL 
Vtotal   11.9µL 
Thermocycler program 
ABCG2 
 Initial denaturation 5min 95°C 
Cycle 35x 
DNA denaturation 45sec  95°C 
Primer annealing 60sec 62°C 
Elongation 90sec 72°C 
 Final elongation 5min 72°C 
 Storage ∞ 4°C 
Table 14: ABCG2 PCR mastermix and thermocycler protocol 
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ABCC1 Cstock Cfinal V 
H2O   4.7µL 
Taq mastermix   5.5µL 
Primer N131 25µM 1µM 0.4µL 
Primer N221 25µM 0.55µM 0.2µL 
Primer N207 25µM 0.25µM 0.1µL 
Vmastermix   10.9µL 
VDNA   1µL 
Vtotal   11.9µL 
Thermocycler program 
ABCC1 
 Initial denaturation 5min 95°C 
Cycle 35x 
DNA denaturation 45sec  95°C 
Primer annealing 60sec 62°C 
Elongation 90sec 72°C 
 Final elongation 5min 72°C 
 Storage ∞ 4°C 
Table 15: ABCC1 PCR mastermix and thermocycler protocol 
 
APP/PS1 Cstock Cfinal V 
H2O   3.5µL 
Taq mastermix   5.5µL 
Primer N205 (APP/PS1) 10µM 0.45µM 0.5µL 
Primer N206 (APP/PS1) 10µM 0.45µM 0.5µL 
Primer N278 (Actin) 10µM 0.45µM 0.5µL 
Primer N279 (Actin) 10µM 0.45µM 0.5µL 
Vmastermix   11µL 
VDNA   1µL 
Vtotal   12µL 
Thermocycler program 
APP/PS1 
 Initial denaturation 5min 95°C 
Cycle 35x 
DNA denaturation 45sec  95°C 
Primer annealing 45sec 62°C 
Elongation 45sec 72°C 
 Final elongation 5min 72°C 
 Storage ∞ 4°C 
Table 16: APP/PS1 PCR mastermix and thermocycler protocol 
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3.9.1.3 RNA-extraction 
RNA extraction was performed according to the technique initially established by 
Chomczynski and Sacchi in 1987 [111]. The TRIzol (Invitrogen product name) method 
combines the advantages of the acid phenol and guanidine isothiocyanate extraction methods 
leading to powerful protein denaturation, inactivating RNases (guanidine isothiocyanate) and 
enabling RNA separation into the aqueous supernatant phase (acidic phenol/chloroform) for 
easy RNA extraction. The method is widely considered as to deliver best quality RNA yield.  
Tissue samples were incubated in TRIzol (Invitrogen) for protein denaturation and RNase 
inactivation using 1mL/100mg tissue. The samples were homogenized at 5000rpm for 15sec 
using a cell homogenizer (Precellys24, Bertin Technologies). The mixture was incubated with 
chloroform 100µl/1mL TRIzol for DNA precipitation for 3min at room temperature. The 
upper aqueous phase was carefully aspirated for further processing into a sterile microfuge 
tube (1.5mL). RNA was precipitated incubating aqueous phase with 500µL/mL TRIzol for 
15min at room temperature. The samples were centrifuged at 12.000g for 15min at 4°C. The 
supernatant was discarded and the RNA pellet was washed twice with 1mL RNase free 
ethanol (75%) after vigorous vortexing and subsequent centrifugation at 12.000g for 5min at 
4°C. After discarding the ethanol, pellets were dried for 15min at room temperature. The 
dried RNA pellets were solubilized in RNase free water (1µl/1mg tissue sample). The 
solubilized RNA was stored to -80°C until further use. 
To analyze mRNA expression in NSPCs, tissue samples from the neurosphere cultures were 
taken 3 days after their last passage. The neurosphere cultures were aspirated from the culture 
flasks and transferred into 15ml sterile centrifuge tubes. Adhering cells were scraped off the 
flask using a sterile cell scraper and also transferred to the according sterile micro-centrifuge 
tube. The cultures were centrifuged at 200g for 8min at 4°C. The culture medium was 
discarded and the RNA was extracted using the TRIzol method as described above. 
RNA extraction from dissected hippocampi 
The mRNA samples were obtained from brain hemispheres, which were submersed in the 
RNA-preservative RNAlater (Applied Biosystems) to restore the RNA expression profile. The 
hippocampus was dissected for long-term storage or RNA preparation at the latest 48h after 
harvesting the tissue samples. The preservative denatured the tissue samples, making the 
dissection of the hippocampus easy manageable. Therefore the brain hemispheres were put 
under a stereo microscope into a 50mm petri dish containing RNAlater. Using fine forceps 
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and micro-scissors the hippocampus was dissected. The RNA was prepared from the 
hippocampus and stored as described in above. 
3.9.1.4 Quantitative real-time PCR (qRT-PCR) 
For quantification of mRNA expression of distinct genes, the mRNA sample has to be 
transcribed into DNA first, using a reverse transcriptase. To quantify the expression of the 
target gene, the mRNA, transcribed into DNA, has to be amplified and its increasing 
concentration has to be detected in real-time. While early approaches to qRT-PCR used 
fluorescence probes like ethidium bromide, simply intercalating with amplified DNA and 
intensifying fluorescence activity with increasing DNA concentration [112], more recent and 
highly sophisticated approaches use an additional probe sequence that fluoresces upon 
hybridization (LightCycler, Roche) or hydrolysis (TaqMan, Applied Biosystems) [113]. In the 
case of TaqMan chemistry, additionally to the primer pair, needed for DNA amplification, a 
DNA probe (TaqMan probe) is used, binding the DNA sequence between the two primer 
positions. The additional TaqMan probe contains a fluorophore (5’-end) and a quencher (3’-
end). As long as the TaqMan probe is intact, the quencher suppresses the fluorophore’s 
fluorescence activity. During amplification the Taq polymerase is decomposing the TaqMan 
probe due to its 5’ to 3’ exonuclease activity and releases the fluorophore and quencher, 
thereby separation of the fluorophore from its quencher is leading to increased fluorescence 
activity. Here, the amplitude of the fluorescence signal is directly related to the concentration 
of newly amplified DNA. Measuring the fluorescence signal in relation to the number of 
amplification cycles allows conclusions about the initial RNA concentration.  
An integrated Reverse Transcriptase and TaqMan reaction protocol was used to perform 
reverse transcriptase and quantitative real-time PCR in the same reaction tube as subsequent 
reactions. The One-Step RT-PCR kit (Applied Biosystems) allows both, the reverse 
transcription and polymerase chain reaction in one buffer system by utilization of a 
recombinant Moloney Murine Leukemia Virus Reverse Transcriptase (Applied Biosystems) 
and thermal stable DNA polymerase (AmpliTaq Gold, Applied Biosystems). TaqMan probes 
were purchased from Applied Biosystems (Table 17). For qRT-PCR 10pg RNA were used as 
template. Therefore RNA samples were diluted to a concentration of 5pg RNA/µl. 
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Gene of interest Label ID 
GAPDH (reference) FAM Mm99999915_g1 
ABCB1a VIC Mm00440761_m1 
ABCB1b VIC Mm00440736_m1 
ABCG2 VIC Mm00496364_m1 
ABCC1 VIC Mm00456156_m1 
Table 17: TaqMan probes 
The mastermix for RT-PCR was provided according to Table 18. All samples were analyzed 
in triplicates plus two additional blank samples containing only mastermix without RNA 
samples. Analyzes were performed as multiplex measurements simultaneously measuring a 
Vic- and FAM- labeled TaqMan assay in each well. A Rotor-Gene Q (Qiagen) was used for 
lightcycling and analyzes.  
qRT-PCR mastermix 
 
H2O 3.625µl 
MM 7.500µl 
RT-MM 0.375µl 
Assay-VIC 0.750µl 
Assay-FAM 0.750µl 
VMastermix 13.000µl 
VRNA 2.000µl 
VTotal 15µl 
Lightcycler program 
RT reaction  
reverse transcription 30min @ 48°C 
RT inactivation 10min @ 95°C 
PCR-reaction 40x 
DNA denaturation 15sec @ 95°C 
annealing and elongation 60sec @ 95°C 
Table 18: qRT-PCR mastermix and lightcycling program 
The fluorescence intensities of the target genes were compared to those of the according 
internal control (GAPDH) using the ∆∆CT method [114] and were described as fold-changes 
compared to the control.   
3.10 Oligomeric Aβ42 preparation  
Monomerization and storage of Aβ42 
HPLC purified and lyophilized Aβ42 (Sigma-Aldrich, USA) was dissolved in 
hexafluoroisopropanol (HFIP) to obtain a concentration of 1mM Aβ42 in HFIP in 
microcentrifuge tubes. The solution was incubated for 60min at room temperature. Afterwards 
the solution is set back on ice for 5-10min. The HFIP was allowed to evaporate until the 
3 Experimental procedures 
41 
microcentrifuge tubes were completely dried leaving a film of monomeric Aβ42. The 
monomeric Aβ42 was stored at -80°C until further use [115].  
Oligomeric Aβ42 incubation protocol 
Dry monomeric Aβ42 films were dissolved in fresh DMSO (Sigma-Aldrich, USA) to a final 
concentration of 5mM. The solution was further diluted in DMEM/F12 media to a final 
concentration of 100µM. The solution was incubated for 24h at 4°C. The oligomeric Aβ42 
solution was afterwards directly used for cell culture experiments at a concentration of 1µM 
[116]. 
3.11 Behavioral experiments 
3.11.1 Y-maze 
The y-maze testing apparatus consist of a y-shaped maze with three arms at a 120° angle from 
each other. The dimensions of each of the walled arms are 325mm (length), 85mm (width) 
and 150mm (height). The test is used to assess the willingness of mice to explore new 
environments. Due to the explorative nature of rodents, the mice will rather investigate a new 
arm, than entering a previously visited arm. A normally behaving mouse should show a 
tendency to enter the less recently visited arm. The proper function of several parts of the 
brain (hippocampus, basal forebrain, prefrontal cortex) is needed to achieve normally in this 
task.  
Animals were tested once in the y-maze setup. The mice were put in the middle of the maze 
and were allowed to move freely within the maze. The movement was automatically tracked 
with an infrared camera and analyzed with the Video Mot software package (TSE Systems). 
The following parameters were assessed: running distance, number of arm entries, and 
percentage of alternating entries [117].  
3.11.2 Elevated plus-maze 
With the elevated plus maze (EPM) the overall anxiety level of the different mouse strains 
was assessed. The EPM is based on a simple principle, which says that the exploratory drive 
to examine a given arm is equal to each arm, while the anxiety driven avoidance to enter an 
unknown area is lower in enclosed arms compared to open arms, which results in increased 
exploration of the enclosed arms [118]. 
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Each mouse was tested once without prior training in the EPM apparatus (TSE Systems). The 
EPM consisted of plus-shaped platform 50cm above the ground consisting of 4 equal arms 
(300mm x 50mm) of which 2 confronting arms were enclosed by walls (150mm high) while 
the other two were open. Again, the mice were set in the middle of the maze and were 
allowed to move freely within the maze, while being recorded by an infrared camera for 5min. 
The following parameters were analyzed using the Video Mot software package (TSE 
Systems): number of closed arm entries, open arm entries, speed in each compartment, time 
spent in each set of arms and time spent in the central area [119]. 
3.11.3 Light/Dark-box 
The light/dark box (LDB) test incorporates the feature of light and open-space avoidance of 
the open field test, but its setup additionally allows one to monitor mice behavior within the 
dark (non-stress) compartment. 
All mice were tested once in the LDB setup. The box-shaped maze (500mm x 500mm x 
400mm) consisted of a darkened area (1/3
rd
) and an illuminated (~400Lux) compartment 
(2/3
rd
) which are connected by a door (60mm x 60mm). The experiments began by putting the 
animals in the middle of the open compartment, facing away from the door. The animals were 
allowed to move freely for 5min while being recorded by an infrared camera, even in the 
darkened compartment, throughout the test. The following parameters were analyzed using 
the Video Mot software package (TSE Systems):  duration of stay per compartment, distance 
travelled per compartment, transitions between compartments, and number of rearing in each 
compartment [120]. 
3.12 Statistical Analysis 
Data were analyzed using the software package Prism5 (Graph-Pad Software). All data are 
presented as arithmetic means (here referred to as “mean”) with their respective standard error 
of the mean (SEM). The unpaired, two-tailed Student’s t-Test was performed to assess for 
statistical significance. Data were deemed statistically significant with p≤0.05 (*p≤0.05; 
**p≤0.01; ***p≤0.001). 
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4 Results 
4.1 Comparative quantification of hippocampal neurogenesis 
4.1.1 Neurogenesis under normal conditions  
Molecular markers of neurogenic progenitors in the subgranular zone of the dentate gyrus 
were analyzed to assess the ABC transporter’s influence in adult neurogenesis.  To do so, 
NSPC’s at different states of differentiation were comparatively quantified in ABC deficient 
and control mouse strains. Earliest stem and progenitor cells were quantified by labeling with 
antibodies against Sox2, a transcription factor only expressed in early NSPCs making it a 
reliable marker of undifferentiated NSPCs [121, 122]. Beside the earliest NSPCs, also 
neuronal committed progenitors were quantified by labeling for the cytoskeletal protein 
Doublecortin (DCX) [123, 124]. Newly generated postmitotic neurons were quantified as well 
by labeling for the Calcium binding protein Calretinin which is only transiently expressed and 
is substituted by Calbindin during cellular maturation. [125]. 
The Sox2 positive NSPC pool was observed to be significantly altered as a result of distinct 
ABC transporter deficiency. In fact the Sox2
+
 cell pool was significantly increased (+17%) in 
mice lacking expression of ABCC1 compared to control mice. Therefore alterations were 
observed in neither ABCB1
0/0
 nor ABCG2
0/0
 mice (Figure 10A, Table 19). In contrast, 
quantification of the DCX
+
 early neuronal progenitor pool revealed a significant decrease of 
neuronal differentiation in mice lacking either expression of ABCB1 (-36%) or ABCG2 (-
23%) while no significant alterations were observed in ABCC1
0/0
 mice (Figure 10B, Table 
19). Quantification of Calretinin
+
 neurons revealed a similar result. In animals lacking 
expression of ABCB1 neuronal differentiation was decreased on the basis of significantly 
reduced numbers of Calretinin
+
 cells (-37%). No significant alterations were observed in mice 
lacking the expression of either ABCG2 or ABCC1 (Figure 10C, Table 19). Therefore 
quantification of BrdU incorporation did not show ABC deficiency-dependent impairments of 
cell proliferation (Figure 10D, Table 19) 
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Figure 10: ABCB1 deficiency impairs neuronal differentiation in the dentate gyrus. Shown are the relative 
quantities of cells positive for Sox2, DCX, Calretinin and BrdU in the SGZ of the dentate gyrus in ABC-
deficient mice as compared to the FVB controls.  Error bar: SEM; Significance vs. Ctrl: * p<0.05; **p<0.01 
 
NSPC cell counts 
 Strain MEAN rel MEAN ±SEM tTest vs. Ctrl n 
Sox2 
Ctrl 162,7 100,0% 6,4%  6 
ABCB1
0/0
 169,5 104,2% 7,6% p=0,689 6 
ABCG2
0/0
 177,4 109,0% 3,6% p=0,266 6 
ABCC1
0/0
 190,8 117,3% 2,5% p=0,049 4 
DCX 
Ctrl 47,7 100,0% 7,5%  6 
ABCB1
0/0
 30,4 63,7% 6,4% p=0,004 5 
ABCG2
0/0
 36,3 76,2% 5,0% p=0,026 6 
ABCC1
0/0
 44,0 92,3% 18,6% p=0,697 6 
Calretinin 
Ctrl 20,5 100,0% 6,9%  6 
ABCB1
0/0
 12,8 62,5% 7,8% p=0,002 5 
ABCG2
0/0
 19,1 92,8% 4,5% p=0,390 6 
ABCC1
0/0
 19,6 95,3% 14,2% p=0,769 6 
BrdU 
Ctrl 18,0 100,0% 10,6%  5 
ABCB1
0/0
 14,8 81,8% 12,5% p=0,246 5 
ABCG2
0/0
 17,3 95,8% 2,7% p=0,619 6 
ABCC1
0/0
 16,8 93,3% 13,4% p=0,605 6 
Table 19: NSPC cell counts 
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BrdU incorporation experiments revealed ABC transporter deficiency leading to altered rates 
of NSPC differentiation. 
Proliferation activity in the NSPC pool was assessed by quantifying the relative number of 
BrdU
+
 cell numbers in the poll of Sox2
+
, DCX
+
 and Calretinin
+
 cells. Therefore, BrdU was 
administered to the mice 7 days prior to harvesting the brain tissue. The absence of either one 
of the three analyzed ABC transporters led to significant decline of proliferating Sox2
+
 cells  
(-25% ABCB1
0/0
; -28% ABCG2
0/0
; -37% ABCC1
0/0
; Figure 11A/D, Table 20). In contrast, 
there were no significant changes in proliferation capacity observed in the DCX
+
 cell pool 
(Figure 11B/E). Therefore, BrdU uptake was significantly increased in ABCG2
0/0
 (+43%) and 
ABCC1
0/0
 (+51%) mice while there was no changed observed in ABCB1 deficient animals 
(Figure 11C/F, Table 20).   
NSPC cell counts, BrdU positive cell fractions 
 Strain MEAN ±SEM tTest vs. Ctrl n 
Sox2
+
/BrdU
+
 
Ctrl 6,7% 0,5%  4 
ABCB1
0/0
 5,0% 0,6% p=0,045 5 
ABCG2
0/0
 4,8% 0,2% p=0,012 6 
ABCC1
0/0
 4,2% 0,4% p=0,011 6 
DCX
+
/BrdU
+
 
Ctrl 27,4% 6,9%  4 
ABCB1
0/0
 21,3% 2,6% p=0,472 5 
ABCG2
0/0
 25,2% 4,4% p=0,803 6 
ABCC1
0/0
 24,7% 3,7% p=0,747 6 
Calretinin
+
/Brdu
+
 
Ctrl 19,6% 1,5%  4 
ABCB1
0/0
 23,3% 1,7% p=0,152 5 
ABCG2
0/0
 28,0% 3,0% p=0,039 6 
ABCC1
0/0
 29,5% 0,9% p=0,002 6 
Table 20: NSPC cell counts, BrdU positive cell fractions 
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Figure 11: ABCC1 deficiency impairs stem cell proliferation and accelerates late neuronal differentiation. 
The graphs show the newly generated population (BrdU incorporation) of Sox2
+
 (A), DCX
+
 (B) and Calretinin
+
 
(C) cells in the SGZ of the DG. The photomicrographs display expression examples for marker combinations: 
Sox2/BrdU (D), DCX/BrdU (E) and Calretinin/BrdU (F). Arrowheads indicate double-labeled cells. Error bar: 
SEM; Significance vs. Ctrl: * p<0.05; **p<0.01; Scale bar: 20µm 
 
4.1.2 Neurogenesis after controlled cortical impact  
Since traumatic brain injury is known to trigger neurogenesis [107], the controlled cortical 
injury model was utilized for analyzing the involvement of ABC transporters in 
neuroregenerative functions. Because ABC transporter depletion might only affect 
neurogenesis during disease state, the CCI paradigm [108] was chosen to amplify NSPC 
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proliferation and differentiation. As a result of the CCI surgery 7 days prior to analysis, 
neurogenesis was according to the literature [107, 108, 126] significantly increased in the 
dentate gyrus of the ipsilateral hemispheres  in all analyzed mouse strains compared to the 
respective contralateral hemisphere (Figure 12).  
 
Figure 12: Neurogenesis is induced by controlled cortical impact (CCI) trauma. The photomicrographs 
show the SGZ of the DG after CCI (LEFT: Control hemispheres; RIGHT: hemispheres after CCI). Shown are 
the marker combinations Sox2/BrdU (A), DCX/BrdU (B) and Calretinin/BrdU (C). Arrowheads indicate double 
labeled cells. Scale bar: 20µm 
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As a result of CCI surgery, neurogenesis was significantly increased in ipsilateral hemispheres 
compared to the non-affected control hemispheres of all analyzed mice (FVB, ABCB1
0/0
, 
ABCG2
0/0
, ABCC1
0/0
). Beside cell proliferation also the number of Sox2
+
 early NSPCs, 
DCX
+
 neuronal progenitors and newly generated Calretinin
+
 neurons was significantly 
increased in the ipsilateral hemisphere compared to the contralateral control hemispheres 
(Table 21). 
NSPC cell counts CCI 
  contralateral ipsilateral  
 Strain Mean rel 
Mean 
±SEM tTest vs. 
Ctrl 
Mean rel 
Mean 
±SEM tTest vs. 
Ctrl 
n 
S
o
x
2
 
Ctrl 180.7 100.0% 2.7%  216.7 120.0% 10.3%  5 
ABCB1
0/0
 153.8 85.1% 7.0% p=0.063 177.7 98.4% 3.8% p=0.042 6 
ABCG2
0/0
 171.7 95.0% 3.5% p=0.171 198.1 109.7% 3.6% p=0.414 6 
ABCC1
0/0
 162.2 89.8% 2.9% p=0.024 187.3 103.7% 2.8% p=0.048 6 
D
C
X
 
Ctrl 33.7 100.0% 5.3%  73.8 218.9% 4.5%  6 
ABCB1
0/0
 31.3 93.0% 6.8% p=0.215 47.5 140.9% 8.7% p=0.001 6 
ABCG2
0/0
 35.9 106.5% 12.6% p=0.663 64.5 191.2% 10.5% p=0.242 6 
ABCC1
0/0
 34.1 101.1% 4.3% p=0.874 49.6 147.2% 6.5% p=0.000 6 
C
al
re
ti
n
in
 Ctrl 14.6 100.0% 12.4%  31.2 212.9% 9.1%  5 
ABCB1
0/0
 14.5 99.4% 10.3% p=0.972 22.2 151.6% 11.2% p=0.045 5 
ABCG2
0/0
 17.9 120.6% 8.8% p=0.225 32.3 220.5% 10.1% p=0.804 6 
ABCC1
0/0
 15.3 104.5% 4.8% p=0.726 23.7 162.1% 6.6% p=0.039 6 
B
rd
U
 
Ctrl 19.6 100.0% 12.9%  76.6 390.1% 5.9%  6 
ABCB1
0/0
 16.3 83.0% 4.4% p=0.273 40.5 206.3% 15.3% p=0.001 5 
ABCG2
0/0
 15.7 80.1% 4.9% p=0.170 52.7 268.6% 18.5% p=0.049 6 
ABCC1
0/0
 17.0 100.0% 3.4% p=0.335 35.7 181.9% 5.5% p=0.000 6 
Table 21: NSPC cell counts CCI 
According to the results, ABC transporter expression influenced the amount of altered cell 
proliferation. In all ABC deficient strains the proliferation capacity, as observed in the 
ipsilateral hemispheres, was significantly reduced in comparison to the control strain (-47% 
ABCB1
0/0
; -31% ABCG2
0/0
; -53% ABCC1
0/0
, Figure 13A, Table 21). As the increased 
proliferation index implied, results indicated a significant increase in the Sox2
+
 cell pool in 
the CCI-affected brain hemispheres. Independently of ABC transporter expression status the 
Sox2+ cell pool was significantly increased in the ispilateral hemisphere compared to the 
respective contralateral control hemispheres (Figure 13B, Table 21). Even more affected by 
CCI treatment were the pools of DCX and Calretinin positive cells. CCI treatment led to a 
significant increase in neuronal differentiation due to extended numbers of DCX positive 
neuronal progenitors compared to the cell numbers in the control hemispheres. Still, ABC 
transporter deficiency affected the relative increase in neuronal differentiation of induced vs. 
control hemispheres when compared to the control mice. In comparison to the control mice, 
only ABCB1
0/0
 and ABCC1
0/0
 strains revealed a significant decrease of neuronal progenitors 
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(-36% ABCB1
0/0
; -33% ABCC1
0/0
), while ABCG2
0/0
 mice showed no impairments (Figure 
13C, Table 21). According to the quantification of DCX
+
 progenitors also Calretinin
+
 newly 
generated neurons were decreased in numbers in ABCB1
0/0
 (-29%) and ABCC1
0/0
 (-29%) 
while there was no deficit observed in mice lacking expression of ABCG2 (Figure 13D, Table 
4 Results 
50 
21).
 
Figure 13: CCI paradigm reveals ABC transporter’s significance in neurogenesis. Error bars: SEM; Significance vs. 
Ctrl: *p<0.05; **p<0.01; ***p<0.001 
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NSPC cell counts CCI. BrdU positive cell fraction 
  contralateral ipsilateral 
 Strain rel Mean ±SEM 
tTest vs. 
Ctrl 
rel Mean SEM tTest vs. Ctrl n 
Sox2
+
/BrdU
+
 
Ctrl 3.8% 0.7%  16.1% 1.1%  5 
ABCB1
0/0
 6.0% 0.6% p=0.039 11.6% 2.1% p=0.095 5 
ABCG2
0/0
 4.8% 0.3% p=0.181 10.4% 2.0% p=0.042 6 
ABCC1
0/0
 6.4% 0.6% p=0.016 9.1% 1.0% p=0.001 6 
DCX
+
/BrdU
+
 
Ctrl 29.9% 2.9%  51.5% 5.3%  6 
ABCB1
0/0
 25.0% 4.3% p=0.355 32.5% 6.4% p=0.001 5 
ABCG2
0/0
 28.7% 9.0% p=0.895 36.1% 4.4% p=0.050 6 
ABCC1
0/0
 27.4% 3.2% p=0.577 34.8% 5.2% p=0.048 6 
Calretinin
+
/ 
BrdU
+
 
Ctrl 35.1% 7.5%  38.4% 6.4%  5 
ABCB1
0/0
 40.6% 3.9% p=0.570 42.9% 8.0% p=0.671 4 
ABCG2
0/0
 25.5% 4.9% p=0.235 29.5% 4.4% p=0.284 5 
ABCC1
0/0
 42.4% 2.0% p=0.726 42.2% 3.3% p=0.590 6 
Table 22: NSPC cell counts CCI, BrdU positive cell fraction 
 
4.1.3 Impact of ABC transport deficiency on neurogenic functions in a mouse model of 
Alzheimer’s disease 
 
Figure 14: β-amyloid deposition enhances neurogenic functions in the hippocampus. The photomicrograph shows a 
tissue section stained for nuclear DNA (DAPI, blue), A deposition (green), glial fibrillary acid protein (yellow) and Sox2 
(red). Scale bar: 100µm 
Quantification of NSPCs in different states of differentiation was performed on cryo slices of 
transgenic ABC transporter deficient mice to assess the influence of the β-amyloid pathology 
on neurogenic processes within the hippocampal dentate gyrus.  
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Analyzes revealed significant effects of ABC deficiency in transgenic APP/PS1
+/0
 mice. Lack 
of expression of ABCB1 led to a significant increase in the number of Sox2 positive cells by 
16% while the difference in cell number was even greater in mice deficient for ABCG2 
(+19%) and ABCC1 (+22%) (Figure 15A, Table 23). While even non transgenic ABC 
deficient animals showed at least a trend towards increased NSPC cell number, which became 
only significant in ABCC
0/0
 mice, the differences were not yet significantly different in 
comparison to the respective transgenic AD model mice.  
 
Figure 15: AD pathology affects adult neurogenesis in dependency of ABC expression. The diagram 
indicates the relative change of cell counts in ABC deficient transgenic mice in comparison to their respective 
non-transgenic counterparts. The respective non-transgenic counterparts were set as hundred percent each. Error 
bars: SEM; Significance vs. APP/PS1
+/0
 Ctrl: *p<0.05; **p<0.01; ***p<0.001; Significance vs. respective 
APP/PS1
0/0
 strain: +p<0.05; ++p<0.01; +++p<0.001 
The influence of β-amyloid deposition on the number of DCX+ neuronal progenitors appeared 
more significant. By comparing the ABC deficient transgenic mouse strains with the 
transgenic control group, only ABCB1
0/0
-APP/PS1
+/0
 mice revealed a significantly impaired 
number (-28%) of DCX
+
 neuronal progenitors (Figure 15B, Table 23). Interestingly, β-
amyloid deposition led to increased numbers of DCX positive progenitors in APP/PS1
+/0
 
controls (+52%) as like in ABCB1
0/0
 (+71%) and ABCG2
0/0
 (+172%) mice. Only in 
ABCC1
0/0
 transgenic mice the increase of the DCX positive progenitor pool did not become 
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statistically significant while at least indicating a trend towards the same direction (Figure 
15B, Table 23). 
NSPC cell counts of transgenic strains compared to non-transgenic strains 
 Strain rel Mean ±SEM tTest vs.Ctrl 
tTest vs non transgenic 
littermates 
n 
Sox2 
Ctrl 93% 3.4%  p=0.352 6 
ABCB1
0/0
 104% 2.4% p=0.005 p=0.628 6 
ABCG2
0/0
 102% 4.0% p=0.009 p=0.769 6 
ABCC1
0/0
 97% 5.1% p=0.012 p=0.558 4 
DCX 
Ctrl 152% 14.0%  p=0.008 .6 
ABCB1
0/0
 171% 15.8% p=0.032 p=0.004 6 
ABCG2
0/0
 272% 74.6% p=0.372 p=0.045 6 
ABCC1
0/0
 151% 10.2% p=0.505 p=0.064 4 
Calretinin 
Ctrl 264% 60.7%  p=0.023 6 
ABCB1
0/0
 159% 18.9% p=0.039 p=0.012 5 
ABCG2
0/0
 457% 137.7% p=0.284 p=0.027 6 
ABCC1
0/0
 209% 17.1% p=0.425 p=0.001 4 
BrdU 
Ctrl 168% 25.3%  p=0.046 6 
ABCB1
0/0
 141% 15.5% p=0.090 p=0.079 6 
ABCG2
0/0
 275% 59.1% p=0.155 p=0.014 6 
ABCC1
0/0
 142% 8.7% p=0.295 p=0.051 4 
Table 23: Transgene NSPC count relative to non-transgenic strains 
AD related β–amyloid pathology altered the Calretinin positive cell pool in a fashion 
comparable to that shown for DCX positive neuronal progenitors. As like shown for the non-
transgenic mouse groups, even the transgenic mice deficient for ABCB1 showed an impaired 
(-62%) cell number within the pool of Calretinin
+
 newly generated neurons compared to the 
APP/PS1
+/0
 control mice. But even here, all transgenic mice showed a significantly increased 
number of Calretinin
+
 cells in dependency of the β-amyloid deposition compared to their 
respective non-transgenic counterparts. In numbers the increase was +68% for APP/PS1
+/0
 
controls, +41% for ABCB deficient transgenic mice, +175% in ABCG2 deficient transgenic 
mice and +42% in ABCC1 deficient transgenic mice (Figure 15C, Table 23).  
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BrdU positive cell counts of transgenic strains 
 Strain rel Mean ±SEM tTest vs FVB n 
Sox2
+
/BrdU
+
 
Ctrl 11.2% 2.3%  6 
ABCB1
0/0
 5.9% 1.2% p=0.064 6 
ABCG2
0/0
 11.3% 2.4% p=0.982 6 
ABCC1
0/0
 5.8% 0.9% p=0.100 4 
DCX
+
/BrdU
+
 
Ctrl 27.0% 2.9%  6 
ABCB1
0/0
 24.8% 5.5% p=0.720 5 
ABCG2
0/0
 26.7% 5.8% p=0.962 6 
ABCC1
0/0
 23.5% 3.7% p=0.465 4 
Calretinin
+
/ 
BrdU
+
 
Ctrl 17.0% 1.9%  6 
ABCB1
0/0
 22.1% 4.5% p=0.255 3 
ABCG2
0/0
 20.4% 4.2% p=0.477 6 
ABCC1
0/0
 28.2% 2.8% p=0.010 4 
Table 24: BrdU positive progenitor cell fractions in APP/PS1 transgenic mouse strains 
As expected also the overall cell proliferation was affected by Aβ deposition. While the 
proliferation rate was not significantly affected by ABC deficiency when compared to 
transgenic control mice, the differences between transgenic and non-transgenic control 
respectively ABCG2
0/0
 mice were significant. Transgenic control mice showed an increased 
cell count of BrdU positive cells of +68% when compared to their non-trangenic counterpart, 
while the cell number of BrdU
+
 cells was even more drastically increased by +175% in 
ABCG2
0/0
 transgenic mice when compared with ABCG2
0/0
 non-transgenic mice (Figure 15D, 
Table 24). 
4.2 Proliferation and differentiation of NSPCs in vitro 
4.2.1 Proliferation capacity with regard to ABC expression 
To analyze the proliferation capacity of ABC transporter-deficient NSPCs, primary NSPC 
lines from the subventricular zone of control and ABC transporter-deficient animals were 
used. Primary NSPC cultures were generated by isolating NSPC from the subventricular zone 
of control and ABC deficient mouse strains. BrdU incorporation into newly amplified DNA 
was used as an indicator for comparative assessment of cell proliferation capacity in the 
different cell lines. Thirty minutes prior analysis BrdU was added and allowed to be 
incorporated into the DNA during cell proliferation. Comparative analyzes only revealed 
significantly increased proliferation capacity (+62%) in cells lacking expression of ABCG2. 
In neither ABCB1
0/0
 nor ABCC1
0/0
 cell lines the difference in cell proliferation did reach 
significance (Figure 16 A/B, Table 25). 
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4.2.2 Differentiation capacity with regard to ABC expression 
Also the capability for neuronal differentiation was comparatively analyzed in vitro by 
quantifying the relative amount of neuronal cells after 3 days under proliferating conditions. 
Neuronal cells were identified by use of immunofluorescence methods labeling the neuron-
specific β-III-tubulin with a Tuj1 antibody. The results of the differentiation assays did not 
reveal any impairment in neuronal differentiation as a result of single ABC transporter 
deficiency (Figure 16 C/D; Table 26).   
 
Figure 16: ABC transporter-deficiency did not impair neuronal differentiation in vitro. ABCG2
0/0
 cells 
showed a significant increase in proliferation capacity (+62%, A) quantified by detection of BrdU uptake using 
immunofluorescence (B). The differentiation capacity was not impaired by loss of ABC expression (C) as 
revealed by quantification of neuronal cells positive for Tuj1 (D). Error bar: SEM; Significance vs. Ctrl: 
*p<0.05; Scale bar: 50µm 
 
4.2.3 Effects of -amyloid on proliferation and differentiation of NSPCs in vitro 
To test whether Aβ administration affects on NSPC proliferation and differentiation processes 
in a cell-intrinsic manner, we administered 1µM synthetic Aβ42 to NSPC cultures during 
proliferation and differentiation experiments.  
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According to the experiments with the non-transgenic cell lines, cell proliferation was tested 
after 24 hours post-passage with a 30min BrdU incubation protocol. Aβ42 was administered at 
a concentration of 1µM directly at the beginning of the 24 hour experiment. Quantification of 
the BrdU-labeled newly proliferated cells revealed results very comparable to those without 
Aβ42 administration. Only ABCG2
0/0
 cells showed a significant increase (+24%) in 
proliferation capacity compared to the controls after Aβ42 treatment. No significant effects of 
Aβ42 treatment were observed when comparing the proliferation capacity without and after 
Aβ42 administration in none of the analyzed NSPC cultures (Figure 17, Table 25).  
 
Figure 17: A administration did not significantly affect NSPC proliferation. Significance: *p<0.05; 
**p<0.01 
While Aβ42 did not seem to affect cell proliferation capacity in NSPCs, still the question 
remains whether it is able to induce alterations in NSPC maturation. The experiments were 
performed as for the untreated NSPC cultures unless the needed administration of 1µM Aβ42 
at the beginning of the 72 hour differentiation experiment. The following quantification the 
NSPC’s ability for neuronal differentiation revealed an Aβ42-dependent increase in neuronal 
differentiation capacity in NSPCs of the FVB control strain. The control strain showed an 
increase in the proportion of neuronal cells in culture by 23% as a result of Aβ42 treatment 
(Figure 18, Table 26). There were no significant ABC-dependent effects observed. 
 
Figure 18: Administration of Aβ increased pro-neuronal cell differentiation in FVB NSPC strains. 
Significance: *p<0.05 
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BrdU positive cell fraction in NSPC proliferation assay 
 Control Aβ Administration 
tTest Ctrl vs. 
Aβ  Strain MEAN ±SEM 
tTest vs. 
Ctrl 
n MEAN ±SEM 
tTest vs. 
Ctrl 
n 
Ctrl 14.7% 1.9%  11 14.1% 2.2%  12 p=0.845 
ABCB1
0/0
 18.3% 2.4% p=0.257 13 20.6% 2.6% p=0.072 13 p=0.528 
ABCG2
0/0
 23.8% 2.7% p=0.017 15 24.5% 2.1% p=0.002 17 p=0.840 
ABCC1
0/0
 18.2% 1.3% p=0.126 18 19.7% 1.8% p=0.056 18 p=0.493 
Table 25: BrdU positive cell fraction in NSPC proliferation assay 
 
Tuj1 positive cell fraction in NSPC differentiation assay 
 Control Aβ Administration 
tTest Ctrl vs. 
Aβ Strain MEAN ±SEM 
tTest vs. 
Ctrl 
n MEAN ±SEM 
tTest vs. 
Ctrl 
n 
Ctrl 20.7% 1.1%  18 23.9% 1.0%  15 p=0.0496 
ABCB1
0/0
 22.8% 2.1% p=0.361 14 25.9% 2.0% p=0.343 12 p=0.283 
ABCG2
0/0
 18.9% 2.5% p=0.500 16 23.1% 2.1% p=0.750 16 p=0.211 
ABCC1
0/0
 19.3% 2.6% p=0.588 15 22.2% 2.7% p=0.560 14 p=0.430 
Table 26: Tuj1 positive cell fraction in NSPC differentiation assay 
 
4.3 RNA analyzes 
4.3.1 Expression of ABC transporters in NSPCs 
To justify any conclusions about ABC transporter involvement in stem cell functions, the 
actual expression of the questioned ABC transporters had to be verified. Therefore mRNA 
was isolated from the different NSPC lines and the relative expression levels for ABCB1a, 
ABCB1b, ABCG2 and ABCC1 were quantified by utilizing quantitative real-time PCR. 
These analyzes confirmed all three transport proteins (ABCB1, ABCG2, ABCC1) to be 
expressed by revealing also a possible co-regulation between ABCB1 and ABCG2.   
Interestingly, these analyzes showed that only one of the two murine isoforms of ABCB1 
(ABCB1a and ABCB1b) were actually expressed in NSPCs. Only ABCB1b was found to be 
expressed while NSPCs completely lack the expression of ABCB1a. A possible co-regulation 
between ABCG2 and ABCB1 was implicated by the finding that ABCB1b mRNA expression 
was significantly decreased (-28%) in NSPCs lacking the expression of ABCG2 (Figure 19A, 
Table 27). Vice versa, expression levels of ABCG2 mRNA were found to be increased 
(+71%) in ABCB1
0/0
 NSPCs. Even the lack of ABCC1 expression led to an increase of 
ABCG2 mRNA expression (+73%) without reaching statistical significance (Figure 19B; 
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Table 27). In contrast neither expression of ABCB1 or ABCG2 was significantly altered as a 
result of lacking expression of ABCC1. Appropriately, in neither ABCB1
0/0
 nor ABCG2
0/0
 
NSPCs the expression of ABCC1 was significantly impaired (Figure 19C; Table 27). 
 
Figure 19: Expression of ABCB1b and ABCG2 are co-regulated in NSPCs in vitro. Relative mRNA 
expression of ABCB1b, ABCG2 and ABCC1 was measured against mRNA expression of GAPDH using 
TaqMan assays. Expression of ABCB1b was significantly impaired (-28%) in ABCG2
0/0
 cells (A). In reverse, 
expression of ABCG2 was increased significantly (+71%) in animals lacking ABCB1 expression, while a 
comparable effect on ABCC1
0/0
 cells did not reach statistical significance (B). For ABCC1 mRNA expression, 
no significant changes were observed in the other cell lines (C). Error bar: SEM; Significance vs. Ctrl: * p<0.05; 
**p<0.01 
ABC transporter mRNA expression 
Gene Strain Fold change ±SEM tTest vs FVB n 
ABCB1b 
Ctrl 1.00 0.01  3 
ABCB1
0/0
 - - - - 
ABCG2
0/0
 0.72 0.06 p=0.053 3 
ABCC1
0/0
 1.12 0.05 p=0.001 3 
ABCG2 
Ctrl 1.00 0.06  3 
ABCB1
0/0
 1.71 0.13 p=0.008 3 
ABCG2
0/0
 - - - - 
ABCC1
0/0
 1.73 0.33 p=0.099 3 
ABCC1 
Ctrl 1.00 0.06  3 
ABCB1
0/0
 1.02 0.03 p=0.821 3 
ABCG2
0/0
 0.83 0.01 p=0.054 3 
ABCC1
0/0
 - - - - 
Table 27: ABC transporter mRNA expression 
 
4.3.2 Expression of genes relevant to adult neurogenesis  
In vitro 
To analyze whether loss of ABC transporter expression has cell intrinsic effects on neuronal 
stem and progenitor cells, we used mRNA extracts from cell cultures for quantitative RT-PCR 
as described in 3.9.1.3 and 3.9.1.4. The results are described as fold-changes compared to the 
control strain. Analyzes were performed for the E3 ligase Mindbomb 1, the transcription 
factor Mash1, the Notch ligand Jagged1, the transmembrane receptor Notch1, the 
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intermediate filament Nestin and the microtubule-associated protein DCX.  The results are 
plotted in Figure 20 and Table 28. 
 
MibI 
The results show that only loss of ABCB1 was able to significantly affect the expression level 
of distinct genes. The expression of MibI was increased significantly by 37% in comparison 
to the controls. The average increase of MibI expression in ABCG2
0/0
 strains did not reach 
statistical significance due to high variation of the values. The expression of MibI was 
virtually not affected by loss of ABCC1 expression  
Mash1 
The analyzes of the mRNA expression of the Mash1 transcription factor did not show 
significant alterations due to loss of ABC transporter function. 
Jagged1 
The expression of Jagged1, a Notch1 ligand, was as well assessed using quantitative RT-PCR. 
Analyzes show a significant increase of Jagged1 expression in NSPCs lacking the ABC 
transporter ABCB1. Here the expression level was increased by 36%. While the average 
values for Jagged1 mRNA were even increased in ABCG2
0/0
 and ABCC1
0/0
 strains, the 
changes did not reach statistical significance due to high deviation of the single values. 
Notch1 
While the expression of the Notch ligand Jagged1 was at least significantly increased in 
ABCB1
0/0
 NSPCs, there was no significant alteration in Notch1 mRNA expression observable 
for neither of the analyzed ABC deficient NSPC strains.  
Nestin 
Analyzes of mRNA expression levels of the NSPC-specific intermediate filament protein 
Nestin revealed no significant alterations in expression due to loss of ABC transporter 
functions.  
DCX 
Therefore, the microtubule-associated protein DCX, which is first expressed when NSPCs 
become neuronal committed, is surprisingly differentially expressed across the different ABC 
deficient NSPC strains. NSPCS deficient for ABCB1 show a significant increase in DCX 
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mRNA level by 32%. The increased expression in ABCG2
0/0
 and ABCC1
0/0
 did not reach 
statistical significance.  
 
Figure 20: In vitro Expression of genes relevant for neurogenic functions. The diagrams show relative 
expression levels of target genes compared to GAPDH as fold-changes. Only loss of ABCB1 expression 
significantly increased the expression of MibI (A), Jagged1 (C) and DCX (F). All other genes were unaffected 
by loss of either ABCB1, ABCG2 or ABCC1. Error bar: SEM; Significance vs. Ctrl: *p<0.05  
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In vitro mRNA expression 
 Strain ±SEM SEM tTest vs. Ctrl n 
MibI 
Ctrl 1.0 0.1  3 
ABCB1
0/0
 1.4 0.1 p=0.038 3 
ABCG2
0/0
 1.9 1.3 p=0.508 3 
ABCC1
0/0
 1.1 0.5 p=0.803 3 
Mash1 
Ctrl 1.0 0.0  3 
ABCB1
0/0
 1.1 0.1 p=0.348 3 
ABCG2
0/0
 1.0 0.1 p=0.904 3 
ABCC1
0/0
 1.2 0.2 p=0.426 3 
Jagged1 
Ctrl 1.0 0.0  3 
ABCB1
0/0
 1.4 0.1 p=0.036 3 
ABCG2
0/0
 1.4 0.2 p=0.152 3 
ABCC1
0/0
 1.9 0.8 p=0.296 3 
Notch1 
Ctrl 1.0 0.0  3 
ABCB1
0/0
 1.0 0.1 p=0.908 3 
ABCG2
0/0
 1.1 0.2 p=0.599 3 
ABCC1
0/0
 1.2 0.1 p=0.175 3 
Nestin 
Ctrl 1.0 0.1  3 
ABCB1
0/0
 1.0 0.1 p=0.795 3 
ABCG2
0/0
 0.7 0.1 p=0.150 3 
ABCC1
0/0
 1.2 0.3 p=0.487 3 
DCX 
Ctrl 1.0 0.1  3 
ABCB1
0/0
 1.3 0.0 p=0.027 3 
ABCG2
0/0
 1.9 1.3 p=0.508 3 
ABCC1
0/0
 1.1 0.5 p=0.803 3 
Table 28: In vitro mRNA expression 
In vivo 
To analyze whether expression of distinct proteins, involved in neurogenic processes, might 
be altered due to loss of ABC transporter expression, we used mRNA extracts from 
hippocampal tissue for quantitative RT-PCR as described in 3.9.1.3 and 3.9.1.4. The results 
are described as fold-changes compared to the control strain. Analyzes were performed for the 
E3 ligase Mindbomb1, the transcription factor Mash1, the Notch ligand Jagged1, the 
transmembrane receptor Notch1, the intermediate filament Nestin and the microtubule-
associated protein DCX. The results are plotted in Figure 21 and Table 29. 
MibI 
Analyzes showed that the E3 ligase MibI, which is a major key member in Notch1 signaling  
is altered in its mRNA expression due to loss of distinct ABC transporter function. In 
ABCB1
0/0
 mice the mRNA level is increased by 55% compared to the controls. In both 
ABCG2
0/0
 and ABCC1
0/0
 mice the increased mRNA expression did not reach statistical 
significance (Figure 21A).   
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Mash1 
The expression of the NSPC specific transcription factor is only altered in mice lacking 
ABCC1 expression. Here the mRNA level is decreased by 39% compared to the controls. 
Instead, animals lacking the transporters ABCB1 or ABCG2 do not show significant 
alterations, while ABCG2
0/0
 mice show at least a trend towards increased Mash1 levels 
without reaching statistical significance (Figure 21B).  
Jagged1 
The Notch ligand Jagged1 seems not to be altered in its mRNA expression with regard to 
ABC deficiency. In none of the ABC deficient animals the mRNA level was significantly 
changed in comparison to the controls (Figure 21C). 
Notch1 
The transmembrane receptor Notch1, which is significantly involved in stem cell 
differentiation processes, is altered in its mRNA expression by the status of ABC transporter 
expression. In animals lacking the expression of ABCB1, the Notch mRNA level is increased 
by 30%. In contrast to that, loss of ABCC1 expression instead results in decreased Notch 
expression by 33%. In ABCG2
0/0
 mice only an insignificant trend towards increased Notch1 
expression is observed (Figure 21D).  
Nestin 
The intermediate filament protein Nestin, expressed during neuronal differentiation of 
NSPCs, seemed to be increased in expression due to loss of ABCB1 and ABCC1 expression. 
While the expression of Nestin in ABCB1
0/0
 mice was increased by 52%, the increase in 
ABCC1
0/0
 did not reach statistical significance and represents only a trend (Figure 21E). 
DCX 
While the microtubule-associated protein DCX seem to be increased in mRNA expression 
due to loss of all analyzed ABC transporters, this increase only reaches statistical significance 
in ABCB1
0/0
 (+50%) and ABCC1
0/0
 (+90%) mice. 
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Figure 21: Hippocampal Expression of genes relevant for neurogenic functions. The diagrams show relative 
expression levels of target genes compared to GAPDH as fold-changes. Loss of ABCB1 expression significantly 
affected expression of MibI (A), Notch1(D), Nestin (E) and DCX (F), while it did not affect expression of Mash 
1 (B) and Jagged1 (C). Therefore loss of ABCC1 expression significantly affected the expression of Mash 1 (B), 
Notch1 (D) and DCX (F). Lost expression of ABCG2 had no effects on the mRNA levels of the analyzed genes. 
Error bar: SEM; Significance vs. Ctrl: *p<0.05  
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Hippocampal mRNA expression 
 Strain MEAN ±SEM tTest vs. Ctrl n 
MibI 
Ctrl 1.02 0.10  n=6 
ABCB1
0/0
 1.69 0.21 p=0.463 n=4 
ABCG2
0/0
 1.39 0.36 p=0.369 n=7 
ABCC1
0/0
 1.54 0.22 p=0.062 n=7 
Mash1 
Ctrl 1.02 0.10  n=6 
ABCB1
0/0
 1.17 0.16 p=0.476 n=4 
ABCG2
0/0
 1.35 0.34 p=0.387 n=7 
ABCC1
0/0
 0.72 0.05 p=0.025 n=7 
Jagged1 
Ctrl 1.02 0.08  n=6 
ABCB1
0/0
 1.10 0.13 p=0.612 n=4 
ABCG2
0/0
 1.30 0.29 p=0.373 n=7 
ABCC1
0/0
 0.81 0.13 p=0.074 n=7 
Notch1 
Ctrl 1.01 0.06  n=6 
ABCB1
0/0
 1.42 0.12 p=0.034 n=4 
ABCG2
0/0
 1.40 0.37 p=0.334 n=7 
ABCC1
0/0
 0.77 0.07 p=0.041 n=7 
Nestin 
Ctrl 1.01 0.07  n=6 
ABCB1
0/0
 1.65 0.18 p=0.045 n=4 
ABCG2
0/0
 1.22 0.20 p=0.350 n=7 
ABCC1
0/0
 1.61 0.33 p=0.123 n=7 
DCX 
Ctrl 1.02 0.08  n=6 
ABCB1
0/0
 1.63 0.13 p=0.011 n=4 
ABCG2
0/0
 1.60 0.54 p=0.320 n=7 
ABCC1
0/0
 2.04 0.31 p=0.019 n=7 
Table 29: Hippocampal mRNA expression 
 
4.4 Histological analyzes 
4.4.1 Neuronal density and cortex layer cytoarchitecture within the frontal cortex 
To determine whether ABC deficiency also leads to deficits in cortical development, tissue 
was analyzed for changes in cortical neuronal density and alterations in cytoarchitecture. For 
each strain 5 to 7 brains were immunohistochemically stained for the neuronal marker NeuN. 
The digitized brain sections were computer-assisted analyzed for the proportional NeuN
+
 
cortical area. Analyzes revealed a slight increase in neuronal Cortex area which was not yet 
significant (Figure 22B, Table 30).   
To analyze whether ABC deficiency might result in developmental impairments of the 
neocortex, measurements of the proportional cortical layer sizes were performed on the 
digitized NeuN-labeled brain sections. These analyzes revealed changes in cortical layers I 
and VI for distinct ABC deficient strains, while layer II-IV (combined) and layer IV remained 
unaffected. Lack of ABCB1 expression resulted in a significant decrease by 12% in size of 
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layer I, while the other layers remained unaffected. Instead, animals deficient for ABCC1 
showed a significantly increased size of layer VI (+15%) while all other layers were not 
significantly affected. Loss of ABCG2 expression did not seem to affect cortical 
cytoarchitecture due to unaffected sizes of the cortical layers (Figure 22C, Table 31).    
 
Figure 22: ABC deficiency alters neuronal cytoarchitecture but not neuronal density. Paraffin-embedded 
brain sections (A) were labeled with an antibody against NeuN, digitized, and the NeuN+ area was computer-
assisted determined relative to the cortical area to quantify the neuronal density of the cortex (B). The thickness 
of the cortical layers I, II-IV (combined), V and VI were measured (A) and analyzed (C). The loss of ABCB1 
expression significantly decreased the thickness of layer I (-12%) while loss of ABCC1 only affected the 
thickness of layer VI (+15%) Scale bars: 500µm (A); Error bars: SEM; Significance vs. Ctrl:  *<p0.05, **<0.01 
 
NeuN+ cortical area 
Strain MEAN ±SEM tTest vs. Ctrl n 
Ctrl 13% 0.7%  7 
ABCB1
0/0
 13% 1.9% p=0.808 5 
ABCG2
0/0
 13% 0.8% p=0.662 5 
ABCC1
0/0
 15% 0.4% p=0.127 6 
Table 30: NeuN
+
 cortical area 
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Cortical layer distribution 
 Strain Mean ±SEM tTest vs. Ctrl n 
Layer I 
Ctrl 13.0% 0.3%  7 
ABCB1
0/0
 11.4% 0.4% p=0.014 5 
ABCG2
0/0
 12.3% 0.2% p=0.131 7 
ABCC1
0/0
 11.4% 0.8% p=0.068 6 
Layer II - IV 
Ctrl 40.3% 0.7%  7 
ABCB1
0/0
 40.6% 1.0% p=0.845 5 
ABCG2
0/0
 40.4% 0.4% p=0.917 7 
ABCC1
0/0
 40.4% 0.4% p=0.983 6 
Layer V 
Ctrl 27.2% 0.7%  7 
ABCB1
0/0
 29.3% 1.0%  p=0.108 5 
ABCG2
0/0
 26.6% 0.2% p=0.441 7 
ABCC1
0/0
 25.7% 0.2% p=0.068 6 
Layer VI 
Ctrl 19.5% 0.4%  7 
ABCB1
0/0
 18.8% 0.7% p=0.351 5 
ABCG2
0/0
 20.6% 0.6% p=0.140 7 
ABCC1
0/0
 22.6% 0.9% p=0.008 6 
Table 31: Cortical layer distribution 
 
4.4.2 Cellular density of the granular zone of the dentate gyrus 
Impairments of neurogenic functions due to lack of ABC transporter function might be 
reflected in alterations of morphology of the dentate gyrus. To assess possible impairments, 
microphotographs of Nissl-stained cryo-slices were used to perform cell counts of the dentate 
gyrus’ granular zone. The cell counts revealed a significant increase in the cell number of the 
granular zone in animals lacking the transporter ABCC1. In ABCC1
0/0
 animals the cell 
number was increased by 22% compared to controls. Neither ABCB1
0/0 
nor ABCG2
0/0
 mice 
showed significantly altered cell density of the granular zone (Figure 23; Table 32). 
 
Figure 23: Loss of ABCC1 function results in altered cell density of the dentate gyrus.  A fraction of the 
dentate gyrus of known length (606µm) was used for cell counting analyzes (A). The cell number was 
normalized to a fraction of 500µm in length and the measured cell counts were normalized to the controls (B) 
and revealed a significant increase in cell counts of ABCC1
0/0 
animals (+22%). Error bar: SEM; Significance vs. 
Ctrl: *<p0.05 
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Mean number of cells per 500µm granular cell layer 
Strain MEAN ±SEM tTest vs. Ctrl n 
Ctrl 387 19  3 
ABCB1
0/0
 424 23 p=0.316 5 
ABCG2
0/0
 411 31 p=0.647 7 
ABCC1
0/0
 472 15 p=0.015 10 
Table 32: Mean number of cells per 500µm granular cell layer 
 
4.5 Behavioral experiments 
Due to the fact that the hippocampus works as a main interface between cortical inputs and is 
involved in memory consolidation, it was of urgent importance to assess whether ABC 
deficiency is able to affect brain functions in a way impairing the behavioral phenotype. 
Standard behavioral assessments like y-maze, EPM and LDB experiments were utilized to 
evaluate levels of overall activity, anxious behavior  and exploratory behavior [127-130]. 
4.5.1 Y-maze 
The y-maze was used as experimental approach to analyze the overall activity and 
spontaneous alternation behavior. While spontaneous alternation behavior was not 
significantly altered as result of ABC transporter deficiency, overall activity was indeed 
significantly reduced in mice lacking expression of either ABCB1 or ABCG2 due to 
decreased overall running distance (Figure 25A, Table 33)  and number of arm entries (Figure 
24B; Table 33). In those mouse strains running distance was shortened by 13% (ABCB1
0/0
) 
and 17% (ABCG2
0/0
). The number of arm entries was as well significantly reduced in 
ABCB1
0/0
 (-16%) and ABCG2
0/0
 (-23%). 
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Figure 24: ABC deficiency leads to impaired exploratory activity. The diagrams show Y-maze-related 
parameters. Plotting the animals’ course in the Y-maze, the running distance reveals a significant decrease in 
ABCB1- (-13%) and ABCC1- (-17%) deficient animals (A), while this parameter was only slightly, non-
significantly decreased in ABCG2-deficient mice. The same behavioral pattern was detected for exploratory 
activity as assessed by the arm entries (ABCB1
0/0
 -16%; ABCC1
0/0
 -23%)  (B). Error bar: SEM; Significance vs. 
Ctrl: *p<0.05 
 
Y-maze Analysis 
 Strain Mean ±SEM t-Test n 
Running Distance 
Ctrl 2480.4 110.3  19 
ABCB1
0/0
 2149.6 82.0 p=0.022 16 
ABCG2
0/0
 2204.3 89.0 p=0.059 23 
ABCC1
0/0
 2066.9 144.7 p=0.034 11 
Alterations 
Ctrl 37.0 2.1  19 
ABCB1
0/0
 31.2 1.7 p=0.040 16 
ABCG2
0/0
 32.8 1.8 p=0.142 23 
ABCC1
0/0
 28.5 2.4 p=0.013 11 
Table 33: Y-maze Analysis 
 
4.5.2 Elevated plus-maze 
The elevated plus-maze is a standardized experimental approach to assess anxious behavior in 
rodents. This experimental setting is based on the principle of opposing motivations for 
exploring the environment on the one hand while avoiding open surroundings on the other. 
While exploratory drive is equal for each arm of the maze, open surroundings bear an anxiety 
driven aversion modulating the subjects entering probability of entering the open arms and 
resulting in less entries into the open arms [118].  
The time spent in open arms was significantly decreased (-44% ABCB1
0/0
; -31% ABCG2
0/0
) 
in ABCB1 and ABCG2 deficient mice (Figure 25A, Table 34), while the decrease in 
ABCC1
0/0
 mice did not reach statistical significance. In contrast all ABC deficient animals 
remained significantly longer in the enclosed compartments (+43% ABCB1
0/0
, +24% 
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ABCG2
0/0
, +32% ABCC1
0/0
) than animals of the control strain (Figure 25B, Table 34). By 
comparing the running velocity in the open compartment no significant impairments were 
found in neither of the ABC deficient mouse strains (Figure 25C, Table 34). Therefore the 
parameter of running velocity was significantly altered in the enclosed compartment as a 
result of either ABCB1 or ABCC1 deficiency (Figure 25D, Table 34). 
 
Figure 25: ABC transporter deficiency promotes anxiety. The diagrams show parameters assessed via the 
elevated plus maze. Mice deficient for ABCB1 (-44%) and ABCG2 (-32%) showed a significantly decreased 
presence in the open arms (A). The time of residence in the closed compartments was significantly increased in 
all ABC transporter-deficient mouse strains (ABCB1
0/0
 +43%; ABCG2
0/0
 +24%; ABCC1
0/0
 +32%) (B). Running 
speed (celerity) in the open arms was not changed in any of the ABC transporter-deficient mice (C). ABCB1 (-
23%) and ABCC1 (-14%) transporter-deficient mice showed significantly lower celerity values in the closed 
arms (D). Error bar: SEM; Significance vs. Ctrl *p<0.05; **p<0.01; ***p<0.001 
4 Results 
70 
EPM analysis 
Parameter Strain Mean ±SEM tTest vs Ctrl N 
time in open parts 
Ctrl 100% 13.0%  14 
ABCB1
0/0
 56% 13.8% p=0.007 18 
ABCG2
0/0
 68% 10.2% p=0.030 20 
ABCC1
0/0
 72% 14.1% p=0.149 13 
time in closed parts 
Ctrl 100% 7.8%  14 
ABCB1
0/0
 141% 4.7% p=0.000 18 
ABCG2
0/0
 124% 4.6% p=0.014 20 
ABCC1
0/0
 132% 6.9% p=0.015 13 
celerity in open 
Ctrl 100% 15.0%  14 
ABCB1
0/0
 105% 19.6% p=0.749 18 
ABCG2
0/0
 146% 7.8% p=0.182 20 
ABCC1
0/0
 206% 3.3% p=0.817 13 
celerity in closed 
Ctrl 100% 3.7%  14 
ABCB1
0/0
 106% 5.2% p=0.000 18 
ABCG2
0/0
 80% 15.0% p=0.730 20 
ABCC1
0/0
 85% 18.6% p=0.114 13 
Table 34: EPM analysis 
 
4.5.3 Light/Dark-box 
As like in an open-field test the LD-box allows the assessment of overall exploratory behavior 
(running distance, rearing and compartment transition) in an open surrounding while also 
comprising an enclosed compartment which both in combination also allow the assessment of 
anxiety like behavior (light avoidance, differential activity in both compartments). With 
regard to activity within the open maze compartment, comparative analyzes of running speeds 
in ABC deficient animals showed no alterations compared to control mice (Figure 26A, Table 
35).  
In contrast, activity within the dark compartment was significantly altered as a result of ABC 
deficiency. In mice lacking expression of ABCB1 an increased activity was observed within 
the dark compartment due to longer running distance (+64%) in comparison to controls 
(Figure 26B, Table 35). Accordingly ABCB1
0/0
 mice spent significantly more time within the 
dark compartment compared to controls (Figure 26C, Table 35). Both ABCB1 and ABCC1 
deficient animals revealed impairments in exploratory behavior due to number of transitions 
between the two compartments. In both strains the number of transitions was significantly 
decreased compared to controls by 59% in ABCB1
0/0
 and 49% in ABCC1
0/0
 mice compared 
to controls (Figure 26D, Table 35). Rearing activity was also deemed as to be a characterizing 
parameter of exploratory behavior. Observations showed rearing activity in open-field 
compartment as to be decreased (-67%) in ABCC1
0/0 
mice (Figure 26E, Table 35) while no 
differences were observed within the dark compartment (Figure 26F, Table 35). ABCB1
0/0
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mice revealed no alterations in rearing activity in the open field area (Figure 26E, Table 35), 
though rearing activity is significantly increased in the dark compartment (+71%, Figure 26F; 
Table 35). 
 
Figure 26: Light/dark box experiments verified altered anxiety and exploratory behavior. Comparing the 
running distance of the animals in the open field revealed no significant differences (A). However, the distance 
traveled by ABCB1-deficient mice (+64%) in the dark compartment (B) was significantly increased compared to 
the controls. Also, the time in the dark compartment (C) was significantly increased in ABCB1
0/0
 mice (+78%) 
compared to controls. The mean number of transitions between the two compartments (D) was impaired in both 
ABCB1
0/0
 (-59%) and ABCC
0/0 
(-49%) mice. Comparing the rearing frequency in both compartments revealed a 
significant decrease for ABCC1
0/0
 (-67%) mice in the open field (E), while the frequency was increased in the 
dark compartment (F) for ABCB1
0/0
 (+71%) mice. Error bar: SEM; Significance vs. Ctrl: *<p0.05; **p<0.01 
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LDB analysis 
Parameter Strain Mean ±SEM tTest vs. Ctrl n 
traveld in field 
Ctrl 1466 141  9 
ABCB1
0/0
 1054 199 p=0.109 10 
ABCG2
0/0
 1423 106 p=0.809 9 
ABCC1
0/0
 1046 215 p=0.128 21 
traveled in box 
Ctrl 812 116  9 
ABCB1
0/0
 1335 97 p=0.003 10 
ABCG2
0/0
 942 94 p=0.392 9 
ABCC1
0/0
 825 170 p=0.950 21 
time spend in dark 
Ctrl 32 5  9 
ABCB1
0/0
 57 5 p=0.002 10 
ABCG2
0/0
 36 4 p=0.487 9 
ABCC1
0/0
 44 11 p=0.351 21 
transitions 
Ctrl 17 2  9 
ABCB1
0/0
 7 3 p=0.025 10 
ABCG2
0/0
 17 1 p=0.900 9 
ABCC1
0/0
 9 2 p=0.028 21 
rearings in light 
Ctrl 19 3  9 
ABCB1
0/0
 14 4 p=0.337 10 
ABCG2
0/0
 16 2 p=0.482 9 
ABCC1
0/0
 6 4 p=0.036 21 
rearings in dark 
Ctrl 13 2  9 
ABCB1
0/0
 23 4 p=0.048 10 
ABCG2
0/0
 9 1 p=0.155 9 
ABCC1
0/0
 9 4 p=0.410 21 
Table 35: LDB analysis  
 
4.5.4 Effects of AD pathology on behavioral phenotypes in ABC deficient mice 
Due to the significant impact of Aβ-pathology on neurogenic functions in the hippocampal 
dentate gyrus and the pro-neuronal effect of Aβ-administration on differentiating NSPCs, 
possible effects on behavioral phenotypes had to be assessed in transgenic mice. The 
experiments were performed analogues to those performed with non-transgenic mouse strains.  
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Figure 27: AD pathology significantly increases the activity in ABCC1
0/0
 mice. The diagram indicates the 
relative change of behavioral parameters of ABC deficient transgenic mice in comparison to their respective 
non-transgenic counterparts. Shown are running distance and number of arm entries. Error bars: SEM; 
Significance vs. APP/PS1
+/0
 transgenic control *p<0.05; Significance between transgenic and non-transgenic 
counterparts +p<0.05 
 
Y-maze analysis in transgenic mouse strains 
Parameters Strain Mean ±SEM tTest vs APP
+/0
 Ctrl 
tTest vs non-
transgenic littermates 
n 
Running distance 
Ctrl 2384.3 225.8  0.674 12 
ABCB1
0/0
 2217.6 181.5 0.571 0.703 12 
ABCG2
0/0
 1967.8 311.9 0.299 0.423 6 
ABCC1
0/0
 1587.6 244.3 0.028 0.095 9 
Arm entries 
Ctrl 34.8 4.1  0.594 12 
ABCB1
0/0
 30.0 3.7 0.396 0.739 12 
ABCG2
0/0
 26.0 4.9 0.213 0.126 6 
ABCC1
0/0
 21.9 4.4 0.046 0.181 9 
Table 36: Y-maze analysis in transgenic mouse strains 
 
While ABC deficiency clearly led to decreased activity and exploratory behavior as observed 
in ABCB1 and ABCC1 deficient animals, transgenic APP/PS1
+/0
 mouse strains more likely 
showed a similar effect even though transgenic ABCB1
0/0
 mice were mostly inconspicuous. 
The effect of Aβ-deposition on the behavioral phenotype was most obvious in ABCC10/0 
transgenic mice. While the running activity (-29%, Figure 27A, Table 36) and the overall 
number of arm entries (-37%, Figure 27B, Table 36) was still decreased in ABCC1
0/0
 
transgenic mice compared to those parameters in APP/PS1
+/0
 control mice. Therefore no 
significant differences were observed in transgenic mouse strains compared to their non-
transgenic counterparts (Figure 27, Table 36).  
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Figure 28: AD pathology alters anxiogenic behavior in ABC deficient mice. The diagram indicates the 
relative change of behavioral parameters of ABC deficient transgenic mice in comparison to their respective 
non-transgenic counterparts. Error bars: SEM; Significance vs. APP/PS1
+/0
 transgenic control *p<0.05; 
Significance between transgenic and non-transgenic counterparts +p<0.05 
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EPM analysis in transgenic mouse strains 
Parameters Strain Mean ±SEM tTest vs APP
+/0
 Ctrl 
tTest vs non-
transgenic littermates 
n 
Time in open 
arms 
Ctrl 120% 20.6%  p=0.466 13 
ABCB1
0/0
 141% 23.9% p=0.124 p=0.096 12 
ABCG2
0/0
 174% 40.9% p=0.995 p=0.018 4 
ABCC1
0/0
 161% 49.1% p=0.925 p=0.135 5 
Time in closed 
arms 
Ctrl 92% 12.2%  p=0.588 13 
ABCB1
0/0
 88% 6.8% p=0.052 p=0.104 12 
ABCG2
0/0
 76% 21.8% p=0.931 p=0.090 4 
ABCC1
0/0
 84% 16.4% p=0.432 p=0.297 5 
Celerity in open 
arms 
Ctrl 94% 7.1%  p=0.468 13 
ABCB1
0/0
 108% 7.4% p=0.251 p=0.377 12 
ABCG2
0/0
 92% 27.3% p=0.709 p=0.560 4 
ABCC1
0/0
 68% 19.2% p=0.165 p=0.084 5 
Celerity in closed 
arms 
Ctrl 88% 7.8%  p=0.121 13 
ABCB1
0/0
 114% 6.3% p=0.952 p=0.050 12 
ABCG2
0/0
 128% 42.2% p=0.171 p=0.161 4 
ABCC1
0/0
 83% 11.5% p=0.364 p=0.159 5 
Table 37: EPM analysis in transgenic mouse strains 
Also the anxious behavior, which was observed in non-transgenic control and ABC deficient 
mice, was not found to be statistically significant. While non-transgenic ABCB1
0/0
 and 
ABCG2
0/0
 mice showed significant anxious behavior, AD pathology lessened these effects 
and led to insignificant differences in between transgenic controls and ABC deficient mouse 
strains. The effect of Aβ deposition on behavioral parameters was most significant in 
ABCB1
0/0
 and ABCG2
0/0
 mice. The time of stay within the open arms was increased by +41% 
in ABCG2
0/0
 APP/PS1
+/0
 transgenic mice compared to non-transgenic ABCG2
0/0
 animals 
(Figure 28A, Table 37). The other parameter, which was significantly altered by Aβ 
deposition, was the celerity in the closed arms, which was increased in ABCB1
0/0
 transgenic 
mice by +14% (Figure 28D, Table 37). None of the parameters were significantly altered by 
ABC deficiency in transgenic mice compared to APP/PS1
+/0
 controls. 
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Figure 29: AD pathology enhances anxious behavior in ABCG2
0/0
 mice. The diagram indicates the relative 
change of behavioral parameters of ABC deficient transgenic mice in comparison to their respective non-
transgenic counterparts. Error bars: SEM; Significance vs. APP/PS1
+/0
 transgenic control *p<0.05; Significance 
between transgenic and non-transgenic counterparts ++p<0.01 
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Also the LD-box experiments with ABC deficient AD mice showed results which were very 
conflicting to those made by analyzing non-transgenic mouse strains. While non-transgenic 
mice, deficient for ABCB1 and ABCC1, showed clear indications for impaired exploratory 
behavior in dependency of ABC transporter expression and stress level of their surroundings, 
LD-box experiments with transgenic mouse strains showed very different results. In fact the 
either ABCB1 or ABCG2 deficient transgenic mice showed no significant alterations in none 
of the analyzed parameters. Therefore, ABCG2 deficient mice harboring the human APP/PS1 
transgene revealed altered exploratory behavior in the open field. The measured running 
distance in the open and stressful surrounding was significantly altered. This parameter, 
measured for ABCG2
0/0
 transgenic mice, was reduced significantly by 55% compared to 
transgenic control mice. Compared to non-transgenic mice the reduction of the running 
distance was decreased even more by 60% (Figure 29A, Table 38). 
LDB analysis in transgenic mouse strains 
Parameters Strain Mean ±SEM tTest vs APP
+/0
 Ctrl 
tTest vs non-
transgenic littermates 
n 
Distance in field 
Ctrl 1287 161  p=0.411 10 
ABCB1 966 195 p=0.251 p=0.784 5 
ABCG2 576 195 p=0.028 p=0.003 4 
ABCC1 856 160 p=0.080 p=0.491 8 
Distance in box 
Ctrl 1003 143  p=0.307 10 
ABCB1 1065 54 p=0.770 p=0.086 5 
ABCG2 810 276 p=0.509 p=0.584 4 
ABCC1 1067 165 p=0.773 p=0.325 8 
Time in field 
Ctrl 54 7  p=0.116 10 
ABCB1 41 6 p=0.226 p=0.705 5 
ABCG2 51 17 p=0.832 p=0.760 4 
ABCC1 45 5 p=0.296 p=0.415 8 
Time in dark box 
Ctrl 45 6  p=0.113 10 
ABCB1 59 6 p=0.201 p=0.841 5 
ABCG2 47 17 p=0.876 p=0.309 4 
ABCC1 53 4 p=0.345 p=0.447 8 
Rearings in open 
Ctrl 15 5  p=0.512 10 
ABCB1 16 6 p=0.912 p=0.752 5 
ABCG2 5 4 p=0.224 p=0.059 4 
ABCC1 5 2 p=0.090 p=0.789 8 
Rearings in box 
Ctrl 16 4  p=0.625 10 
ABCB1 20 3 p=0.449 p=0.668 5 
ABCG2 13 6 p=0.743 p=0.348 4 
ABCC1 14 4 p=0.816 p=0.436 8 
Table 38: LDB analysis in transgenic mouse strains 
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5 Discussion  
The present study was planned and worked out to answer whether loss of ABC transporters 
would indeed lead to significant changes in neurogenesis or even to functional impairments in 
vivo. The study is motivated by repeated proposals that presumed that ABC transporters might 
be needed to be functionally expressed during NSPC development [53, 55, 62] due to 
observed transient ABC expression in NSPCs in vitro. Thereby it was shown for the first time 
that loss of ABC transporters indeed impairs neurogenic functions and leads to cognitive 
impairments which could possibly be even linked to the observed changes in cortical 
cytoarchitecture. By following different approaches and performing analyzes in vivo and in 
vitro, the results suggest the conclusion that the observed effects of ABC transporter loss 
occur mostly as a result of changes in the brain’s homeostasis rather than being based upon 
cell-intrinsic effects. The results revealed that even ABCC1 as another ABC transporter, not 
mentioned before regarding NSPC functions, is critical for neurogenic functions under 
distinct circumstances like cortical injury.  
5.1 Quantification of hippocampal neurogenesis 
To evaluate changes in neurogenic functions of the adult brain with regard to lost ABC 
transporter functions, neuronal progenitors at different states of differentiation were labeled 
by means of immunofluorescence and quantified for statistical analyzes. Analyzes were 
performed with the goal to label early NSPCs, neuronal restricted progenitors and newly 
generated fully functional neurons. It was also of great importance to simultaneously label for 
BrdU intake as a marker of recent proliferation. Therefore marker proteins were chosen, 
which are reliably expressed during critical phases of NSPC differentiation and maturation. 
Due to the technical limitations only three fluorescence signals were simultaneously 
detectable, which were represented by the marker protein, BrdU and DAPI as the nuclear 
marker. Due to that limitation it was decided to use Sox2 as the marker for the early NSPC 
population, DCX for neuronal progenitors of the type-2b and type-3 phase and Calretinin for 
functional and newly generated neurons. 
As Sox2 is expressed in radial glia cells (type-1 cell) until the late type-2a cell state, it would 
have been desirable if it was possible to simultaneously label for other markers of early neural 
stem cells like for example GFAP. But, the co-expression of GFAP and Sox2 is very difficult 
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to assess by immunofluorescence techniques due to GFAP protein is largely limited to the 
cellular processes and is nearly absent in the cell soma, which would make any conclusions 
about quantities of GFAP
+
/Sox2
+
 stem cells very questionable while marker A (GFAP) is 
mostly expressed in the cellular processes and marker B (Sox2) is a nuclear expressed protein. 
Unlike in reactive astrocytes, GFAP is also often too low expressed in common astrocytes to 
be even detectable by means of immunofluorescence, leading to confusing results [131]. 
Therefore expression of cytoplasmic GFP under control of the GFAP promoter would have 
been necessary [10] as it was used in a number of different studies [132, 133]. 
Unfortunately, for the present study, this approach is very impractical according to analyzes 
needed to be done in different ABC transporter knockout mouse strains, primarily not 
containing this transgene. Another problem is, which was even mentioned in the original 
paper of Nolte et al. [134] who generated the GFAP-eGFP transgenic mice, that the GFP 
expression does not exactly correlate to the actual localization of the GFAP protein. 
Especially, within the hippocampus and the supra chiasm, only a small fraction of astrocytes 
are actually eGFP
+
. By labeling GFAP in retinal slices, it became most obvious that eGFP 
expression occurred only in distinct astrocyte populations like the Müller glial cells, while 
astrocytes of the same layer apparently lacked eGFP expression [134]. Even the possibility of 
false-positive labeled non-astrocytes by means of GFAP-driven marker expression has been 
discussed and cannot be excluded [131]. According to these mentioned shortcomings, co-
staining for GFAP would rather not significantly improve the results. 
Even the consideration of a possible advantage of co-staining for another early NSPC marker 
like for example Tbr2 appeared doubtful according to the following argumentation. In 
particular Tbr2 was often presumed as to be expressed only in early NSPCs, in 2008 Hodge 
and Kempermann showed that Tbr2 is even still expressed in neuronal committed type-2b 
neuronal progenitors, while Sox2 seems to be expressed only until the type-2a differentiation 
state [135]. So, Tbr2 expression would significantly overlap with DCX expression and would 
also label intermediate progenitors (type-2) and neuronal committed type-3 precursors. Yet, 
Englund et al. showed in 2005, that Tbr2 seems to be expressed during neuronal commitment 
in the type-2b state and is even found in 20% NeuN
+
 cells, which from there on should be 
clearly considered as neurons beyond the progenitor state [136]. Indeed only 5% of the Tbr2
+
 
cells were actually positive for Nestin, a marker which is widely considered as to be 
expressed robustly in the earliest stem cells until type-2b differentiation [10]. Due to Nestin 
expression lasting even longer than that of Sox2, it appears very odd to assume having a more 
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robust marker for early NSPCs when labeling for Tbr2 and Sox2 if only 5% of the Tbr2
+
 cells 
show expression of another well-established NSPC marker. The value of Tbr2 labeling 
appears even more dubious in regard to another study, published in 2008 by Hodge and 
colleagues [135], who apparently used the same anti-Tbr2 antibody as Englund before 
(provided by the Lab of R.F. Hevner, without designation of the actual clone), which led to 
very different results showing that Tbr2 expression mostly overlaps with that of DCX.  
In favor for the approach used here, the paper of Steiner and colleagues [10] should be cited, 
who prepared a very comprehensive analysis on morphology and marker expression of 
NSPCs at distinct states of differentiation. It supports the argument that, Sox2
+
 cells of the 
hippocampal SGZ are mostly early neuronal progenitors of the typ-1 and type-2 state. 
According to the microphotographs shown in their publication, only a subset of cells of at 
most 10-15% of the Sox2
+
 cells found in the hippocampal SGZ could perhaps be mistakenly 
counted S100β+ astrocytes. Taken the progenitor cells as basis, virtually all Type-1 
progenitors are Sox2
+
 while at least 80% of the type-2a progenitors are expressing Sox2. Only 
about 25% of the yet neuronal restricted type-2b progenitors show a significant Sox2 
expression, while the expression of Sox2 becomes absent when reaching the type-3 progenitor 
state. The Sox2 labeled progenitor pool is thereby composed out of ca. 40% type-1 
progenitors and over 50% type-2a cells while a minor fraction of under 10% are actually type-
2b and type-3 cells [10]. Therefore it’s absolutely valid to address the SGZ’s progenitor 
collectivity by labeling with Sox2 alone, whereas an overwhelming majority of around 90% 
of those cells are or could become neuronal committed and would thereby very well reflect 
possible changes in progenitor quantities due to loss of distinct ABC transporter expression.  
For each state of cellular differentiation several useful marker proteins whose expression is 
largely overlapping during these distinct phases of cellular differentiation could be cited. 
Nevertheless DCX and Calretinin are, as largely agreed to in the literature, very specifically 
expressed during early neuronal commitment in type-2b and typ-3 cells until the cells become 
postmitotic as in the case of DCX [123, 124], or become first expressed in postmitotic 
neurons during cell migration and dendritic targeting [125]. Therefore the quantification of 
either DCX
+
 or Calretinin
+
 cell populations should very well reflect changes in neuronal 
progenitor cell populations and those postmitotic newly generated neurons. 
Inasmuch as the Sox2
+
 cell population was not significantly altered, it should be legal to 
address the early NSPC pool as not being impaired by lack of ABC transporter function. At 
least the BrdU
+
 cell fraction of the Sox2 positive cells was impaired by lack of ABC 
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transporter expression, which might indicate alterations in the NSPC turnover. This 
assumption might even fit to the finding of increased numbers of BrdU incorporated cells in 
the Calretinin
+
 cell fraction which might also indicate a somehow enhanced NSPC turnover in 
animals lacking ABC transporter expression. So, ABC transporter expression might be needed 
in NSPCs for maintenance of their stem cell character. Otherwise, lack of ABC function leads 
to fastened NSPC differentiation. Although NSPC differentiation may be fastened, 
neurogenesis is in contrast impaired in general due to loss of ABC transporters ABCB1 and 
ABCC1 as indicated by significantly decreased numbers of cells positive for DCX or 
Calretinin. 
5.1.1 Effects of cortical injury on adult neurogenesis 
By performing CCI experiments, involvement of another ABC transporter, formerly not 
mentioned with regard to neurogenic processes, could be disclosed as to be involved in 
neurogenic processes under distinct circumstances like cortical injuries. The cortical injury 
and the thereby demanded increased neuronal regeneration potential revealed that even 
ABCC1 plays a role in homeostatic processes that control neuroregenerative processes. Mice, 
deficient for ABCC1
0/0
, showed severe impairments in neuronal differentiation, which did not 
occur under normal circumstances. These circumstances support the idea of ABC transporters 
being very important for maintaining the brain’s homeostasis, especially that of the stem cell 
niche. Because ABC transporters convey a lot of biological and metabolic substrates [22-24], 
loss of ABC transporter function could severely change the brain’s homeostasis leading to the 
observed results. 
Due to the location of the stem cell niche between the vascular and the ventricular system, 
impairments in ABC mediated transport of metabolites might directly affect the NSPC’s fate. 
This seems realistic due to NSPCs even interact with both systems [137] which makes the 
possibility even more realistic that NSPC fate is depending on ABC transporter functions. It is 
thinkable that in absence of ABC transporter function, distinct metabolites can reach 
functional or even toxic concentrations within the stem cell niche due to insufficient transport 
activity. Distinct cell types like for example endothelial cells are able to release soluble 
factors which directly affect NSPC functions [138]. Assuming such factors as to be possible 
ligands for ABC transporters it is very likely that ABC transporter function could indirectly 
intervene on neurogenic functions by maintaining the homeostasis of the microenvironment of 
the stem cell niche. 
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5.1.2 AD pathology and neurogenesis 
Evaluating the effect of AD pathology, especially that of Aβ deposition, seems to be 
depending heavily on the used transgene model. Various mouse models used for studying the 
Aβ deposition aspect of Alzheimer’s disease are already described in the literature. In 
dependency of the use of specific human APP isotypes and promoters for expressing the 
transgene, the effects on neurogenic functions differ heavily. Some studies suggest increased 
neurogenesis in general [95] or at distinct time points [97]. However, most studies reported 
impairing effects on neurogenic functions [101, 139]. For the combined Thy1-
APPKM670/671NL - Thy1-PS1L166P AD model [105] which was used here, no studies on 
neurogenic functions have been performed before. Interestingly, these mice show a very early 
and heavy β-amyloid plaque load [36, 105] which separates them from most of the other 
available AD mouse models.  
Due to the fact that the function of APP and its metabolites are still under heavy discussion, 
the differences in APP isotypes and expressional properties within the different AD models 
might contribute to the differential effects on neurogenic functions. While the Aβ peptides, 
generated as a result of amyloidogenic APP degradation, are deemed to be neurotoxic in a low 
oligomeric state, there is even evidence for a neuroprotective role for the β-amyloid. Indeed, 
Aβ was found to be cleaved from APP during early embryogenesis and seems to be important 
for normal brain development [140, 141]. Aβ monomers have shown to promote survival of 
developing neurons in vitro under withdrawal of neurotrophic factors [142]. Also beneficial 
effects of low dose administration of Aβ1-40 and Aβ1-42 to proliferating NSPCs were observed 
in vitro while both isoforms differentially altered the cell fate of differentiating NSPCs [143]. 
The properties of β-amyloids as neurotrophic and neuroprotective factors imply far-ranging 
influence in physiological brain functions like neurogenesis [144].  
Interestingly, these pro-neurogenic effects of AD pathology were strongly depending on ABC 
transporter equipment of the different mouse strains. As like ABC transporter equipment 
heavily and differentially altered the intracortical quantities of soluble and insoluble Aβ [36], 
even the rate of neuroregeneration is depending on ABC transporter expression in AD 
pathology as results of NSPC quantification in transgenic mice revealed when compared to 
their non-transgenic counterparts. The fact that neurogenesis does not seem to be altered 
simply in a way of Aβ concentration-depending manner – neurogenesis was most 
significantly increased in transgenic ABCG2
0/0
 mice compared to their non-transgenic 
counterparts, while transgenic control mice showed significantly lower Aβ-deposition which 
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was therefore heavily increased in ABCC
0/0
 transgenic mice –moreover might depend on the 
exact oligomeric state of β-amyloid. Specific quantification of soluble and insoluble Aβ 
indeed showed decreased concentrations of soluble Aβ42 in ABCG2
0/0
 transgenic mice 
compared to ABCC1
0/0
 and control transgenic mice while the concentration of insoluble Aβ 
lied somewhere between that of the ABCC1
0/0
 and control AD mice. The delicate differences 
in concentration of soluble and insoluble Aβ imply different binding affinities of Aβ in 
distinct states of oligomerization to the analyzed ABC transporters. Lack of distinct 
transporters might therefore not only alter the overall concentration of intracortical Aβ but 
also alter the homeostasis of oligomeric states of the β-amyloids leading to the observed 
effects on adult neurogenesis. 
5.2 In vitro analyzes of NSPC functions with regard to ABC transporter 
equipment 
According to the presumptions of Islam and colleagues [53, 55, 62], functional ABC 
transporter expression should be necessary for proper NSPC functions and their loss should in 
contrast lead to cell-intrinsic malfunctions and impaired NSPC differentiation capacity. While 
the results of the in vivo assessment of neurogenic functionality in ABC transporter deficient 
mouse strains indicated that loss of ABCB1 and ABCG2 hampers NSPC maturation, the 
question remained open whether these effects were of cell-intrinsic nature or a result of 
impaired brain homeostasis. To gain more insight into this question, NSPCs were harvested 
from mouse brains and were cultivated in vitro for performing experiments on proliferation 
and differentiation capacity. Interestingly, proliferation experiments did not show any 
impairment due to loss of ABC transporter expression. In contrast, NSPCs lacking ABCG2 
expression displayed even increased proliferation potential, a manner which did not fit 
properly to the observations made in vivo. Beside the small changes in proliferation capacity 
observed with regard to loss of ABC transporters, differentiation experiments did not show 
any correlation between ABC transporter expression and differentiation capacity.  
However this outcome might be owed to the artificial cell culture environment which 
ABCG2
0/0
 NSPCs might be able to cope best with. In fact these observations otherwise 
correctly support the idea of ABC transporters maintaining a critical microenvironment within 
the stem cell niche that is needed for proper stem cell functions. 
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5.2.1 Effects of Aβ42 administration on NSPC cultures 
In the view of the many differing results from studies analyzing the effects of Aβ 
administration on NSPC cultures in vitro, analogous experiments were performed for this 
study. To assess the nature of Aβ’s influence on NSPC functions, NSPC cultures were 
incubated with 1µM Aβ42 during proliferation and differentiation. The results revealed a 
significant pro-neuronal change in NSPC’s differentiation fate at least for NSPC cultures of 
the control mouse strain due to significantly more generated neurons after Aβ treatment. 
Otherwise NSPCs showed no alterations under proliferative conditions with regard to Aβ 
treatment. 
While several indications allow the assumption of Aβ having a neuroprotective effect because 
of transiently increased Aβ concentrations found in the interstitial fluid of patients with acute 
brain injury [145] and beneficial effects of Aβ administration to neuronal cell cultures [142, 
146, 147], it is still under discussion whether cytotoxic or pro-neuronal effects predominate in 
NSPC functions. Here, a huge problem is Aβ’s property of spontaneously aggregating into a 
variety of oligomers and fibrils of different sizes. Though, there are protocols in use for 
forcing Aβ oligomerization and providing solutions containing distinct oligomer species 
[115]. Studies on these distinct oligomeric species revealed different traits mostly concerning 
their respective level of cytotoxicity [115] but also their potential influence on stem cell 
functions [116]. Even though most of the experimenters abode to the original Aβ preparation 
protocol [115], the study’s results often did not integrate easily. While oligomeric Aβ42 was 
deemed to impair neuronal differentiation in neural stem cells at low micromolar 
concentrations [143], the opposite effect was found elsewhere [116, 148]. With regard to the 
different effects of distinct oligomeric Aβ species [116], it is very conceivable that minor and 
involuntary changes in the Aβ preparation protocol lead to unpredictable changes in the 
configuration of the comprising Aβ oligomer species and thereby leading to those conflicting 
results. 
The present study’s results did not reveal significant cytotoxic effects on neither proliferating 
nor differentiating NSPCs at concentrations around 1µM oligomeric Aβ42. Instead Aβ42 
enhanced neuronal differentiation when applied to NSPCs of the control strain without having 
any significant effect on proliferation in neither of the analyzed control and ABC knock out 
strains. Due to the negating effect of ABC deficiency on the pro-neuronal differentiation trait 
of Aβ42, it is conceivable that ABC transporters are of functional importance for cellular 
homeostasis with regard to trans-membrane Aβ efflux.  
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Unfortunately the results of the in vitro experiments are not directly comparable with those of 
the in vivo NSPC quantifications. However at least all APP/PS1
+/0
 transgenes showed more or 
less increased rates of neurogenesis compared to their respective non-transgenic counterparts. 
But still the question remains whether enhanced neurogenesis is more or less a result of AD 
pathology-dependent neuronal loss or triggered by increased concentration of interstitial Aβ 
species. 
5.3 mRNA expression analyzes 
5.3.1 Expression of ABC transporter mRNA in NSPCs 
Expression of distinct ABC transporters in stem cells has been excessively discussed and was 
observed even in neural stem and progenitor cells before [55]. Transient protein expression 
was directly observed for ABCB1 and ABCG2 [53, 62]. Due to the vast number of different 
ABC transporters, which often largely overlap in their metabolite binding profile, it is very 
conceivable to find these proteins highly co-regulated, like it is known for other gene families, 
for ensuring redundant transporter protein expression. Concerning that, expression analyzes 
regarding the expression of the three transport proteins of interest were performed. These 
analyzes showed also, that the murine ABCB1 transporter, which in contrast to the human 
analogue comprises out of two subtypes namely ABCB1a and ABCB1b, is differentially 
expressed in NSPCs. However, only the subtype ABCB1b was found to be expressed in 
NSPCs while ABCB1a lacked expression. Previous studies also sought for possible co-
regulations in the expression of ABC transporters but remained inconclusive, though they 
only analyzed whole brain homogenates without concerning cell type specific expression 
and/or regulation [149]. 
According to the present results, for the first time a co-regulation between the expression of 
ABCB1 and ABCG2 has been found. Even ABCC1 might be altered due to state of ABCG2 
expression. With regard to previous studies, that never found significant co-regulation 
between these genes, this regulatory effect might only occur in distinct cell types like stem 
and progenitor cells. Otherwise, the regulatory momentum impedes the assessment of 
importance of single ABC transporter expression to stem cell functions due to the co-
regulations of other transporters, possibly masking the resulting impact of the lost transporter 
on NSPC function. Still, in view of the contradicting findings of the in vivo and in vitro 
analyzes concerning NSPC functions, the possibly protective effect co-regulated ABC 
transporter expression in NSPCs might still be overrun by the more far-ranging effects of 
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ABC deficiency on the brain’s homeostasis, especially that of the stem cell niche, though 
impairing neurogenic functions. 
5.3.2 Expression of genes relevant to neurogenesis 
MibI expression  
Mindbomb 1 (MibI), as an E3 ligase, is one major key member of the Notch signaling 
network which controls a number of cell determination events like neurogenic processes  
within NSPCs. Together with Neuralized (Neur), Mib1 cooperatively regulates the 
endocytosis of Notch ligands like Jagged1 and Delta and ubiquinates Delta  [150]. Mib1 
activity might also be required in the S3 cleavage of the Notch receptor to form the Notch 
intracellular domain 1 (NICD1), which itself has transcriptional activity on several genes, like 
for example the members of the hairy and enhancer split domain (HES) genes, that have great 
influence on the differentiation fate of NSPCs [151]. Thus, Mib1 indirectly influences the cell 
fate of NSPCs. Its expression level could indirectly be linked to changes in NSPC 
differentiation. Studies showed that Notch signaling is critical for maintaining the stem cell 
character of radial glia cells. By conditional inactivation of Mib1, Notch ligand endocytosis 
was blocked leading to loss of Notch signaling and thereby to complete depletion of radial 
glia cells in transgenic mice [152].  
The analyzes performed on MibI mRNA expression levels revealed significantly higher 
expression rates of MibI in vitro and in vivo. That seemed at least to be consistent to 
observations of impaired neuronal differentiation capacity in ABCB1 deficient mice. As 
significantly impaired neuronal differentiation was only observed in vivo and therefore 
implicated that these impairments might be owed mostly to changes in brain homeostasis 
alone, these data might reflect also slight cell-intrinsic imbalances in signaling cascades 
impairing neuronal differentiation. 
Mash1 
Mash1 or Ascl1 for archaete scute complex homologe 1, is a pro-neuronal transcription factor 
which is found being expressed in a number of different progenitor populations during 
embryonic development of the telencephalon [153, 154]. Functional overexpression led to 
increased numbers of differentiated neurons in transduced progenitor cells in vitro. On the 
other hand, loss of Mash1 expression accordingly led to loss of basal ganglia neurons and 
cortical interneurons in the telencephalon.  
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Otherwise, Mash1 seems to play an ambivalent role as a regulator of NSPC differentiation. 
While it is often simply referred to as a neuronal specific regulator of NSPC differentiation, it 
was also found to be expressed in oligodendrocytic precursors [155]. Analyzes with Mash1
0/0
 
mutants revealed a special role for Mash1 expression in developmental processes of the 
telencephalon where early oligodendrocytic precursor populations are lost when lacking 
Mash1 expression [156]. Hence Mash1 is not simply affecting neuronal but also 
oligodendrocytic lineage expression.  
Mash1expression levels were not affected by the status of ABC transporter expression as a 
cell-intrinsic effect like in vitro analyzes revealed. That was not surprising with regard to the 
in vitro NSPC differentiation results, which did not indicate any impairments of neuronal 
differentiation capacity due to loss of ABC transporter expression.    
Otherwise, analyzes of hippocampal tissue from ABCC
0/0
 mice revealed a significantly 
decreased mRNA expression of Mash1 compared to control animals which was not linked 
with impairments in neuronal differentiation as demonstrated by immunofluorescence 
analyzes of NSPC quantities. These data might instead indicate possible alterations in 
oligodendrocytic cell populations which were not further analyzed in this study. 
Notch1 
The Notch signaling system represents a cell-to cell signaling cascade which provides 
adjacent cells the ability to influence the cell fate of their direct neighbors. This cell-across 
feedback system has the function to maintain cellular diversity and to suppress uncontrolled 
cell proliferation or differentiation, ensuring the maintenance of a cell-type homeostasis. 
While Notch signaling is active in a given cell, this cell itself is not able to express Notch 
activating ligands by itself and thereby disabling the cell’s possibility to activate Notch in 
their direct neighbors, leading to sharply distinct expression patterns in neighboring cells and 
a mosaic like cell distribution [157]. Different studies also suggest that Notch activation is 
leading to differential effects depending on the exact nature of neuronal progenitor 
population. Activation of Notch1 in neuronal and oligodendrocytic progenitors actually 
inhibits further differentiation into the according cell linage while activation in glial 
progenitors is promoting their differentiation into astrocytes as revealed by several loss and 
gain of function studies [158].  
The mRNA analyzes of NSPCs in vitro and in vivo showed contradicting results. Matching 
the mostly unaltered proliferation capacity in vitro, also the Notch1 mRNA expression levels 
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remained inconspicuous. Therefore the expression of Notch1 seemed to be influenced by 
lacking ABC transporter expression in vivo. Analyzes of hippocampal mRNA samples 
showed significantly increased levels of Notch1 expression in ABCB1 deficient mice, while 
in contrast, Notch expression was slightly but significantly decreased in ABCC1
0/0
 mice 
compared to controls. The increased Notch1 expression fits well to the results of NSPC 
quantification which indicated impaired neuronal differentiation. This effect might be owed to 
increasing Notch signaling in ABCB1
0/0
 mice. On the other hand ABCC1
0/0
 mice showed 
slightly decreased Notch expression while neuronal differentiation remained mostly 
unaffected. This slight increase in NSPC quantities might be the result of Notch signaling 
altered into the observed direction.  
Jagged1 
Beside Delta, Jagged1 is one key ligand for Notch receptor activation. Binding of Jagged1 to 
Notch leads to activation of the Notch pathway, which is a major signaling pathway in 
neurogenic functions. Thus Jagged expression is found widely expressed across the 
neurogenic zones of the adult central nervous system [159]. Binding of the membrane bound 
Notch ligand to the Notch receptor leads to intracellular cleavage of Notch and thereby to 
activation of the Notch pathway and the suppression of pro-neuronal gene expression.   
At least the changes in Notch signaling, which were observed in vivo, seemed not to be the 
result of altered Jagged1 signaling, due to the fact that the expression of this Notch ligand 
remained unchanged. Therefore the expression of Notch1 appeared to be increased in vitro in 
all ABC deficient cell lines while this increase only reached statistical significance in 
ABCB1
0/0
 cell lines compared to control lines. The alteration in Jagged1 expression in vitro 
does not easily integrate into the results of the proliferation and differentiation experiments 
which were also performed in vitro. The results of those experiments showed that 
differentiation was not affected by lacking ABC expression and proliferation capacity was 
only significantly altered in ABCG2
0/0
 NSPCs. Altered Jagged1 expression might reflect the 
differential coping abilities of the cell lines depending on their distinct ABC transporter 
equipment.  
Nestin 
Nestin is a specific intermediate filament protein which is expressed in neuronal stem and 
progenitor cells. It is first expressed in type-1 cells or radial glia cells which also express the 
astrocytic marker GFAP and the radial glia marker BLBP while showing a characteristic 
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morphology. The expression of Nestin is still found in neuronal committed type-2b cells and 
thereby makes Nestin a classical marker for neuronal stem and progenitor cells [135, 160].  
Due to the fact that Nestin is expressed during a very early phase of NSPC development, it 
was not surprising to find Nestin expression unaltered in regard to ABC transporter deficiency 
in NSPC cultures. All cells in culture have a comparable state of differentiation and are 
rapidly proliferating, implying a relatively stable gene expression profile.  
In contrast to the findings of the in vitro experiments, expression analyzes of Nestin mRNA 
revealed increased mRNA levels in ABCB1
0/0
 and ABCC1
0/0
 mice, while the values at least 
reached statistical significance only in ABCB1
0/0
 mice in comparison to controls. Altered 
Nestin gene expression levels into that direction does not easily integrate to the findings of the 
NSPC quantification results, where neuronal differentiation was observed as being impaired 
in mice lacking ABCB1 expression. But these data might indicate impaired signaling 
transduction within the NSPC compartment leading to malfunctions during neuronal 
commitment of NSPCs resulting in impaired numbers of DCX positive neuronal progenitors. 
The increased Nestin expression might be seen as an artifact, maybe resulting from frustrating 
overexpression of Nestin within NSPCs during malfunctioning differentiation processes. It 
could be also possible to find early NSPCs, responsible for the enhanced Nestin expression, 
differentiated instead into glial or oligodendroglial lineage which was not analyzed during the 
NSPC quantification experiments in vivo. Contrariwise, one would have assumed to find 
increased numbers of early NSPCs which was not observed by quantifying the number of 
Sox2 positive cells. 
DCX 
The microtubule associated protein DCX is mostly expressed during neuronal commitment of 
late typ-2 cells and type-3 cell stadium where neuronal progenitors become postmitotic late 
neuronal progenitors while the expression of DCX sharply decreases with the beginning 
expression of adult neuronal markers [161].  
In order to complete the mRNA analyzes, even the proliferating NSPC cultures were tested 
for DCX expression. In general, the expression level of this gene would have been expected 
as to be very low, due to the fact that DCX is mostly expressed in later stages of NSPC 
differentiation. Though, studies regarding the in vitro proliferation capacity of NSPCs have 
often shown that NSPCs tend to start differentiation even under proliferative conditions and 
show several markers of advanced differentiated progenitor cells like Nestin and DCX [162]  
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Otherwise it’s quite interesting that ABC transporter equipment seems to alter the expression 
level of DCX mRNA. While all ABC deficient cell lines showed a trend towards increased 
expression of the pro-neural marker DCX, statistical significance was only reached in 
ABCB1
0/0
 deficient cell lines, which might be a hint suggesting that even though ABC 
transporter equipment decides about NSPC’s proliferation capacity within certain limits. 
It is also quite intriguing that even in vivo, significantly increased DCX mRNA expression 
was observed while the number of DCX positive cells was contrarily significantly decreased. 
Unfortunately mRNA expression and protein concentration do not necessarily correlate very 
well. It is known that even the same mRNA expression rate of eukaryotic genes could result 
in a very wide range of protein concentration (up to 20-fold) [163]. There are many factors 
hampering the correlation of mRNA and protein levels like complicated and varied post-
transcriptional mechanisms and differing protein half-lives in vivo [164] which could explain 
the contradicting results of hippocampal mRNA levels and NSPC quantification results. 
5.4 Histological analyzes 
The observed changes in hippocampal neurogenesis brought up the question whether these 
impairments might also impact upon the brain’s cytoarchitecture. The ontogenesis of the 
brain, like even all other organs, is a very delicate process which relies on the extreme 
precision of all undergoing proliferative and migratory proceedings, finally culminating in the 
most complexity of the mammalian brain. Developmental disorders can affect the laminar 
positioning of cortical pyramidal neurons. Such displacements can dramatically affect 
cognitive functions [165]. Like it was shown for neurogenic functions of the adult brain, 
alterations of the brain’s homeostasis might have impairing effects on neuronal differentiation 
also during ontogenesis and thereby on developmental processes of the whole brain, which 
might result in altered cytoarchitecture.  
Histological analyzes have been performed to answer this question. For quantification of 
neuronal density and measurements of the cortical lamination, paraffin embedded brain slices 
were stained for the neuronal marker NeuN. To exclude possible miss-interpretations of 
cellular density due to unequal staining intensities, all brain slices were stained using an 
automated staining system and the same batch of chemicals and antibodies. All brain 
hemispheres were digitized using a computerized microscope and area quantifications were 
performed using the same software macro for all slices. 
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These analyzes did not reveal any significant changes in neuronal density of the neocortex as 
a result of lacking ABC transporter expression. However, significant changes in the cortical 
layer’s cytoarchitecture were observed. Lack of ABC transporter ABCB1 led to a significant 
decrease of thickness of layer 1 while all other layers were not affected. Also ABCC1
0/0 
mice 
showed significant alterations in cortical cytoarchitecture due to significantly increased 
thickness of cortical layer VI, while even here all other layers seemed not to be affected.  
While impairments in cortical layer’s cytoarchitecture lead to a vast number of different 
cognitive malfunctions [165-167], these alterations could possibly explain the behavioral 
phenotypes like shown in 4.5., which were most significant even in ABCB1 and ABCC1 
deficient animals. While anxious behavior and drive are not primarily related to cortical 
functions, the changes in cytoarchitecture observed in the cortical areas might be only the tip 
of the iceberg, implying far ranging changes also in other brain areas.  
At least for the ABCC1
0/0
 mice, measurements of the cell density of the hippocampal gyrus 
dentatus evidenced such alterations even in other brain regions.  
5.5 Behavioral experiments 
Analyzes of ABC deficient animals revealed functional interactions between ABC transporter 
expression and neurogenic functions of the adult brain and even indicated possible alterations 
during brain ontogenesis due to altered cortical cytoarchitecture. These results demanded 
further analyzes of possible significant behavioral phenotypes in ABC knockout mice. Several 
behavioral tests were performed to investigate the mice’s overall activity, their exploratory 
behavior and in general their level of anxiety.   
5.5.1 Y-maze  
The Y-maze is used for assessing the spontaneous alternation behavior. Studies revealed that 
during exploration of a y-shaped mace, rodents prefer to enter an arm which was previously 
not investigated, due to alternations rates significantly above chance. This behavior is 
considered as to be showing their willingness for exploring their environment [168] and is 
meant to reflect the performance of the mice’s spatial working memory [169]. The alternation 
behavior also depends on the subject’s level of anxiousness and the alternation level decreases 
with increasing anxiety [170].   
ABC transporter deficiency seemed not to affect the performance of the mice’s spatial 
working memory in accordance to the results of the y-maze analyzes. There were no changes 
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in the alternation behavior observable. In contrast, the y-maze analyzes revealed impairments 
in the mice’s anxiety levels accompanied by a decreased exploratory drive. Both parameters, 
total running distance and number of arm entries were significantly decreased in animals 
deficient for either ABCB1 or ABCC1 compared to the control mice. Interestingly, these 
strains were both also most conspicuous due to altered neurogenic functions and cortical 
cytoarchitecture.  
5.5.2 Plus-maze 
The results of the y-maze analyzes suggested impaired anxiety levels and altered exploratory 
drive in animals deficient for distinct ABC transporters. As a result of these indications, 
further analyzes needed to be done to assess anxiety behavior. The elevated plus-maze is an 
advanced procedure based on the early work of Montgomery, who used different y-shaped 
mazes with different open and enclosed alleys, observing increased exploratory behavior in 
rats within the enclosed arms [118]. Years of debate followed the studies of Montgomery 
concerning the relationship between novelty fear and exploration. Finally in 1984, Handley 
and Mithani introduced their “elevated x-maze” which was formed plus-shaped, was elevated 
above ground level and comprised two open and enclosed arms [171]. Studies on anxiolytic 
drugs using the elevated plus maze revealed its potency in studying anxious behavior in 
rodents [172]. From there on the plus-maze was the medium of choice when coming to assess 
anxious behavior in rodents.  
The distance traveled in the different arms is evaluated as the locomotive activity of the 
subjects, while parameter of rearing frequency is supposed to reflect the animal’s exploratory 
drive [173]. While even the number of counted transitions between the open and enclosed 
compartments comprises an explorative momentum, this parameter should be considered as to 
be much more influenced by the anxiety level. At last, the length of stay in the enclosed 
compartment should be considered as a direct indicator of the subject’s anxiety level.  
The results of the plus-maze support the implications from the y-maze, that ABC-deficiency 
is impairing the explorative drive of the animals by altering the anxiety level of these animals. 
Again, strains deficient for expression of either ABCB1 or ABCC1 appeared most 
conspicuous during the plus-maze experiments. ABCB1
0/0
 mice showed the most significant 
preference for the enclosed compartments and appeared even more active and explorative in 
the enclosed compartments compared to the controls, while their behavior did not appear 
conspicuous in the open areas. ABCC1 deficient animals showed themselves only to be less 
explorative in the open field and less often switched between open and enclosed areas. Hence, 
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the impact of ABCB1 deficiency on behavioral parameters appeared more severe than that 
after loss of ABCC1. ABCB1 deficiency seemed to affect both, anxiety level and explorative 
drive in general. Here the motivation for explorative behavior might be even increased but 
overrun by increased anxiety level. In ABCC1
0/0
 mice, only the frequency of rearing is 
decreased in the open areas and the frequency of switching into these areas, indicating that 
here only anxiety levels might by slightly increased   
5.5.3 LDB maze 
To complete the assessment for spontaneous behavior in terms of locomotive activity, 
exploration and anxiety, the mice were finally tested in the light-dark-box maze. The LDB 
setup is based on the ethological view of shifting the relative propensities of exploring a new 
surrounding and avoiding to be exposed within the open space. It was first developed by 
Crawley and Goodwin [174] and was used from thereon in numbers of behavioral studies. 
The test, as like as exploration tests in general, reflects a type of anxiety linked with 
uncontrollable stress or a kind of depressive anxiety due to the fact that the animal is exposed 
to an aversive environment from which it cannot escape [175]. 
Complex behavioral alterations in ABC deficient mouse strains were revealed by LD-box 
experiments. Here, both ABCB1
0/0
 and ABCC1
0/0
 mice showed a significant avoidance of the 
lighted compartment compared to the controls. Interestingly, ABCB1
0/0
 mice revealed an 
increased exploratory behavior under non-stress conditions in the dark area while behavior is 
not altered under stressful light exposure. Otherwise, ABCC1
0/0 
showed no altered behavior 
under non-stress conditioned while seemed to be more anxious under light exposure. These 
data indicate complex alteration within the neuronal networking due to lost ABC transporter 
function.  
While altered neurogenic functions might also contribute to cognitive performance in spatial 
learning and orientation tasks [176], the mouse strains used in this study were unfortunately 
not suitable for use in tests based on visual cues. Due to a mutation of the retinal 
phosphodiesterase, FVB/N mice suffer from retinal degeneration leading to visual deficits 
within the first 30 days of live [177, 178]. The performance in other behavioral tasks should 
not be impaired by this mutation due to the left ability for light perception and the rodent’s 
nature of strongly relying on tactile stimuli for orientation [179]. Like shown in previous 
studies the mice are able to orient within the mazes narrow corridors and can easily recognize 
open areas, as like in the LDB, or the abyss of the plus-maze [180].  
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Still it remains unclear whether the impaired transport capacity leads to an actual impairment 
of the wiring of distinct neuronal networks, as indicated by altered cortical cytoarchitecture, 
or rather the behavioral alterations are an effect based on changes of the biological milieu 
within the brain. In fact steroids for example are ABC transporter substrates [181] and are 
also able to alter anxious behavior within a special set of hippocampal neurons [182]. Further 
investigation should be performed on possible ontogenetic effects of ABC transporter 
deficiency and the exact nature of changed milieu within the brain.  
5.5.4 Behavioral phenotypes of APP/PS1+/0 transgenic mouse strains 
Due to the fact that alterations in ABC transporter expression had significant effects on the 
behavioral phenotypes, the question remained whether AD pathology additionally affects 
mice’s behavior and in which dimension it does. Since transgenic AD mouse models were 
generated to model aspects of AD pathology like Aβ deposition, studies on behavioral 
phenotypes were performed and mostly found significant behavioral deficits analogous to 
Alzheimer’s disease in humans. Independent from the used human APP transgenes and their 
promoters used for driving their expression, most mouse strains showed behavioral deficits 
like neophobia [117], increased anxiety and aggressiveness [183] and either increased [183, 
184] or decreased [185] activity/motility levels. They also revealed a significantly declined 
cognitive performance due to decreased alternation rates in the y-maze [117, 128, 184, 185] 
and decreased escape latencies in the Morris-water-maze [185]. Quantitative differences of 
behavioral deficits between the various transgenic AD mouse models might result from the 
different quantities of Aβ deposition and localization depending on the used transgenes and 
promoters driving their expression. 
The results from behavior assessment of the ABC deficient APP/PS1
+/0
 transgenic mice did 
not easily integrate. While y-maze analyzes revealed only significantly increased activity rates 
for ABCC1
0/0
 transgenic mice compared to their respective non transgenic counterparts and 
APP/PS1
+/0
 controls, results of the plus-maze and LDB analyzes only showed significantly 
altered anxious behavior for ABCG2
0/0
 transgenic mice. Those animals showed themselves to 
be most affected by open surroundings in the open arms of the plus-maze and the lighted 
compartment of the LDB, resulting in increased anxiety related behavior. Comparing the 
relative changes in behavioral parameters between transgenic and non-transgenic animals, the 
changes were not found to be congruent throughout the different ABC-deficient strains and 
the controls.  
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A possible explanation for these incongruent relative changes in behavioral parameters 
throughout the analyzed transgenic mouse strains might be the ABC transporter specific 
transport capacity for distinct Aβ species. One of the latest publications of our workgroup 
showed the distinct effects of ABC transporter deficiency on the cortical Aβ deposition rate 
[36]. The study confirmed distinct transport capacities for each of the analyzed transporters. 
These specific clearance capacities resulted in specific deposition rates of insoluble Aβ and 
even more significantly differing concentrations of its soluble forms. The data also showed 
cyclic correlations between concentrations of soluble and insoluble Aβ species over time. 
This suggests a complex connection between Aβ production, clearance and deposition, 
significantly depending on ABC transporter specific transport capacities. Although overall Aβ 
burden might became predictable using mathematical modeling, still the exact localization of 
each Aβ deposition remains random. The defects of neuronal circuitry and the resulting 
effects stay unpredictable and might contribute to the scattering results of the behavioral 
assessment.   
5.6 Conclusions 
The present study contributes basic knowledge about the various physiological functions of 
ATP binding cassette transporters. The results documented herein could partly support the 
hypothesis of ABC transporters, ABCB1 and ABCG2 in particular, being involved in 
neuroregenerative processes. But according to the presented results, this functional 
involvement is taken place less likely on the cellular level of the NSPCs themselves. It seems 
that ABC transporter deficit much more likely intrigues the delicate homeostasis of the stem 
cell niche, thereby altering neurogenic functions in the way it has been observed here. Just as 
like as ABC transporters are responsible for extrusion of cytotoxic metabolites across the 
blood brain barrier to prevent pathogenesis of proteopathies like Alzheimer’s disease, they are 
even necessary for maintaining the brain’s stem cell pool and thereby secure the brain’s 
regeneration capacity even into late adulthood. Indication has been found that loss of single 
ABC transporter is actually able to affect brain homeostasis resulting even in altered 
cytoarchitecture and behavioral phenotypes. 
With regard to the vast number of ABC transporter modulating drugs used in treatment of 
chronic and acute diseases, more understanding of the specific transport capacities for 
metabolites, cytokines and such alike has to be achieved in order to fully understand the links 
between disease pathologies and regenerative processes. Such knowledge would allow the 
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invention of new treatment options for various kinds of neurodegenerative diseases by simply 
modulating the transport activity for distinct compounds for instance to advocate the extrusion 
of toxic compounds or otherwise selectively modulate transport of physiologically active 
metabolites to enhance regenerative processes. 
 
6 Appendix 
97 
6  Appendix 
6.1 References 
1. Sidman, R.L., I.L. Miale, and N. Feder, Cell proliferation and migration in the primitive ependymal zone: an 
autoradiographic study of histogenesis in the nervous system. Exp Neurol, 1959. 1: p. 322-33. 
2. Altman, J. and G.D. Das, Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in 
rats. J Comp Neurol, 1965. 124(3): p. 319-35. 
3. Kaplan, M.S. and J.W. Hinds, Neurogenesis in the adult rat: electron microscopic analysis of light 
radioautographs. Science, 1977. 197(4308): p. 1092-4. 
4. Paton, J.A. and F.N. Nottebohm, Neurons generated in the adult brain are recruited into functional circuits. 
Science, 1984. 225(4666): p. 1046-8. 
5. Reynolds, B.A. and S. Weiss, Generation of neurons and astrocytes from isolated cells of the adult mammalian 
central nervous system. Science, 1992. 255(5052): p. 1707-10. 
6. Richards, L.J., T.J. Kilpatrick, and P.F. Bartlett, De novo generation of neuronal cells from the adult mouse brain. 
Proc Natl Acad Sci U S A, 1992. 89(18): p. 8591-5. 
7. Eriksson, P.S., et al., Neurogenesis in the adult human hippocampus. Nat Med, 1998. 4(11): p. 1313-7. 
8. Gage, F.H., Mammalian neural stem cells. Science, 2000. 287(5457): p. 1433-8. 
9. Kriegstein, A. and A. Alvarez-Buylla, The glial nature of embryonic and adult neural stem cells. Annu Rev 
Neurosci, 2009. 32: p. 149-84. 
10. Steiner, B., et al., Type-2 cells as link between glial and neuronal lineage in adult hippocampal neurogenesis. Glia, 
2006. 54(8): p. 805-14. 
11. Ming, G.L. and H. Song, Adult neurogenesis in the mammalian brain: significant answers and significant 
questions. Neuron, 2011. 70(4): p. 687-702. 
12. Huangfu, D. and K.V. Anderson, Cilia and Hedgehog responsiveness in the mouse. Proc Natl Acad Sci U S A, 
2005. 102(32): p. 11325-30. 
13. Mirzadeh, Z., et al., Neural stem cells confer unique pinwheel architecture to the ventricular surface in neurogenic 
regions of the adult brain. Cell Stem Cell, 2008. 3(3): p. 265-78. 
14. Doetsch, F., et al., Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell, 1999. 
97(6): p. 703-16. 
15. Lois, C. and A. Alvarez-Buylla, Long-distance neuronal migration in the adult mammalian brain. Science, 1994. 
264(5162): p. 1145-8. 
16. Carleton, A., et al., Becoming a new neuron in the adult olfactory bulb. Nat Neurosci, 2003. 6(5): p. 507-18. 
17. Brill, M.S., et al., Adult generation of glutamatergic olfactory bulb interneurons. Nat Neurosci, 2009. 12(12): p. 
1524-33. 
18. Zhao, C., W. Deng, and F.H. Gage, Mechanisms and functional implications of adult neurogenesis. Cell, 2008. 
132(4): p. 645-60. 
19. Kosaka, T. and K. Hama, Three-dimensional structure of astrocytes in the rat dentate gyrus. J Comp Neurol, 1986. 
249(2): p. 242-60. 
20. Filippov, V., et al., Subpopulation of nestin-expressing progenitor cells in the adult murine hippocampus shows 
electrophysiological and morphological characteristics of astrocytes. Mol Cell Neurosci, 2003. 23(3): p. 373-82. 
21. Seri, B., et al., Cell types, lineage, and architecture of the germinal zone in the adult dentate gyrus. J Comp Neurol, 
2004. 478(4): p. 359-78. 
22. Ferreira, M.J. and I. Sa-Nogueira, A multitask ATPase serving different ABC-type sugar importers in Bacillus 
subtilis. J Bacteriol, 2010. 192(20): p. 5312-8. 
23. Gisin, J., et al., A Rhodobacter capsulatus member of a universal permease family imports molybdate and other 
oxyanions. J Bacteriol, 2010. 192(22): p. 5943-52. 
24. Linton, K.J., Structure and function of ABC transporters. Physiology (Bethesda), 2007. 22: p. 122-30. 
25. Tournier, N., et al., Opioid transport by ATP-binding cassette transporters at the blood-brain barrier: implications 
for neuropsychopharmacology. Curr Pharm Des, 2011. 17(26): p. 2829-42. 
26. Hirano, T., At the heart of the chromosome: SMC proteins in action. Nat Rev Mol Cell Biol, 2006. 7(5): p. 311-22. 
27. Hopfner, K.P., et al., Structural biology of Rad50 ATPase: ATP-driven conformational control in DNA double-
strand break repair and the ABC-ATPase superfamily. Cell, 2000. 101(7): p. 789-800. 
28. Kozak, L., et al., Elf1p, a member of the ABC class of ATPases, functions as a mRNA export factor in 
Schizosacchromyces pombe. J Biol Chem, 2002. 277(37): p. 33580-9. 
29. Dean, M., Y. Hamon, and G. Chimini, The human ATP-binding cassette (ABC) transporter superfamily. J Lipid 
Res, 2001. 42(7): p. 1007-17. 
30. Dean, M. and T. Annilo, Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu 
Rev Genomics Hum Genet, 2005. 6: p. 123-42. 
31. Sarkadi, B., et al., ABCG2 -- a transporter for all seasons. FEBS Lett, 2004. 567(1): p. 116-20. 
32. Juliano, R.L. and V. Ling, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell 
mutants. Biochim Biophys Acta, 1976. 455(1): p. 152-62. 
6 Appendix 
98 
33. Kartner, N., et al., Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-
surface P-glycoprotein. Cancer Res, 1983. 43(9): p. 4413-9. 
34. Pahnke, J., M. Krohn, and K. Scheffler, [The role of blood-brain barrier in the pathogenesis of Alzheimer 
dementia--implications for immunological therapies for plaque dissolution]. Fortschr Neurol Psychiatr, 2009. 77 
Suppl 1: p. S21-4. 
35. Pahnke, J., et al., Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies 
failed to prevent dementia progression? Neurosci Biobehav Rev, 2009. 33(7): p. 1099-108. 
36. Krohn, M., et al., Cerebral amyloid-beta proteostasis is regulated by the membrane transport protein ABCC1 in 
mice. J Clin Invest, 2011. 121(10): p. 3924-31. 
37. Hoof, T., et al., Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human 
P-glycoprotein MDR1. J Biol Chem, 1994. 269(32): p. 20575-83. 
38. Choudhuri, S. and C.D. Klaassen, Structure, function, expression, genomic organization, and single nucleotide 
polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol, 
2006. 25(4): p. 231-59. 
39. Borst, P. and A.H. Schinkel, Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet, 1997. 
13(6): p. 217-22. 
40. Gottesman, M.M. and I. Pastan, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu 
Rev Biochem, 1993. 62: p. 385-427. 
41. Higgins, C.F. and M.M. Gottesman, Is the multidrug transporter a flippase? Trends Biochem Sci, 1992. 17(1): p. 
18-21. 
42. Jones, P.M. and A.M. George, The ABC transporter structure and mechanism: perspectives on recent research. 
Cell Mol Life Sci, 2004. 61(6): p. 682-99. 
43. Karwatsky, J., et al., Binding of a photoaffinity analogue of glutathione to MRP1 (ABCC1) within two cytoplasmic 
regions (L0 and L1) as well as transmembrane domains 10-11 and 16-17. Biochemistry, 2003. 42(11): p. 3286-94. 
44. Loscher, W. and H. Potschka, Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev 
Neurosci, 2005. 6(8): p. 591-602. 
45. Leschziner, G.D., et al., ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical 
review and recommendations for future research. Pharmacogenomics J, 2007. 7(3): p. 154-79. 
46. Cordon-Cardo, C., et al., Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-
brain barrier sites. Proc Natl Acad Sci U S A, 1989. 86(2): p. 695-8. 
47. Schinkel, A.H., P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev, 1999. 36(2-3): p. 
179-194. 
48. Lam, F.C., et al., beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem, 2001. 76(4): p. 1121-8. 
49. Vogelgesang, S., et al., The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early 
pathogenesis of Alzheimer's disease. Curr Alzheimer Res, 2004. 1(2): p. 121-5. 
50. Cirrito, J.R., et al., P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an 
Alzheimer disease mouse model. J Clin Invest, 2005. 115(11): p. 3285-90. 
51. Alison, M.R., Tissue-based stem cells: ABC transporter proteins take centre stage. J Pathol, 2003. 200(5): p. 547-
50. 
52. Borovski, T., et al., Cancer stem cell niche: the place to be. Cancer Res, 2011. 71(3): p. 634-9. 
53. Islam, M.O., et al., Characterization of ABC transporter ABCB1 expressed in human neural stem/progenitor cells. 
FEBS Lett, 2005. 579(17): p. 3473-80. 
54. Yamamoto, A., et al., ABCB1 is predominantly expressed in human fetal neural stem/progenitor cells at an early 
development stage. J Neurosci Res, 2009. 87(12): p. 2615-23. 
55. Lin, T., O. Islam, and K. Heese, ABC transporters, neural stem cells and neurogenesis - a different perspective. 
Cell Res, 2006. 16(11): p. 857-71. 
56. Bates, S.E., et al., The role of half-transporters in multidrug resistance. J Bioenerg Biomembr, 2001. 33(6): p. 503-
11. 
57. Litman, T., et al., The multidrug-resistant phenotype associated with overexpression of the new ABC half-
transporter, MXR (ABCG2). J Cell Sci, 2000. 113 ( Pt 11): p. 2011-21. 
58. Rocchi, E., et al., The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the 
plasma membrane. Biochem Biophys Res Commun, 2000. 271(1): p. 42-6. 
59. Leslie, E.M., R.G. Deeley, and S.P. Cole, Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and 
BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol, 2005. 204(3): p. 216-37. 
60. Krishnamurthy, P., et al., The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions 
with heme. J Biol Chem, 2004. 279(23): p. 24218-25. 
61. Diestra, J.E., et al., Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 
in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol, 2002. 
198(2): p. 213-9. 
62. Islam, M.O., et al., Functional expression of ABCG2 transporter in human neural stem/progenitor cells. Neurosci 
Res, 2005. 52(1): p. 75-82. 
63. Leslie, E.M., R.G. Deeley, and S.P. Cole, Toxicological relevance of the multidrug resistance protein 1, MRP1 
(ABCC1) and related transporters. Toxicology, 2001. 167(1): p. 3-23. 
64. Cole, S.P., et al., Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. 
Science, 1992. 258(5088): p. 1650-4. 
65. Gradhand, U. and R.B. Kim, Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug 
Metab Rev, 2008. 40(2): p. 317-54. 
6 Appendix 
99 
66. Rao, V.V., et al., Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-
associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S 
A, 1999. 96(7): p. 3900-5. 
67. Chaudhary, P.M. and I.B. Roninson, Expression and activity of P-glycoprotein, a multidrug efflux pump, in human 
hematopoietic stem cells. Cell, 1991. 66(1): p. 85-94. 
68. Wolf, N.S., et al., In vivo and in vitro characterization of long-term repopulating primitive hematopoietic cells 
isolated by sequential Hoechst 33342-rhodamine 123 FACS selection. Exp Hematol, 1993. 21(5): p. 614-22. 
69. Goodell, M.A., et al., Isolation and functional properties of murine hematopoietic stem cells that are replicating in 
vivo. J Exp Med, 1996. 183(4): p. 1797-806. 
70. Lechner, A., et al., Nestin-positive progenitor cells derived from adult human pancreatic islets of Langerhans 
contain side population (SP) cells defined by expression of the ABCG2 (BCRP1) ATP-binding cassette transporter. 
Biochem Biophys Res Commun, 2002. 293(2): p. 670-4. 
71. Norwood, K., et al., An in vivo propagated human acute myeloid leukemia expressing ABCA3. Leuk Res, 2004. 
28(3): p. 295-9. 
72. Chiba, T., et al., Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like 
properties. Hepatology, 2006. 44(1): p. 240-51. 
73. Ueda, T., et al., Cloning and functional analysis of the rhesus macaque ABCG2 gene. Forced expression confers an 
SP phenotype among hematopoietic stem cell progeny in vivo. J Biol Chem, 2005. 280(2): p. 991-8. 
74. Bunting, K.D., et al., Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of 
side population stem cells in vitro and repopulating cells in vivo. Blood, 2000. 96(3): p. 902-9. 
75. Broccardo, C., et al., ABCA2 is a marker of neural progenitors and neuronal subsets in the adult rodent brain. J 
Neurochem, 2006. 97(2): p. 345-55. 
76. Sulkava, R., et al., Accuracy of clinical diagnosis in primary degenerative dementia: correlation with 
neuropathological findings. J Neurol Neurosurg Psychiatry, 1983. 46(1): p. 9-13. 
77. De Strooper, B. and W. Annaert, Proteolytic processing and cell biological functions of the amyloid precursor 
protein. J Cell Sci, 2000. 113 ( Pt 11): p. 1857-70. 
78. Anderson, J.P., et al., An alternative secretase cleavage produces soluble Alzheimer amyloid precursor protein 
containing a potentially amyloidogenic sequence. J Neurochem, 1992. 59(6): p. 2328-31. 
79. Mattson, M.P., et al., Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms 
of the beta-amyloid precursor protein. Neuron, 1993. 10(2): p. 243-54. 
80. Small, D.H., et al., A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in 
the regulation of neurite outgrowth. J Neurosci, 1994. 14(4): p. 2117-27. 
81. Barrantes, F.J., V. Borroni, and S. Valles, Neuronal nicotinic acetylcholine receptor-cholesterol crosstalk in 
Alzheimer's disease. FEBS Lett, 2010. 584(9): p. 1856-63. 
82. Haass, C., Take five--BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide 
generation. Embo J, 2004. 23(3): p. 483-8. 
83. Suh, Y.H. and F. Checler, Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis 
and pharmacological applications in Alzheimer's disease. Pharmacol Rev, 2002. 54(3): p. 469-525. 
84. Nicoll, J.A., et al., Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol, 2006. 65(11): p. 
1040-8. 
85. Lesne, S., L. Kotilinek, and K.H. Ashe, Plaque-bearing mice with reduced levels of oligomeric amyloid-beta 
assemblies have intact memory function. Neuroscience, 2008. 151(3): p. 745-9. 
86. Chen, Y.R. and C.G. Glabe, Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides 
Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42. J Biol Chem, 2006. 281(34): p. 24414-22. 
87. Bernstein, S.L., et al., Amyloid-beta protein oligomerization and the importance of tetramers and dodecamers in 
the aetiology of Alzheimer's disease. Nat Chem, 2009. 1(4): p. 326-31. 
88. Maurer, K. and S. Hoyer, Alois Alzheimer revisited: differences in origin of the disease carrying his name. J Neural 
Transm, 2006. 113(11): p. 1645-58. 
89. Jin, K., et al., Increased hippocampal neurogenesis in Alzheimer's disease. Proc Natl Acad Sci U S A, 2004. 
101(1): p. 343-7. 
90. Yang, Y., E.J. Mufson, and K. Herrup, Neuronal cell death is preceded by cell cycle events at all stages of 
Alzheimer's disease. J Neurosci, 2003. 23(7): p. 2557-63. 
91. Phillips, W., A.W. Michell, and R.A. Barker, Neurogenesis in diseases of the central nervous system. Stem Cells 
Dev, 2006. 15(3): p. 359-79. 
92. Boekhoorn, K., M. Joels, and P.J. Lucassen, Increased proliferation reflects glial and vascular-associated changes, 
but not neurogenesis in the presenile Alzheimer hippocampus. Neurobiol Dis, 2006. 24(1): p. 1-14. 
93. Lovell, M.A., et al., Isolation of neural precursor cells from Alzheimer's disease and aged control postmortem 
brain. Neurobiol Aging, 2006. 27(7): p. 909-17. 
94. Ziabreva, I., et al., Altered neurogenesis in Alzheimer's disease. J Psychosom Res, 2006. 61(3): p. 311-6. 
95. Jin, K., et al., Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw,Ind) mice. Proc Natl Acad 
Sci U S A, 2004. 101(36): p. 13363-7. 
96. Donovan, M.H., et al., Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer's 
disease. J Comp Neurol, 2006. 495(1): p. 70-83. 
97. Ermini, F.V., et al., Neurogenesis and alterations of neural stem cells in mouse models of cerebral amyloidosis. 
Am J Pathol, 2008. 172(6): p. 1520-8. 
98. Wen, P.H., et al., The presenilin-1 familial Alzheimer disease mutant P117L impairs neurogenesis in the 
hippocampus of adult mice. Exp Neurol, 2004. 188(2): p. 224-37. 
99. Verret, L., et al., Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived 
from adult hippocampal neurogenesis. J Neurosci, 2007. 27(25): p. 6771-80. 
6 Appendix 
100 
100. Zhang, C., et al., Long-lasting impairment in hippocampal neurogenesis associated with amyloid deposition in a 
knock-in mouse model of familial Alzheimer's disease. Exp Neurol, 2007. 204(1): p. 77-87. 
101. Haughey, N.J., et al., Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell 
homeostasis, in models of Alzheimer's disease. J Neurochem, 2002. 83(6): p. 1509-24. 
102. Schinkel, A.H., et al., Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-
transporting) P-glycoproteins. Proc Natl Acad Sci U S A, 1997. 94(8): p. 4028-33. 
103. Jonker, J.W., et al., The breast cancer resistance protein protects against a major chlorophyll-derived dietary 
phototoxin and protoporphyria. Proc Natl Acad Sci U S A, 2002. 99(24): p. 15649-54. 
104. Wijnholds, J., et al., Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking 
the multidrug resistance-associated protein. Nat Med, 1997. 3(11): p. 1275-9. 
105. Radde, R., et al., Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. 
EMBO Rep, 2006. 7(9): p. 940-6. 
106. Gratzner, H.G., Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: A new reagent for detection of DNA 
replication. Science, 1982. 218(4571): p. 474-5. 
107. Kernie, S.G., T.M. Erwin, and L.F. Parada, Brain remodeling due to neuronal and astrocytic proliferation after 
controlled cortical injury in mice. J Neurosci Res, 2001. 66(3): p. 317-26. 
108. Yu, T.S., et al., Traumatic brain injury-induced hippocampal neurogenesis requires activation of early nestin-
expressing progenitors. J Neurosci, 2008. 28(48): p. 12901-12. 
109. Ferrari, D., et al., Isolation of neural stem cells from neural tissues using the neurosphere technique. Curr Protoc 
Stem Cell Biol, 2010. Chapter 2: p. Unit2D 6. 
110. Mullis, K., et al., Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction. Cold Spring 
Harb Symp Quant Biol, 1986. 51 Pt 1: p. 263-73. 
111. Chomczynski, P. and N. Sacchi, Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-
chloroform extraction. Anal Biochem, 1987. 162(1): p. 156-9. 
112. Higuchi, R., et al., Simultaneous amplification and detection of specific DNA sequences. Biotechnology (N Y), 
1992. 10(4): p. 413-7. 
113. VanGuilder, H.D., K.E. Vrana, and W.M. Freeman, Twenty-five years of quantitative PCR for gene expression 
analysis. Biotechniques, 2008. 44(5): p. 619-26. 
114. Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and 
the 2(-Delta Delta C(T)) Method. Methods, 2001. 25(4): p. 402-8. 
115. Dahlgren, K.N., et al., Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal 
viability. J Biol Chem, 2002. 277(35): p. 32046-53. 
116. Shruster, A., et al., Wnt signaling pathway overcomes the disruption of neuronal differentiation of neural 
progenitor cells induced by oligomeric amyloid beta-peptide. J Neurochem, 2011. 116(4): p. 522-9. 
117. Hsiao, K.K., et al., Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer 
amyloid precursor proteins. Neuron, 1995. 15(5): p. 1203-18. 
118. Montgomery, K.C., The relation between fear induced by novel stimulation and exploratory behavior. J Comp 
Physiol Psychol, 1955. 48(4): p. 254-60. 
119. Arendash, G.W., et al., Progressive, age-related behavioral impairments in transgenic mice carrying both mutant 
amyloid precursor protein and presenilin-1 transgenes. Brain Res, 2001. 891(1-2): p. 42-53. 
120. Maldonado, E. and J.F. Navarro, Effects of 3,4-methylenedioxy-methamphetamine (MDMA) on anxiety in mice 
tested in the light-dark box. Prog Neuropsychopharmacol Biol Psychiatry, 2000. 24(3): p. 463-72. 
121. Graham, V., et al., SOX2 functions to maintain neural progenitor identity. Neuron, 2003. 39(5): p. 749-65. 
122. Kandasamy, M., et al., Stem cell quiescence in the hippocampal neurogenic niche is associated with elevated 
transforming growth factor-beta signaling in an animal model of Huntington disease. J Neuropathol Exp Neurol, 
2010. 69(7): p. 717-28. 
123. von Bohlen Und Halbach, O., Immunohistological markers for staging neurogenesis in adult hippocampus. Cell 
Tissue Res, 2007. 329(3): p. 409-20. 
124. Ming, G.L. and H. Song, Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci, 2005. 
28: p. 223-50. 
125. Kempermann, G., et al., Milestones of neuronal development in the adult hippocampus. Trends Neurosci, 2004. 
27(8): p. 447-52. 
126. Bye, N., et al., Neurogenesis and glial proliferation are stimulated following diffuse traumatic brain injury in adult 
rats. J Neurosci Res, 2011. 89(7): p. 986-1000. 
127. Conrad, C.D., et al., The effects of type I and type II corticosteroid receptor agonists on exploratory behavior and 
spatial memory in the Y-maze. Brain Res, 1997. 759(1): p. 76-83. 
128. Holcomb, L., et al., Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid 
precursor protein and presenilin 1 transgenes. Nat Med, 1998. 4(1): p. 97-100. 
129. Cruz, A.P., F. Frei, and F.G. Graeff, Ethopharmacological analysis of rat behavior on the elevated plus-maze. 
Pharmacol Biochem Behav, 1994. 49(1): p. 171-6. 
130. Rodgers, R.J. and A. Dalvi, Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev, 1997. 21(6): p. 
801-10. 
131. Wang, D.D. and A. Bordey, The astrocyte odyssey. Prog Neurobiol, 2008. 86(4): p. 342-67. 
132. Wigley, R., et al., Morphological and physiological interactions of NG2-glia with astrocytes and neurons. J Anat, 
2007. 210(6): p. 661-70. 
133. Leoni, G., M. Rattray, and A.M. Butt, NG2 cells differentiate into astrocytes in cerebellar slices. Mol Cell 
Neurosci, 2009. 42(3): p. 208-18. 
134. Nolte, C., et al., GFAP promoter-controlled EGFP-expressing transgenic mice: a tool to visualize astrocytes and 
astrogliosis in living brain tissue. Glia, 2001. 33(1): p. 72-86. 
6 Appendix 
101 
135. Hodge, R.D., et al., Intermediate progenitors in adult hippocampal neurogenesis: Tbr2 expression and coordinate 
regulation of neuronal output. J Neurosci, 2008. 28(14): p. 3707-17. 
136. Englund, C., et al., Pax6, Tbr2, and Tbr1 are expressed sequentially by radial glia, intermediate progenitor cells, 
and postmitotic neurons in developing neocortex. J Neurosci, 2005. 25(1): p. 247-51. 
137. Shen, Q., et al., Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of niche cell-cell interactions. 
Cell Stem Cell, 2008. 3(3): p. 289-300. 
138. Shen, Q., et al., Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science, 
2004. 304(5675): p. 1338-40. 
139. Feng, R., et al., Deficient neurogenesis in forebrain-specific presenilin-1 knockout mice is associated with reduced 
clearance of hippocampal memory traces. Neuron, 2001. 32(5): p. 911-26. 
140. Herms, J., et al., Cortical dysplasia resembling human type 2 lissencephaly in mice lacking all three APP family 
members. Embo J, 2004. 23(20): p. 4106-15. 
141. Guenette, S., et al., Essential roles for the FE65 amyloid precursor protein-interacting proteins in brain 
development. Embo J, 2006. 25(2): p. 420-31. 
142. Giuffrida, M.L., et al., Beta-amyloid monomers are neuroprotective. J Neurosci, 2009. 29(34): p. 10582-7. 
143. Chen, Y. and C. Dong, Abeta40 promotes neuronal cell fate in neural progenitor cells. Cell Death Differ, 2009. 
16(3): p. 386-94. 
144. Chasseigneaux, S. and B. Allinquant, Functions of Abeta, sAPPalpha and sAPPbeta : similarities and differences. J 
Neurochem, 2012. 120 Suppl 1: p. 99-108. 
145. Brody, D.L., et al., Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science, 
2008. 321(5893): p. 1221-4. 
146. Franke, T.F., D.R. Kaplan, and L.C. Cantley, PI3K: downstream AKTion blocks apoptosis. Cell, 1997. 88(4): p. 
435-7. 
147. Soucek, T., et al., The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid 
beta peptide. Neuron, 2003. 39(1): p. 43-56. 
148. Heo, C., et al., Effects of the monomeric, oligomeric, and fibrillar Abeta42 peptides on the proliferation and 
differentiation of adult neural stem cells from subventricular zone. J Neurochem, 2007. 102(2): p. 493-500. 
149. Lee, Y.J., et al., Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse 
blood-brain barrier: a minor role of breast cancer resistance protein. J Pharmacol Exp Ther, 2005. 312(1): p. 44-
52. 
150. Koo, B.K., et al., An obligatory role of mind bomb-1 in notch signaling of mammalian development. PLoS One, 
2007. 2(11): p. e1221. 
151. Barsi, J.C., et al., Mind bomb1 is a ubiquitin ligase essential for mouse embryonic development and Notch 
signaling. Mech Dev, 2005. 122(10): p. 1106-17. 
152. Yoon, K.J., et al., Mind bomb 1-expressing intermediate progenitors generate notch signaling to maintain radial 
glial cells. Neuron, 2008. 58(4): p. 519-31. 
153. Casarosa, S., C. Fode, and F. Guillemot, Mash1 regulates neurogenesis in the ventral telencephalon. Development, 
1999. 126(3): p. 525-34. 
154. Horton, S., et al., Correct coordination of neuronal differentiation events in ventral forebrain requires the bHLH 
factor MASH1. Mol Cell Neurosci, 1999. 14(4-5): p. 355-69. 
155. Parras, C.M., et al., Mash1 specifies neurons and oligodendrocytes in the postnatal brain. Embo J, 2004. 23(22): p. 
4495-505. 
156. Parras, C.M., et al., The proneural gene Mash1 specifies an early population of telencephalic oligodendrocytes. J 
Neurosci, 2007. 27(16): p. 4233-42. 
157. Brooker, R., K. Hozumi, and J. Lewis, Notch ligands with contrasting functions: Jagged1 and Delta1 in the mouse 
inner ear. Development, 2006. 133(7): p. 1277-86. 
158. Louvi, A. and S. Artavanis-Tsakonas, Notch signalling in vertebrate neural development. Nat Rev Neurosci, 2006. 
7(2): p. 93-102. 
159. Stump, G., et al., Notch1 and its ligands Delta-like and Jagged are expressed and active in distinct cell populations 
in the postnatal mouse brain. Mech Dev, 2002. 114(1-2): p. 153-9. 
160. Ehninger, D. and G. Kempermann, Neurogenesis in the adult hippocampus. Cell Tissue Res, 2008. 331(1): p. 243-
50. 
161. Brown, J.P., et al., Transient expression of doublecortin during adult neurogenesis. J Comp Neurol, 2003. 467(1): 
p. 1-10. 
162. Steffenhagen, C., et al., Identity, fate and potential of cells grown as neurospheres: species matters. Stem Cell Rev, 
2011. 7(4): p. 815-35. 
163. Gygi, S.P., et al., Correlation between protein and mRNA abundance in yeast. Mol Cell Biol, 1999. 19(3): p. 1720-
30. 
164. Greenbaum, D., et al., Comparing protein abundance and mRNA expression levels on a genomic scale. Genome 
Biol, 2003. 4(9): p. 117. 
165. Spalice, A., et al., Neuronal migration disorders: clinical, neuroradiologic and genetics aspects. Acta Paediatr, 
2009. 98(3): p. 421-33. 
166. Lipoff, D.M., et al., Neocortical molecular layer heterotopia in substrains of C57BL/6 and C57BL/10 mice. Brain 
Res, 2011. 1391: p. 36-43. 
167. Schwartzkroin, P.A. and C.A. Walsh, Cortical malformations and epilepsy. Ment Retard Dev Disabil Res Rev, 
2000. 6(4): p. 268-80. 
168. Lalonde, R., The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev, 2002. 26(1): p. 91-
104. 
6 Appendix 
102 
169. Hooper, N., C. Fraser, and T.W. Stone, Effects of purine analogues on spontaneous alternation in mice. 
Psychopharmacology (Berl), 1996. 123(3): p. 250-7. 
170. Bats, S., et al., The effects of a mild stressor on spontaneous alternation in mice. Behav Brain Res, 2001. 118(1): p. 
11-5. 
171. Handley, S.L. and S. Mithani, Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model 
of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch Pharmacol, 1984. 327(1): p. 1-5. 
172. Pellow, S., et al., Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. 
J Neurosci Methods, 1985. 14(3): p. 149-67. 
173. Moser, P.C., An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone. 
Psychopharmacology (Berl), 1989. 99(1): p. 48-53. 
174. Crawley, J. and F.K. Goodwin, Preliminary report of a simple animal behavior model for the anxiolytic effects of 
benzodiazepines. Pharmacol Biochem Behav, 1980. 13(2): p. 167-70. 
175. Bourin, M. and M. Hascoet, The mouse light/dark box test. Eur J Pharmacol, 2003. 463(1-3): p. 55-65. 
176. Snyder, J.S., et al., A role for adult neurogenesis in spatial long-term memory. Neuroscience, 2005. 130(4): p. 843-
52. 
177. Errijgers, V., et al., FVB.129P2-Pde6b(+) Tyr(c-ch)/Ant, a sighted variant of the FVB/N mouse strain suitable for 
behavioral analysis. Genes Brain Behav, 2007. 6(6): p. 552-7. 
178. Crawley, J.N., et al., Behavioral phenotypes of inbred mouse strains: implications and recommendations for 
molecular studies. Psychopharmacology (Berl), 1997. 132(2): p. 107-24. 
179. Krupa, D.J., et al., Behavioral properties of the trigeminal somatosensory system in rats performing whisker-
dependent tactile discriminations. J Neurosci, 2001. 21(15): p. 5752-63. 
180. Mineur, Y.S. and W.E. Crusio, Behavioral and neuroanatomical characterization of FVB/N inbred mice. Brain Res 
Bull, 2002. 57(1): p. 41-7. 
181. Becker, K.F., H. Allmeier, and V. Hollt, New mechanisms of hormone secretion: MDR-like gene products as 
extrusion pumps for hormones? Horm Metab Res, 1992. 24(5): p. 210-3. 
182. Korte, S.M., Corticosteroids in relation to fear, anxiety and psychopathology. Neurosci Biobehav Rev, 2001. 
25(2): p. 117-42. 
183. Moechars, D., et al., Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes 
disturbed behavior, neuronal degeneration and premature death in transgenic mice. Embo J, 1996. 15(6): p. 1265-
74. 
184. Holcomb, L.A., et al., Behavioral changes in transgenic mice expressing both amyloid precursor protein and 
presenilin-1 mutations: lack of association with amyloid deposits. Behav Genet, 1999. 29(3): p. 177-85. 
185. Galvan, V., et al., Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation 
of Asp664. Proc Natl Acad Sci U S A, 2006. 103(18): p. 7130-5. 
 
 
6 Appendix 
103 
6.2 Acknowledgements/Danksagung 
Zu guter Letzt möchte ich all den Menschen danken, die mich während der Promotionsarbeit 
so tatkräftig, moralisch wie auch fachlich unterstützt haben und ohne die dieses Projekt wohl 
kaum möglich gewesen wäre.  
Zuerst einmal möchte ich meinem Betreuer Prof. Jens Pahnke meinen Dank aussprechen. Ich 
danke Ihnen nicht nur für die Bereitstellung des Forschungsprojektes und der notwendigen 
Ressourcen sondern insbesondere auch für die fachlichen Anregungen und Ihre andauernde 
Unterstützung.  
Neben der vielen Arbeit hatten wir auch eine Menge Spaß im Labor. Daher möchte ich allen 
NRLern für die Zusammenarbeit danken, insbesondere auch denen die mir von Kollegen zu 
Freunden geworden sind. Am meisten wohl sicherlich während der Prokrastinationsphasen 
und Diskussionsrunden über Fachliches und Gott und die Welt mit Markus und Johannes.  
Insbesondere danke ich auch Freunden wie Martha, Peggy und Tom, die einen daran erinnern 
dass es neben dem Labor auch eine Welt da draußen gibt oder mir wie Martha auch als 
hilfreiche Lektoren zur Seite standen.  
Die größte Unterstützung aber war mir immer Jaqueline, die mir als Kollegin den Rücken frei 
hielt und mir als Freundin in den schwierigen Momenten die nötige Zuversicht zurückgab! 
Mit Sicherheit aber wäre ich nie so weit gekommen ohne die Unterstützung meiner Eltern. Ich 
danke Euch von Herzen. Und seht Ihr: Was lange währt, wird gut!  
 
 
 
 
6 Appendix 
104 
6.3 Curriculum vitae 
Personal Information 
Name: Toni Schumacher 
Date & Place of Birth 14.03.1982 in Rostock, Germany 
 
Education 
10/2008 – 05/2012 PhD thesis in the Neurodegeneration Research Lab of Prof. J. 
Pahnke , University of Rostock 
10/2001 – 02/2008 Studies of Biology and Diploma at the University of Rostock 
  
09/1995 – 06/ 2000  High School “Erasmus-Gymnasium” in Rostock, Abitur 
09/1992 – 06/1995  High School “Albert Schweitzer” in Rostock 
09/1988 – 06/1992  Comprehensive School “Egon Schulz”, Rostock 
 
Practical Experience 
Since 10/2008 Doctoral student in the Neurodegeneration Research Lab – 
Performed research regarding the role of ABC transporters in 
neuroregeneration in vivo and in vitro 
03/2008 – 10/2008 Research assistant at Neuroproof GmbH Rostock, Germany – 
Functional screening with primary neuronal networks for drug 
development 
2007 – 2008  Undergraduate student assistant at the Clinic for Internal Medicine 
in Rostock, Germany – Molecular diagnosis of lung pathogens like 
Pneumocystis jerovecii 
2004 – 2007  Undergraduate student assistant at the “Institut für Zellbiologie und 
Systemtechnik” in Rostock, Germany – Field potential analyzes of 
neuronal networks by multiple electrode arrays 
 
 
6 Appendix 
105 
Scholarship 
10/2008 – 10/2011 Scholarship holder of the “Landesgraduiertenförderung M.-V.” 
 
Publications 
Peer-reviewed articles 
1 Schumacher T, Krohn M, Hofrichter J, Lange C, Stenzel J, et al. (2012) ABC 
Transporters B1, C1 and G2 Differentially Regulate Neuroregeneration in Mice. 
PLoS ONE 7(4): e35613. doi:10.1371/journal.pone.0035613 
2 Krohn M, Lange C, Hofrichter J, Scheffler K, Stenzel J, Steffen J, Schumacher T, et 
al. (2011) Cerebral amyloid-β proteostasis is regulated by the membrane transport 
protein ABCC1 in mice. J Clin Invest. 2011 October 3; 121(10): 3924–3931. doi:  
10.1172/JCI57867 
3 Scheffler K, Stenzel J, Krohn M, Lange C, Hofrichter J, Schumacher T, et al. (2011) 
Determination of spatial and temporal distribution of microglia by 230nm-high-
resolution, high-throughput automated analysis reveals different amyloid plaque 
populations in an APP/PS1 mouse model of Alzheimer's disease. Curr Alzheimer Res. 
2011 November; 8(7):781-788 
Poster 
1 Schumacher T, Pahnke J. (2009) Transient ABC transporter expression during 
neurogenesis – Cause or effect of stem cell differentiation? Acta Neuropathol. (2009) 
118 (3), 460-461  
 
 
6 Appendix 
106 
6.4 Declaration/ Eidesstattliche Erklärung 
 
Ich gebe folgende Erklärung ab: 
1. Die Gelegenheit zum vorliegenden Promotionsvorhaben ist mir nicht kommerziell 
vermittelt worden. Insbesondere habe ich keine Organisation eingeschaltet, die gegen Entgelt 
Betreuerinnen/Betreuer für die Anfertigung von Dissertationen sucht oder die mir 
obliegenden Pflichten hinsichtlich der Prüfungsleistungen für mich ganz oder teilweise 
erledigt. 
2. Ich versichere hiermit an Eides statt, dass ich die vorliegende Arbeit selbstständig 
angefertigt und ohne fremde Hilfe verfasst habe. Dazu habe ich keine außer den von mir 
angegebenen Hilfsmitteln und Quellen verwendet und die den benutzten Werken inhaltlich 
und wörtlich entnommenen Stellen habe ich als solche kenntlich gemacht. 
 
 
Toni Schumacher      Rostock, den 11. Mai 2012 
 
 
